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ABSTRACT OF THE DISSERTATION
Genetic Variations in the Regulation and Biosynthesis of Polycyclic Tetramate Macrolactams
by
Yunci Qi
Doctor of Philosophy in Biology and Biomedical Sciences
Plant and Microbial Biosciences
Washington University in St. Louis, 2021
Professor Joshua Blodgett, Chair
Streptomyces are Gram-positive and filamentous bacteria with high-G+C genomes, which have
yielded over half of all clinically used antibiotics plus many other useful compounds. Genome
analyses indicate that these bacteria possess biosynthetic gene clusters (BGCs) encoding for
many more antibiotic-like compounds than they are known to produce. The apparent silence of
many BGCs poses a significant roadblock to genome-mining efforts for novel drugs. To
understand BGC silence, I compared several Streptomyces that harbor the widespread BGC for
polycyclic tetramate macrolactam (PTM) antibiotics to explore the genetic variations that
differentiate robustly expressed BGCs from silent BGCs. To test the prevalent hypothesis that
silent BGCs are transcriptionally downregulated, I specifically compared the promoters of the
PTM BGCs encoded within closely related members of the S. griseus clade. I found that PTM
production by S. griseus clade strains indeed varies due to differences in the strengths of their
PftdA promoters that drive PTM production. A key finding from these experiments was an ‘AG’
indel that differentiated strong and ‘silent’ PftdA promoters. This ‘AG’ indel tuned PTM
production by strongly changing PftdA strength when deleted or reintroduced in wild-type PftdA
sequences. I also showed that the global quorum-responsive transcription regulator, AdpA,
xiv

upregulated S. griseus clade PftdA promoters. Unexpectedly, I also found that PTM expression in
the S. griseus clade strain JV180 was dependent on the griseorhodin BGC, which was only
present in the genomes of S. griseus clade strains having robust PTM expression. This finding
suggested that strain-to-strain differences in PTM expression is caused by more complex factors
than just promoter sequence variations alone. Finally, I also explored the diversity of
biosynthetic genes in PTM BGCs, and the effects of these genes on the structures of PTM
molecules. These results demonstrate a clear utility for PTM biosynthesis as a model system for
understanding how genetic variations ranging from the short indels to entire BGCs can tune
antibiotic production in Streptomyces.

xv

Chapter 1: Introduction – Genomics-Guided
Drug Discovery in Streptomyces and
Polycyclic Tetramate Macrolactam
Biosynthesis as a Model System
1.1 Abstract
The genomes of Streptomyces and related bacteria contain numerous biosynthetic gene clusters
(BGCs) for antibiotics and other drug-like compounds. However, the majority of these BGCs
may be silent, hindering genomics-guided drug discovery. Here, I review numerous approaches
that have been used to activate silent BGCs. To better understand the underlying biology behind
BGC silence, I highlight polycyclic tetramate macrolactam (PTM) biosynthesis as a suitable
model system due to its extensive conservation in Streptomyces and genetic simplicity.
Additionally, I review recent work that have further elucidated how PTM BGCs produce such
diverse molecules with numerous potential biotechnological applications.

1.2 Introduction
Streptomyces and related actinobacteria have been long studied for their diverse secondary
metabolism (1) as well as their complex life cycle (2, 3). These bacteria belonging to the order
Actinomycetales are characterized by Gram-positive cell walls, often filamentous growth, and
high-G+C genomes (>70%). As non-motile bacteria, Streptomyces are thought to produce
various specialized metabolites to interact with their environments and nearby organisms (4).
The diversity of compounds produced by these strains are additionally thought to reflect the wide
range of ecological niches they occupy, as Streptomyces have been isolated from terrestrial soil
globally, marine sediments (5, 6), plants (7, 8), insects (9–11), and other sources.
1

The discovery of the antibiotic streptomycin in 1944 (1) illustrated that certain Streptomyces
metabolites could have extraordinary value in advancing human medicine. This triggered a
worldwide effort to isolate and screen novel strains of Streptomyces and related genera for new
antibiotics and other drugs. Actinomycetes have yielded more than half of all clinical antibiotics
(12, 13) as well as immunosuppressants (14, 15), chemotherapeutics (16), agricultural pesticides
(17), and veterinary drugs (18, 19) (Figure 1).
Streptomyces also contribute to biotechnology beyond drug production in several ways. This
includes the production of many highly stable extracellular enzymes for decomposing
recalcitrant organic matter with industrial applications such as cellulases and proteases (20).
There is also significant interest in Streptomyces as biocontrol agents in agriculture, based on
their ability to inhibit pathogenic microbes and promote plant growth (21, 22).

2

Figure 1. Streptomyces produce structurally diverse antibiotics that target similarly a diverse
range of biological processes
a) Streptomycin; b) Chloramphenicol; c) Thienamycin; d) Amphotericin B; e) Daptomycin; f)
Tetracycline; g) Lincomycin; h) Fosfomycin; i) Avermectin B1a; j) Tunicamycin A

Many antibiotics from Streptomyces were discovered between 1940’s and the 1970’s by
screening environmental isolates for their ability to inhibit the growth of target microbes on an
agar overlay plate, a method sometimes referred to as the Waksman platform (23). However, the
discovery rate of novel antibiotics decreased greatly in later years, hampered by high rates of rediscovery of known antibiotics (24, 25). For example, some antibiotics such as streptothricin and
streptomycin are estimated to be produced by one in ten and one in one hundred Streptomyces
isolates, respectively (26). As a result, discovery platforms needed to be increasingly complex to
de-replicate a massive collection of already known molecules and discover new molecules. This
3

trend also created worries that most useful classes of antibiotics from Streptomyces had already
been discovered (27, 28) and diminishing returns on research investment caused many
pharmaceutical companies to shift their efforts elsewhere.
While the development of novel antibiotics has slowed down, the spread of antibiotic resistance
genes has continued to accelerate due to overuse of existing antibiotics in medicine and
agriculture (29). In recent years, clinical reports have documented patients infected with “panresistant” pathogens that are resistant to all tested antibiotics (30). Raising fears of a return to
pre-antibiotic era rife with “superbugs” (31), global health organizations have called for more
careful stewardship of antibiotic usage and the development of novel antibiotics with unique
mechanisms of action as well as the exploration of alternative treatments such as phage therapy
(32).
Encouragingly, whole-genome sequencing of Streptomyces suggests that these bacteria may be
able to produce many more antibiotics than previously discovered. Here, I will review recent
advances in genomics-guided study of Streptomyces secondary metabolism and highlight key
challenges that remain. Finally, I will introduce the model system we are using to improve our
understanding of the regulation of Streptomyces secondary metabolite BGCs.

1.3 Genomics-guided drug discovery in Streptomyces is
hindered by silent metabolism
Streptomyces linear chromosomes range in size between approximately 6 to 12 Megabases (33).
The genome is considered as being divided into three regions. The central core region of the
chromosome is typically enriched in genes involved in housekeeping processes, while the two
outer “arm” regions that flank the core tend to encode for more specialized processes including
4

secondary metabolism. The arm regions of Streptomyces genomes exhibit frequent
recombination, deletion, and duplication events (34, 35). In classical genetic linkage
experiments, the biosynthetic genes for Streptomyces antibiotics were found to be co-localized in
biosynthetic gene clusters (BGCs) (36, 37). The co-localization of antibiotic biosynthetic genes
in these BGCs and the plasticity of Streptomyces chromosomal arm regions likely facilitate the
acquisition of novel BGCs through conjugal horizontal gene transfer (38).
The advent of whole-genome sequencing facilitated the identification of BGCs for compounds
previously discovered through activity-based screening, but also revealed the presence of many
more BGCs whose products had never been observed (39). Based on bioinformatic predictions, it
was possible to develop targeted screens for the products of these BGCs, which resulted in the
discovery of novel compounds (40). These observations suggested that genome-mining of
Streptomyces and related bacteria should be able to produce many more drug candidates.
The development of high-throughput sequencing technologies has allowed for many more
Streptomyces genomes to be sequenced. Sequencing of Streptomyces genomes has continued to
reveal numerous and diverse BGCs (41). However, factors such as the high G+C enrichment
(~70%) and repeats in telomeric regions pose challenges in the assembly of Streptomyces from
shotgun short-read sequencing. Furthermore, two major classes of natural products, polyketide
synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs), use large assembly-line
enzyme complexes with repetitive modules with similar enzymatic domains, which can also
confound draft genome assemblies. As a result of these factors, some BGCs in draft genomes of
Streptomyces are often fragmented across multiple contigs. Recent improvements in long-read
technologies such as Nanopore and PacBio sequencing have facilitated the assembly of more
complete Streptomyces genomes and their BGCs (42).
5

In recent years, bioinformatic tools have been developed to identify secondary metabolite BGCs,
which have been extensively reviewed elsewhere (43, 44). In brief, representative tools include
the Natural Product Domain Seeker, NaPDoS (45), the antibiotics and Secondary Metabolite
Analysis SHell, antiSMASH (46, 47), ClusterFinder (48), and PRediction Informatics for
Secondary Metabolomes, PRISM (49, 50). These tools scan genome sequences for signatures of
biosynthetic enzymes and compare the nearby gene neighborhood with documented BGCs.
Concurrently, several databases have been developed to curate BGC sequences and their
reported products, such as ClusterMine360 (51), the Integrated Microbial Genomes – Atlas of
Biosynthetic gene Clusters, IMG–ABC (52, 53), the Minimum Information about a Biosynthetic
Gene cluster (MIBiG) Data Standard and Repository (54, 55), and the antiSMASH database (56,
57). Biosynthetic gene cluster identification, annotation, and sequence collection have improved
in lockstep with the growing number of sequenced genomes and characterized biosynthetic gene
clusters.
As new genomes are sequenced, researchers have continued to discover novel clusters encoding
for potential antibiotics and other drugs. For example, only seven BGCs were conserved between
the first three completed Streptomyces genomes (58). Unique biosynthetic clusters can typically
be found even when the genomes of closely related strains are compared, which indicates that
this trend is likely to continue (59–61). Comparison of orthologous biosynthetic gene clusters in
databases has also revealed potential chemical diversity from genetic variations in biosynthetic
gene clusters (62, 63). Similarly, improvements in the ability to grow previously unculturable
microbes as well as metagenome sequencing has provided access to a larger diversity of bacterial
genomes to mine for novel BGCs. Continued advances in genome sequencing and bioinformatic
tools will facilitate the discovery of novel BGCs.
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While genomics-guided strategies appear to be a promising new paradigm for drug discovery,
the characterization of the products of newly discovered BGCs has become a bottleneck. These
numerous, newly discovered BGCs were termed “cryptic” due to the lack of a known cognate
product. While there was some success in using targeted metabolomic approaches based on
bioinformatic predictions of what these BGCs might make (40), this approach failed to yield the
expected products for the majority of cryptic BGCs. These BGCs are thought to be “silent” due
to poor transcription (64, 65). Unfortunately for the purposes of drug discovery, many more
BGCs appear to be silent than actively expressed, severely limiting the accessible candidates in
drug discovery (66).
It is commonly hypothesized that these silent BGCs are downregulated in laboratory cultures due
to the lack of stimulatory signals such as stress or competition (67). Without the necessary
stimulus, it would be more efficient for the bacteria to not devote resources toward unnecessary
metabolism, aside from a few BGCs which are expressed to protect the nutrients released by
autolytic degradation of vegetative mycelia during sporulation (68). As such, significant effort
has been put into activating silent BGCs by increasing their transcription.

1.4 Strategies to activate biosynthetic gene clusters
1.4.1 Regulatory manipulation
One group of strategies for activating secondary metabolite production focuses on manipulating
the regulation of BGCs. As Streptomyces are non-motile bacteria commonly found in soil, they
possess complex gene regulatory networks that allow them to respond to various changes in their
environment. This is reflected by the fact that strains such as Streptomyces coelicolor encode
almost 900 transcriptional regulators, of which almost 100 are part of two-component sensorhistidine kinase systems (69). Some well-characterized transcriptional regulators in Streptomyces
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include nutrient-responsive regulators such as ppGpp (70), PhoP (71), Crp (72, 73), and DasR
(74). Many Streptomyces sense and respond to cell density via small molecules such as γbutyrolactones (75, 76) and butenolides (77). Many of these are global regulators that regulate
numerous genes to coordinate morphological development and antibiotic production (68, 78).
Numerous studies have also shown how these global regulators interact with each other through
direct regulation or competitive binding (79–81). These global regulators often respond to
various incoming signals to control expression of cluster-situated regulators (CSRs) within
BGCs. Many CSRs belong to the SARP (Streptomyces antibiotic regulatory protein), LAL
(Large ATP-binding regulators of the LuxR family), or PAS-LuxR (Per-Arnt-Sim sensory
domain-LuxR type HTH domain) family of transcriptional regulators.
Due to the complex regulatory networks in Streptomyces, various cultivation conditions have
been tested as a means of activating silent BGCs. Stress factors such as nutrient deprivation, pH,
heat, rare earth elements, ethanol toxicity, and phage infection have been shown to induce
various antibiotics (82–84). Additionally, co-culturing Streptomyces with other bacteria or fungi
has been shown to trigger the production of novel antibiotics, possibly through competition
sensing (85, 86). Similarly, upregulation of antibiotic production has been reported with the
addition of chitin, which is a component of fungal cell walls (87). Recent research has also
shown how signaling molecules, siderophores, and even antibiotics can mediate interspecies
signaling between Streptomyces strains and other microbes (88–92). Recently, high-throughput
elicitor screens (HiTES) have been developed to screen libraries of chemicals for potential
signaling elicitors (93, 94). These approaches typically use promoters from silent BGCs fused to
reporter genes, but imaging mass spectrometry has also been applied to directly detect
production of cryptic secondary metabolites (95).
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Aside from searching for triggers that activate native gene regulatory networks, much research
has also focused on activating biosynthetic gene clusters by genetically manipulating their
regulatory network (96). This may involve deletion or overexpression of global regulators or
CSRs. Recently, transcription factor decoys, originally developed in mammalian systems, have
also been explored as a method to de-repress BGCs (97, 98). However, manipulating global
transcription regulators can lead to pleiotropic effects and not all antibiotic biosynthetic gene
clusters have cluster-situated regulators. Global changes in regulation and gene expression have
also been induced with spontaneous antibiotic resistance mutations in RNA polymerase or
ribosome proteins (99). These mutations are easy to generate but have the downside of inducing
uncontrollable pleiotropic changes like manipulation of global regulators. Although various
strategies have been demonstrated for activating silent BGCs, no single approach has proven to
be universally applicable. Further understanding of gene regulatory networks, the signals they
respond to, and the targets of regulators in Streptomyces may yield new and improved strategies
for activating silent BGCs (100–102).

1.4.2 Bypassing regulation
A different strategy to activating silent BGCs involves applying the synthetic biology toolkit to
genetically re-engineer BGCs of interest. Rather than relying on potentially insufficient
regulatory knowledge, these approaches aim to re-wire and deregulate the BGCs. One common
approach involves replacing the native promoters of BGCs with stronger promoters to upregulate
their expression. One of the most commonly used promoters in Streptomyces is derived from a
strong constitutive promoter upstream of the erythromycin resistance gene, ermE, of
Saccharopolyspora erythraea (103, 104). As Streptomyces gained more interest from synthetic
biologists, several libraries of constitutive promoters and Shine-Dalgarno sequences have been
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developed using transcriptomic datasets as well as computational modeling, which can be used to
fine-tune and balance expression (105–110). Libraries of inducible promoters have also been
characterized to provide more control over gene expression in Streptomyces (111, 112).
However, as large biosynthetic clusters can contain dozens of genes, this approach can be
laborious and requires the ability to rapidly engineer the Streptomyces genome. Additionally,
many strains can be difficult to genetically manipulate due to native restriction systems,
hindering direct genetic manipulation of biosynthetic gene clusters of interest. Recently, several
groups have also explored the usage of CRISPR to facilitate rapid and efficient genome edits
(113, 114). Some major challenges have included optimizing the efficiency of CRISPR editing in
Streptomyces and decreasing toxicity from non-specific activity (115). Genome editing
technologies that have been applied in Streptomyces have been reviewed recently (116).
The difficulty of editing Streptomyces genomes has often been circumvented by cloning the
BGCs of interest into large low-copy vectors (117). The resulting plasmids can be readily edited
in E. coli cloning hosts then be heterologously expressed in more genetically tractable host
strains. Several studies in recent years have shown improvements such as larger insert sizes and
assembly of more fragments simultaneously (118). Additionally, several new site-specific
integrases and their att sites have been characterized from various actinophages (119), providing
more genomic loci which can host heterologous gene clusters (120–124). This has also been used
to increase production titers by expressing multiple copies of the BGC of interest. An additional
benefit of cloning biosynthetic gene clusters into large plasmids is the ability for the BGC to be
engineered with constitutive promoters more rapidly in E. coli cloning hosts before they are
conjugated into Streptomyces.
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Another approach that has been applied to discover new antibiotics is the deletion of other
BGCs. Deletion of these BGCs can help to identify compounds whose activities were masked by
the more predominantly expressed antibiotics (125). Additionally, deletion of other biosynthetic
pathways seems to sometimes cause regulatory and metabolic rewiring, leading to upregulation
of quiet biosynthetic clusters (126). Furthermore, eliminating competing pathways can increase
antibiotic titers and also result in a better suited host for expressing heterologous biosynthetic
gene clusters (127–129).

1.4.3 Challenges and caveats
While the described strategies have produced promising results, activating a silent BGC typically
still involves a significant amount of time and effort to yield. In comparison, improvements in
genome sequencing and bioinformatic tools have made the discovery of novel biosynthetic gene
far easier. Taken together, current approaches for activating silent BGCs are unable to keep pace
with the rate of discovery, preventing genomics-guided discovery from fulfilling its potential. In
addition, the reasons for why certain BGCs are expressed while others are silent are still poorly
understood. This question can be difficult to address given the diversity of BGCs in
Streptomyces strains, which each have their own regulatory pathways. These differences can
mean that the findings from one BGC may not be broadly applicable to all BGCs.
An alternative possibility for our inability to detect the products of cryptic BGCs that is
underexplored that their encoded enzymes could have poor catalytic activity. Even when the
products of BGCs cannot be detected, transcripts of cryptic BGCs may still be detected at some
level in transcriptomic studies. Although overexpression of weak enzymes could overcome
pathway bottlenecks and result in the activation of observable production, the optimization of
these enzymes through protein engineering could be another approach to increasing production
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while also being less taxing on the cell. However, examining enzymatic defects would be a much
more laborious process. Since many BGCs have been activated by regulatory manipulation and
rewiring, the success of these approaches has encouraged their proponents by demonstrating that
the enzymes encoded within these silent BGCs are catalytically functional at some level.
To facilitate the discovery of novel drug candidates, a better understanding of the differences
between active and silent BGCs is needed. While approaches such as transcriptomics and
proteomics can be used to identify strongly expressed BGCs, these methods are still relatively
cost-prohibitive and less accessible. Improved regulatory understanding of BGC promoters could
create guidelines for identifying BGCs that should already be expressed strongly based on
genome sequences and also lead to new approaches for engineering weakly expressed
biosynthetic clusters.

1.5 Polycyclic tetramate macrolactam biosynthesis as a
model system for studying BGC silence
To better understand the underlying differences between strongly and weakly expressed BGCs,
we turned to polycyclic tetramate macrolactam (PTM) biosynthesis as a model system. The BGC
for PTM biosynthesis is widely conserved in Streptomyces, other actinomycetes, and even some
Gram-negative bacteria (Figure 2). At the time the BGC for the frontalamide PTMs were
originally identified, 10 of the 21 published Streptomyces genome sequences contained a PTM
BGC (130). Strikingly, many of these strains were not known to produce PTMs. The authors
demonstrated the pervasiveness of PTM BGCs in Streptomyces by using degenerate PCR primer
screening to detect 10 PTM-encoding strains from a soil-isolate strain collection (JV176 - JV182
and JV184 - JV186). The unusually high conservation of PTM BGCs and the discrepancy in
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PTM production between strains allows for the comparison of directly orthologous BGCs that
are strongly or weakly expressed.

Figure 2. Representative PTM BGCs and their products.

Another advantage of PTM biosynthesis as a model system is that PTM BGCs are very simple
and compact, typically containing only 3 to 6 genes and spanning less than 20 kilobases. Most
PTM BGCs appear to be organized as single operons controlled by one promoter, although some
PTM BGCs have been reported to have two promoters (64). Since the precursors for PTMs,
ornithine and malonyl-CoA, are common metabolites, they do not require additional genes
encoding for specialized precursor units. As such, PTM regulation should be less complex than
other BGCs, which can contain many more genes and promoters. Interestingly, many PTM
BGCs do not appear to be associated with a CSR.
PTM molecules are also of interest for potential applications in agriculture and healthcare. One
highly studied PTM, dihydromaltophilin (also known as heat-stable antifungal factor, HSAF), is
an effective broad-range fungicide (131). Lysobacter strains which produce HSAF have been
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tested as biocontrol agents to control crop pathogens in several studies (132, 133). HSAF is
thought to disrupt the function of ceramide synthases in filamentous fungi, and further studies
are still being performed to better understand its mechanism of action (134–136). In additionally,
ikarugamycin, which was originally isolated as an anti-protozoal metabolite (137), and PTM
molecules with similar structures have attracted recent interest for their ability to inhibit cancer
cell line proliferation (138, 139).
Since the identification of the PTM BGC, several groups have attempted to characterize the
PTMs produced by BGCs found in previously sequenced genomes. The first such study targeted
the PTM BGC in Streptomyces griseus subsp. griseus strain IFO13350 (140). This S. griseus
strain has been a model strain for studies in the AdpA quorum-responsive global regulator as
well as streptomycin biosynthesis (141). Despite S. griseus being a well-studied strain, there had
been no reports on any PTMs being isolated from S. griseus. Upon observing no PTM
production, the authors reconstructed the PTM BGC with strong constitutive promoters inserted
in front of each gene and heterologously expressed the refactored BGC in S. lividans strain 66.
This study suggested that the native IFO13350 PTM BGC was silent, and that promoter rewiring
could be an effective way to activate silent PTM BGCs PTMs. A further study in 2015 by the
same group used an optimized combination of promoters to increase PTM production (108).
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Figure 3. Maximum likelihood phylogenetic tree of selected S. griseus clade strains. S. griseus
strain IFO13350 and Streptomyces sp. strain JV180 are highlighted red. atpD, gyrB, recA, rpoB,
and trpB sequences of previously established S. griseus clade strains were taken from previous
published lists (142, 143). S. griseus clusters I-IX, as defined by Rong et al (142, 143) were
represented in the tree. Sequences were aligned with MUSCLE and the alignments were
concatenated. The maximum likelihood tree was built using the GTR+I+G model using CLC
Main Workbench. Branches supported by less than 50% of 500 bootstrap simulations were
collapsed.

Interestingly, one of the soil-derived Streptomyces strains isolated by Blodgett et al. that
exhibited robust PTM production, strain JV180, is phylogenetically closely related to S. griseus
strain IFO13350, with >99% identical 16S rRNA sequences (Figure 3). These strains both
belong to the S. griseus clade, a large group of strains with highly identical 16S rRNA, which
have been heavily sampled in drug-discovery screens (142, 143). Many S. griseus clade strains in
the Northern Regional Research Laboratory (NRRL) culture collection run by the U.S.
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Agricultural Research Service had their genomes sequenced and published in 2015 as part of a
project working to mine actinomycete genomes for phosphonate natural products (144). Many of
these genome-sequenced S. griseus clade strains also possess PTM biosynthetic clusters on their
chromosomes, further demonstrating how widespread this biosynthetic cluster. Indeed, when
PTM production by strains IFO13350, JV180, and eight other S. griseus clade strains from
NRRL (JV251-JV258) were compared, four strains had active PTM BGCs while the others,
including strain IFO13350, had silent PTM BGCs (Figure 4A). Similarly, when I characterized a
panel of strains containing the newly discovered clifednamide-type PTM BGC, I found that some
strains barely produced trace amounts that could only be detected by highly sensitive LCMS/MS while other strains produced over 20 µM (Figure 4B). These observations show that
PTM biosynthesis may be a highly suitable model system for studying the underlying differences
between active and silent BGCs. Recently, a similar study demonstrated the potential of such
comparative approaches by using comparative transcriptomic analysis to study factors that
caused differences in the expression of conserved BGCs in four strains belonging to the marine
actinomycete genus Salinispora (145). However, this study highlighted changes in CSRs as
possible causes for the observed differences in transcription of BGCs, and such a model likely
does not apply to silent PTM BGC as they lack CSRs.
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Figure 4. PTM BGCs may be active or silent. LC-MS chromatograms of PTM production by (A)
a panel of strains with clifednamide BGCs and (B) S. griseus clade strains with ftdABCDEF
BGCs, including strains IFO13350 and JV180. Panel A was adapted from reference (146).

1.6 Regulation of PTM biosynthesis
Due to the recent discovery of the PTM BGC, there is relatively scant knowledge regarding how
these BGCs are regulated. While many other BGCs in Streptomyces are regulated by CSRs,
which are in turn regulated by global transcriptional regulators, PTM BGCs do not appear to
contain a conserved CSR. The lack of CSRs may be due to the genetic simplicity of PTM BGCs,
which eliminates the necessity for such proteins. Here, I will review prior studies related to the
regulation of PTM BGCs.

1.6.1 AdpA, a global quorum-responsive regulator, may regulate the PTM
BGC of S. griseus strain IFO13350
A genome-wide survey of AdpA binding sites suggested that the PTM biosynthetic cluster of S.
griseus strain IFO13350 was directly regulated by the global transcription factor AdpA, which is
part of the A-factor regulatory cascade (147). In addition to an AdpA binding signal from ChIPSeq, transcription of the PTM biosynthetic gene cluster was reduced in a ΔadpA mutant.
However, as S. griseus strain IFO13350 was not known to produce PTMs, this connection went
ignored. A-factor (2-isocapryloyl-3R-hydroxymethyl-γ-butyrolactone) was originally discovered
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in 1967 as a diffusible extracellular molecule that caused sporulation and streptomycin
production in bald mutants of S. griseus (148).
As the concentration of A-factor molecules increases, they bind ArpA (A-factor receptor protein
A), which is a transcriptional repressor of adpA (Figure 5). Binding of A-factor to ArpA causes a
conformational shift and causes it to dissociate from the adpA promoter, allowing for the
expression of AdpA (A-factor dependent protein A). AdpA then binds to numerous promoters
and acts as a transcriptional activator. In S. griseus, AdpA is estimated to directly bind to and
regulate transcription from hundreds of promoters (147). These promoters control genes involved
in numerous processes including differentiation and secondary metabolism. AdpA also appears
to repress its own transcription. This is supported by AdpA binding to its own promoter in vitro
and repressing transcription in an in vitro runoff transcription experiment (149). AdpA may also
repress A-factor production, as evidenced by a ΔadpA mutant producing ten times more A-factor
than the wild-type strain (150). However, transcription of afsA was not affected, so the
mechanistic link is still unclear. AdpA also forms a positive feedback loop with bldA, which
encodes for a rare leucine codon tRNA that is present in adpA (151).
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Figure 5. The A-factor regulatory cascade.

A-factor is produced in a growth-dependent manner and reaches maximum concentration during
late stationary phase, after which it rapidly disappears (152). A-factor is produced from 8methoxy-3-oxononanoyl-ACP (a fatty acid derivative) and dihydroxyacetone phosphate (a
glycolysis intermediate) and involves the enzymes AfsA (A-factor synthase A) and BprA
(butenolide phosphate reductase A), which appear to form a two-gene operon, and a non-specific
phosphatase (153). A BprA-independent pathway has also been observed in cell-free lysate and
feeding experiments of ΔbprA mutants. Since the discovery of A-factor, numerous other
diffusible signaling molecules have been characterized in various other Streptomyces strains,
including similar γ-butyrolactones, butenolides, and 2-alkyl-4-hydroxymethylfuran-3-carboxylic
acids (154).
AdpA contains a N-terminal ThiJ/PfpI/Dj1-like dimerization domain and a C-terminal
AraC/XylS-type DNA-binding domain. Consistently, AdpA dimerizes in solution and usually
binds as a dimer to its target promoters (155). AdpA binds the consensus sequence
TGGCSNGWWY. A structural study has shown that AdpA only directly interacts with the
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second and fourth nucleotides in its operator consensus sequence, which explains the high degree
of degeneracy in its consensus sequence (156). This is likely related to the large number of
promoters that AdpA regulates.
AdpA homologs are found in many Streptomyces strains, though not all. Although the full extent
of the AdpA regulon in other Streptomyces strains have not been explored as thoroughly as in S.
griseus, many studies have shown that AdpA homologs directly control the expression of
biosynthetic gene clusters in many Streptomyces. For example, S. coelicolor A3(2), the most
extensively studied Streptomyces model strain, contains one AdpA homolog, AdpA-c. adpA-c
(also known as bldH), is required for morphological differentiation and production of the
antibiotic actinorhodin (157, 158). However, AdpA-c also appears to inhibit production of
undecylprodigiosin. Furthermore, adpA-c is not controlled by γ-butyrolactones. These
observations show how AdpA homologs in various Streptomyces have evolved to occupy
different roles in their gene regulatory networks.

1.6.2 Other studies on PTM regulation
Recently, the ikarugamycin PTM BGC of S. xiamenensis strain 318 was reported to be regulated
by the AdpA homolog of this strain (159, 160). The authors observed that the AdpA protein of S.
xiamenensis appears to have diverged from its well-studied homologs in S. griseus and S.
coelicolor by sequence-based phylogenetic analysis. Furthermore, while AdpASg and AdpASc
upregulate genes for morphological differentiation, AdpASx appears to repress morphological
differentiation genes as well as transcription of the PTM BGC. In another study in S.
xiamenensis strain 318, three genes were found to upregulate PTM BGC transcription when they
were overexpressed (161). However, these proteins did not directly bind the promoter region of
the PTM BGC, so it is unclear how they indirectly upregulate PTM production. Finally, several
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studies have examined the regulation of the HSAF BGC in Lysobacter enzymogenes, which will
not covered here in detail as it is unlikely that similar regulatory mechanisms are conserved
across bacterial phyla (162–168).
Several studies have used commonly applied synthetic biology strategies such as promoter
replacement and heterologous expression to activate silent PTM BGCs (Table 1). One example is
the PTM BGC belonging to S. albus strain J1074. This strain is a derivative of S. albus strain G,
lacking the SalI restriction and modification enzymes, which makes it more genetically tractable,
and has a compact genome of 6.8 Megabases (169). S. albus strain J1074 has been used as a
heterologous host for antibiotic production in numerous studies, which have been reviewed
elsewhere (127). A PTM BGC was identified in the genome sequence of S. albus strain J1074 in
2010 (130), but this strain had not been reported to produce PTMs previously, like S. griseus
strain IFO13350. Insertion of the strong constitutive promoter PermE* in front of either the first
ORF, encoding the sterol desaturase, or the second ORF, encoding the iPKS-NRPS, resulted in
strongly increased production of 6-epi-alteramide A and 6-epi-alteramide B (170). This led the
authors to also realize a small peak for 6-epi-alteramide A could also be found in extracts from
wild-type S. albus strain J1074. Additionally, a gene encoding for a LuxR-type transcriptional
regulator was found approximately 7.6 kilobases upstream of the cluster. When this protein was
overexpressed on a high-copy number plasmid, PTM production was strongly upregulated.
However, the gene encoding the LuxR-type regulator is not co-localized with PTM biosynthetic
gene clusters in strains aside from S. albus, and further studies would be required to investigate
whether this protein directly or indirectly regulates the PTM BGC of S. albus strain J1074.
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Table 1. Previous studies focused on activation of silent PTM biosynthetic gene clusters.
Source of PTM BGC
Strategy used
Ref
S. griseus IFO13350
Heterologous expression in S. lividans and (140)
promoter replacement
(108)
S. albus J1074
Promoter replacement or overexpression of (170)
LuxR-family regulator sshg_05706
(64)
Transposon library screening with PTM
promoter-reporter fusion construct
(171)
S. pactum SCSIO 02999
Promoter replacement
S. roseosporus NRRL
Promoter replacement by CRISPR
(114)
15998
(172)
S. sp. S10
Heterologous expression in S. sp. LZ35derived host and promoter replacement
(173)
Umezawaea sp. RD066910 Co-culture with Tsukamurella pulmonis
TP-B0596
(174)
S. somaliensis SCSIO
Media optimization
ZH66

Another study in S. albus strain J1074 examined transcriptomic data and found that the PTM
BGC appeared to be poorly transcribed compared to the overall transcriptome (64). Transposon
mutagenesis was used to identify genes that affected expression of a reporter gene fused
downstream of the PTM promoter. This resulted in the identification of XNR_3174, which
encodes a transcriptional regulator which appears to downregulate several secondary
metabolites. The protein encoded by XNR_3174 may be part of a butanolide-sensing regulatory
system in S. albus. However, further experiments are needed to determine if the product of
XNR_3174 directly regulates the S. albus PTM BGC.

1.7 An introduction to PTM biosynthesis
In the course of collecting PTM biosynthetic gene cluster sequences for promoter comparisons, I
noticed a marked difference in the gene content between certain strains. I hypothesized that
closer analysis of the enzymes encoded by different PTM biosynthetic gene clusters and the
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molecules produced by these strains could help shed light on the biosynthetic pathway of PTMs
and identify novel PTM-modifying enzymes. These findings can contribute to engineering of
novel PTM structures molecules by combining PTM genes from various BGCs. This could
produce PTMs with increased inhibitory activity or novel targets. Here, I will briefly summarize
the results of publications by other groups on the roles of various enzymes on PTM biosynthesis.
In Chapters 4-6, I will detail the hypotheses I developed from my own analyses and the
experiments that were performed to test some of the hypotheses using available strains.

1.7.1 PTM biosynthesis begins with an iterative polyketide synthase/nonribosomal peptide synthetase fusion protein
PTM biosynthesis begins with an iterative polyketide synthase/non-ribosomal peptide synthetase
fusion protein (iPKS-NRPS), which has been named FtdB, IkaA, CbmA, or PtmA in various
systems. Polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs) are
modular enzymes which work like assembly lines to combine and modify various precursors to
produce the scaffold of many natural products. PKSs are evolutionarily and functionally related
to fatty acid synthases and polymerize acyl-CoA precursor molecules, and NRPSs function
similarly but use amino acid substrates. Unlike fatty acid synthases and ribosomes, PKSs and
NRPSs can use various acyl-CoA molecules and non-proteinogenic amino acids precursor
molecules. Additionally, PKS modules may omit some of the domains required to completely
reduce the carbon-carbon bonds between each subunit unlike fatty acid synthases, which usually
produce completely saturated fatty acids. Finally, both PKSs and NRPSs can have domains for
further chemical modifications. These features allow them to produce complex and diverse
chemical structures. Iterative polyketide synthases are very similar to fatty acid synthases and
use one set of enzymatic domains to produce a polyketide chain.
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Figure 6. The iterative polyketide synthase module uses twelve malonyl-CoA molecules to build
two polyene chains. Shown here are the steps for the formation of the first polyene chain.
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This protein is notably one of few iterative polyketide synthase found in Streptomyces, although
recent genomic analyses suggest that more exist than previously thought (175). In vitro studies
on the iPKS-NRPS of the Lysobacter enzymogenes strain C3 HSAF cluster has shown that one
L-ornithine and twelve malonyl-CoA precursor molecules are used to produce a polyene
intermediate, which has been named lysobacterene A (176). The iPKS module uses one set of
acyltransferase (AT), acyl carrier protein (ACP), ketosynthase (KS), ketoreductase (KR), and
dehydratase (DH) domains to create two 12-carbon polyene chains (Figure 6). After the first
polyene chain is formed, the condensation (C) domain of the NRPS module forms a peptide bond
between it and the amine group in the side chain of the nonproteinogenic amino acid L-ornithine
loaded on the peptidyl carrier protein (PCP) domain by the adenylation (A) domain (Figure 7).
The iPKS module then produces a second polyketide chain, which interestingly retains an extra
unreduced ketone group. A second peptide bond is formed between the second polyketide chain
and the backbone amine group of the ornithine. Finally, the thioesterase (TE) domain catalyzes
an intramolecular cyclization between the carboxyl group of the ornithine and the second
polyketide chain, producing a tetramic acid ring.
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Figure 7. The iPKS-NRPS attaches two polyene chains to an L-ornithine molecule, which
undergoes an intramolecular cyclization to produce a tetramic acid on release.
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1.7.2 The PTM cyclization cascades
After the production of the intermediate lysobacterene A, a series of oxidoreductases catalyze the
cyclization of the two polyene chains. PTMs can have systems such as 5-5, 5-5-6, 5-6-5 carbon
ring systems with differing stereochemistry, which was recently shown to be dependent on the
oxidoreductase enzymes encoded for by their BGCs (177, 171, 172, 178). A recent study
showed that a 5-6-5 ring system PTM producer could be engineered to produce 5-5-6 ring
system PTMs by replacing the oxidoreductases in its BGC with those from a 5-5-6 ring system
producing PTM BGC (179).
Ikarugamycin, the first PTM to be discovered, is a prototypical 5-6-5 carbon ring system PTM
(137). Ikarugamycin was found to be produced by a three-gene BGC, ikaABC, where IkaA is the
iPKS-NRPS which produces the intermediate lysobacterene A (180). IkaB is an oxidoreductase,
whose homologs are often annotated as phytoene dehydrogenases, and contains a Rossman-fold
NAD(P)H binding domain. IkaC is another oxidoreductase, whose homologs are often annotated
as alcohol dehydrogenases. The functions of IkaB and IkaC were tested in mutant studies by
cloning the ikaABC biosynthetic gene cluster of Streptomyces sp. strain ZJ306 and
heterologously expressing truncated biosynthetic gene clusters in S. lividans strain TK64 (177).
These experiments revealed that IkaB catalyzes the formation of a 5-6 carbon ring intermediate
(Figure 8). In an NADPH-dependent mechanism, IkaC forms the final 5-carbon ring through a
Michael addition mechanism, which also results in the isomerization of a trans C=C bond to a cis
C=C bond. There are examples of PTM biosynthetic gene clusters which contain ikaAB
homologs in addition to other tailoring enzymes. The strains containing these clusters would
presumably produce PTMs with only a 5,6-carbon ring system.
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Figure 8. Proposed biosynthetic pathway for ikarugamycin.

Dihydromaltophilin, which is also known as Heat-Stable Antifungal Factor (HSAF), is the 5-5-6
carbon ring system PTM whose biosynthesis has been studied the most extensively is. The
HSAF biosynthetic gene cluster in Lysobacter enzymogenes strain C3 encodes for a sterol
desaturase, an iPKS-NRPS, and four oxidoreductase genes, OX1-OX4. In addition, two genes
encoding for a ferrodoxin reductase and an arginase upstream of the sterol desaturase and on the
opposite DNA strand appear to support increased HSAF production but are not required for
HSAF biosynthesis. Extensive genetic and biochemical studies have shown how OX1-4 produce
the 5-5-6 carbon ring system of HSAF (131, 181, 178, 182) (Figure 9). OX1-OX3 are similar in
amino acid sequence to IkaB. Genetic studies have shown that OX3 acts first and forms a 5carbon ring with loose stereospecificity. Depending on the stereochemistry of the 5-carbon ring,
either OX1 or OX2 form a second 5-carbon ring. Finally, OX4, is a homolog of IkaC, and gives
rise to a 6-carbon ring, resulting in a 5-5-6 carbon ring system.
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Figure 9. Proposed biosynthetic pathway for 5-5-6 ring system PTMs in Lysobacter
enzymogenes strain C3.

The biosynthetic clusters for many other 5-5-6 carbon ring system PTMs which have been
characterized such as frontalamides, pactamides, and combamides contain two IkaB homologs.
FtdD, PtmB2, and CbmC are all homologs of OX3 and presumably carry out the same function
to form the first 5-carbon ring. FtdC, PtmB1, and CbmB are all homologs of OX1 and OX2, and
presumably form the second 5-carbon ring. Finally, FtdE and PtmC are homologs of OX4 and
presumably form the final 6-carbon ring. Some biosynthetic gene clusters lack OX4 homologs,
such as the combamide biosynthetic gene cluster (172). It is also noteworthy that the 5-5-6
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carbon ring systems of frontalamides, pactamides, combamides, and HSAF have some differing
stereochemistries, suggesting slight differences between the oxidoreductases in these BGCs.
Another interesting difference is that while OX1, OX2, and FtdC add a hydroxyl group adjacent
to the 5-5 carbon ring system in a cylization-coupled mechanism, PtmB and CbmB do not appear
to (183).

1.7.3 PTM tailoring reactions
After their cyclization, PTMs can be modified by various tailoring enzymes. One of the most
commonly found modifications on PTM molecules is the addition of the hydroxyl group on the
macrolactam ring, adjacent to the tetramic acid. This hydroxylation has been found in PTMs with
5-5, 5-5-6, and 5-6-5 carbon ring systems. This modification is added by a sterol desaturase,
which is often encoded for by the first gene in PTM biosynthetic gene clusters (Figure 10). The
role of this enzyme was first demonstrated in HSAF production by Lysobacter enzymogenes
strain C3 (184). This hydroxylation was required for the antifungal activity of HSAF against test
organisms such as Penicillium avellaneum, which demonstrates the importance of this
modification and may explain why the sterol desaturase is so widely conserved in biosynthetic
gene clusters that produce diverse PTM molecules. They also found that the product of the
ferrodoxin reductase gene that is co-localized with the HSAF biosynthetic gene cluster
significantly enhanced the activity of the sterol desaturase.
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Figure 10. A sterol desaturase (FtdA) adds a commonly found hydroxylation to PTMs.

In the subsequent study, the sterol desaturase homologs of Lysobacter capsisi strain DSM 19286
and Saccharophagus degradans strain DSM 17024 were shown to add the same hydroxylation to
the 5-6-5 carbon ring system PTM, ikarugamycin (185). These experiments also demonstrated
the promiscuity of the sterol desaturases as the sterol desaturase from a biosynthetic gene cluster
for a 5-5-6 carbon ring PTM was functional on a 5-6-5 carbon ring PTM substrate. The sterol
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desaturases in other PTM biosynthetic clusters have been named FtdA, PtmD, CbmE, and such.
However, some PTM clusters lack a sterol desaturase homolog.
Aside from FtdA, many PTM biosynthetic gene clusters encode for cytochrome P450 enzymes
such as FtdF, IkaD, CftA, and CbmD. Some of these cytochrome P450 enzymes, such as CftA
and IkaD, have been reported to modify PTMs in various ways (Figure 11). The functions of
other cytochrome P450 enzymes have not been fully characterized, but they may add slightly
different modifications. Aside from other cytochrome P450 enzymes, there are likely other PTMtailoring enzymes that have yet to be discovered, such as halogenases and methyltransferases,
based on published structures of PTMs (186, 187). A more comprehensive understanding of
PTM biosynthesis could allow for the engineering of PTM BGCs with genes from different
strains, which could be tailored for new structures.

Figure 11. Tailoring of ikarugamycin by two cytochrome P450 enzymes, IkaD and CftA.
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1.7.4 PTM metabolomics
Due to structural similarities between PTMs, similar methods can be used to analyze PTMs
produced by a variety of organisms. PTMs are commonly detected by UV absorbance in HPLC
analysis. All PTMs with either 5-6-5 or 5-5-6 carbon ring systems have absorbance maxima at
approximately 222 nm and 322 nm. On the other hand, PTMs with 5-6 or 5-5 carbon ring
systems, which may be intermediates or terminal products depending on the oxidoreductases
encoded by their BGCs, have absorbance maxima at approximately 270 and 365 nm instead.
Such methods for PTM detection tended to be used in earlier studies of PTMs and were useful in
identification of PTMs by matching peak absorbance spectra to known compound libraries (130,
188). Liquid chromatography coupled mass spectrometry (LC-MS) has also been frequently used
for PTM detection.
As part of this thesis, we developed several metabolic tools for improved detection of novel
PTMs in uncharacterized strains. Firstly, since all PTMs require the non-proteinogenic amino
acid L-ornithine, we could add deuterium or 13C-labeled L-ornithine to growth media. Our lab
has found that many actinomycetes are able to uptake exogenous ornithine and directly
incorporate them into NRPS products (189). The appearance of additional peaks in the mass
spectra due to the heavier isotopes helped identity putative PTM peaks as ornithine-incorporating
molecules. Secondly, we also took advantage of the fact that the tetramic acid-containing
macrolactam ring of most PTMs is the same in almost all PTMs and that diversification of PTM
structures mostly occurs in the polycyclic portion of PTMs, except for a commonly found
hydroxylation adjacent to the tetramic acid moiety. Using tandem mass spectrometry (MS/MS),
were able to identify common daughter ions produced from both hydroxylated and nonhydroxylated PTMs by collision-induced dissociation (Figure 12). This method greatly improved
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sensitivity for PTMs by filtering out most parent ions that did not fragment into daughter ions
that were indicative of PTM structures. This method was also compatible with the previously
described isotopic L-ornithine feeding, as the tetramic acid is derived from the ornithine
precursor. One caveat to the usage of LC-MS/MS filtering is that changes to the tetramic acidcontaining fragment would result in different daughter ions. A few PTMs are known to undergo
a N-methylation on the tetramic acid, which would make the molecules undetectable by the
current version of the method (186). However, to this day, the BGC for these PTMs have not
been characterized, and none of the PTM BGCs described in this thesis have nearby N- or Omethyltransferases. Nevertheless, the precursor ion scan method should be adaptable to include
N-methylated PTMs, should the need arise.

Figure 12. LC-MS/MS can be used to identify diverse PTMs through common daughter ions
produced in collision-induced dissociation. Atoms derived from ornithine, which can be fed in
isotopic labeling experiments, are indicated in red.
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1.8 Conclusions
Streptomyces and related bacteria were once the focus of intense screening by pharmaceutical
companies, which yielded over half of all clinically used antibiotics and numerous other drugs.
Recent advances in whole-genome sequencing and bioinformatic tools has revealed that the
genomes of these organisms contain many more BGCs for drug-like compounds than previously
known. However, many of these BGCs are apparently silent in laboratory cultures, posing a
major roadblock to genomics-based drug discovery. Researchers have developed various
approaches to activate these BGCs, which are thought to be downregulated. These include
screening for various factors which can trigger increased expression from these BGCs as well as
leveraging the growing synthetic biology toolkit to replace the native regulatory elements of
these BGCs.
Although these approaches have resulted in the discovery of numerous new molecules, none of
them are universally applicable to all BGCs and activating a silent BGC can still be a laborious
process. Additionally, the reason some BGCs are silent while others are active remains largely
unaddressed. A better understanding of why active and silent BGCs are different could
streamline genomic-based discovery by predicting which BGCs should be expressed as well as
help develop new engineering strategies to activate silent BGCs. In this work, I used the widely
conserved BGC for PTMs as a study system to try to address this and other questions: 1) How do
mutations in promoter sequences result in active and silent PTM BGC expression? 2) Are there
other genetic changes that affect PTM BGC expression? 3) How do genetic changes in PTM
BGCs affect the structures of PTM molecules.
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Chapter 2: Genetic Variations in
Transcriptional Regulation of Polycyclic
Tetramate Macrolactam Biosynthesis
This chapter was previously submitted in the journal Proceedings of the National Academy of
Sciences, and is currently in revision after undergoing peer review:
Qi Y., Nepal K. K., and Blodgett J. A., A Comparative Metabologenomic Approach Reveals
New Mechanistic Insights into Streptomyces Antibiotic Crypticity, PNAS (In revision).

2.1 Personal contribution
S. griseus strain IFO13350 and eight other S. griseus clade strains (JV251-258) were obtained
from the Agricultural Research Service culture collection (NRRL – Northern Regional Research
Laboratory). Strains JV180 and SP18CM02 are soil isolates (see Chapter 6). Dr. Nepal, who
joined the Blodgett lab postdoc in late 2018, and I each designed and generated roughly half of
all strains, plasmids, and oligonucleotides described in this manuscript (see Tables S1-S3). I
performed the phylogenetic, LC-MS/MS, and RT-qPCR analyses. Dr. Nepal cloned, expressed,
and purified AdpA and performed the EMSA assays. Dr. Nepal, Dr. Blodgett, and I wrote the
manuscript.

2.2 Abstract
Streptomyces genomes harbor numerous biosynthetic gene clusters (BGCs) encoding for druglike compounds. While some of these BGCs readily yield expected products, many do not.
Biosynthetic crypticity represents a significant hurdle to drug discovery, and the biological
mechanisms that underpin it remain poorly understood. Polycyclic tetramate macrolactam (PTM)
antibiotic production is widespread within the Streptomyces genus, and examples of active and
cryptic PTM BGCs encoded by Streptomyces griseus are known. To reveal new insights into the
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causes of biosynthetic crypticity, we employed a PTM-targeted comparative metabologenomics
approach to analyze a panel of S. griseus strains that included both poor and robust PTM
producers. By comparing the genomes and PTM production profiles of these strains, we
systematically mapped PTM promoter architecture within the group, revealed that these
promoters are directly activated via the global regulator AdpA, and discovered that small
promoter indels differentiate weaker PTM producers from stronger ones. We also revealed an
unexpected link between robust PTM expression and griseorhodin pigment co-production, with
weaker S. griseus PTM producers being unable to produce the latter compound. This study
highlights promoter indels and biosynthetic interactions as important genetically encoded factors
that impact BGC outputs, providing mechanistic insights that will undoubtedly extend to other
Streptomyces BGCs as well. We highlight comparative metabologenomics as a powerful
approach to expose genomic features that differentiate strong antibiotic producers from weaker
ones. This should prove useful for rational discovery efforts and is orthogonal to current
engineering and molecular signaling approaches now standard in the field.
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2.3 Introduction
Many therapeutics derive from natural products and their synthetic analogs (1). Historically,
Streptomyces and related actinobacteria were heavily screened for these molecules, which
resulted in numerous essential medicines. These include many clinical antibiotics (2), and there
is an urgent need for new anti-infectives to counter increasing drug-resistance (3). A massive
reservoir of uncharacterized biosynthetic gene clusters (BGCs) encoding drug-like molecules
resides within Streptomyces genomes, which has triggered resurgent interest in these organisms
(4). However, a large proportion of these BGCs fail to produce detectable expected compounds
under laboratory conditions. This phenomenon of cryptic or silent metabolism thus poses a
significant hurdle to genomics-driven drug discovery (5, 6). Silent BGCs are often thought to be
transcriptionally deficient, and synthetic biology, cell signaling, and stress mechanisms are
commonly used to activate silent BGCs for molecule discovery (7). However, a deeper
mechanistic understanding of Streptomyces silent metabolism is still needed to access the full
biosynthetic potential of these organisms to overcome the drug discovery gap (8).
Here, we employed a comparative metabologenomic approach to dissect why certain
Streptomyces strains are ready antibiotic producers while others have apparently silent BGCs.
Polycyclic tetramate macrolactam (PTM) antibiotics were specifically targeted in this study
because they provide an opportune model system for multi-strain comparative analyses. This is
because PTM BGCs are atypically common within Streptomyces genomes compared to most
other antibiotic families, and this commonality is leverageable for deep trait comparisons
between several individual producers. The environmentally and biotechnologically- important
Streptomyces griseus clade (9) was identified as a particularly advantageous cohort for these
comparisons; multiple strains within it have established active or cryptic PTM BGCs (10, 11),
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plus several additional family members with sequenced genomes and yet-unstudied PTM
clusters were available from public collections. Finally, PTM biosynthesis is increasingly
understood, and this foundational knowledge was necessary to enact a targeted metabolomics
approach to document sensitive production differences. PTMs have experienced intense study
towards understanding their unusual hybrid non-ribosomal peptide/polyketide origins,
investigating PTM therapeutic potential, and leveraging their ease of manipulation via synthetic
biology (12).
This study was initiated by comparing the genomes and PTM production profiles among a cohort
of PTM locus-bearing S. griseus strains, which included known examples of both strong and
poor PTM producers. This led to the discovery a S. griseus phylogenetic subclade that has
consistently higher PTM production and PTM BGC promoter strengths compared to the rest of
the test strains. Despite the exceptional commonality of PTM biosynthetic loci in Streptomyces
bacteria, PTM regulation remains poorly understood. To reveal how promoter sequence
variations might underpin the observed PTM phenotype differences, the promoter driving
production in the robust producer Streptomyces sp. strain JV180 was thus mapped and compared
against the rest of the clade. Overall, many promoter features appeared to be largely conserved
within the group, regardless of host-strain PTM capability. Additionally, the global regulator
AdpA was confirmed to play a direct positive role on PTM locus control through gene deletion,
binding site mutation, and in vitro binding experiments. AdpA binding sites were detected in the
PTM promoters of all tested clade members, where they display a contextually unusual
arrangement downstream of promoter -10 boxes. Critically, comparisons of strong and weak
PTM promoters from several S. griseus clade members identified a 2-3 bp indel, located between
the −10 box and AdpA operator site, that strongly influences PTM production strength. Yet
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another PTM control mechanism that differentiates weak from stronger PTM producers was
discovered following the mutagenesis of strain JV180’s griseorhodin BGC. Weak S. griseus
clade PTM producers natively lack griseorhodin BGCs, and loss the JV180 cluster severely
curtailed PTM production. Further dissection revealed that strain JV180s PTM production likely
benefits from PTM-griseorhodin co-expression via a yet-uncharacterized transcriptional
mechanism. In sum, this work revealed two new mechanisms by which stronger and weaker
PTM producers are differentiated, and it highlights the application of targeted comparative
metabologenomics to cohorts of highly related strains to successfully reveal otherwise difficultto-detect genomic features that tune antibiotic production.

2.4 Results
2.4.1 The S. griseus clade is an ideal model group to compare and reveal
genetic underpinnings of PTM crypticity
Several features of the S. griseus clade make the group attractive for comparison-based
approaches to reveal BGC silencing mechanisms. Clade-member Streptomyces sp. strain JV180
is a ready producer of the compounds (10, 13), while S. griseus subsp. griseus strain IFO13350
harbors a silent PTM BGC (11, 14). The PTM production status of most other clade members
remained unknown, and to benefit from the increased analytical depth afforded by expanded
cohort sizes, several additional clade-members having PTM loci in their sequenced genomes (15)
were obtained from public strain repositories (JV251-JV258). To complete the cohort, the
environmental clade-member Streptomyces sp. strain SP18CM02, whose genome was recently
reported by our group was also added (13) (Table S1). The close phylogenetic relationships of
these strains were confirmed through multi-locus phylogeny (9) (Fig. S1). Further, the exact
synteny observed among their PTM coding regions (Fig. 1A) and the high pairwise PTM enzyme
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sequence identities encoded within each strain indicate that their PTM BCGs are orthologous
(Table S4).

Figure 1. Differences in S. griseus PTM production correlate with putative PTM promoter
region sequence variation. (A) In all tested S. griseus strains, the PTM locus is comprised of a
conserved set of genes ftdA-F. The non-PTM upstream and downstream genes in all test strains
respectively encode a cysteine desulfrase (ORF -1) and mandelate racemase (ORF +1). (B) PTM
production is most robust on solid media (blue bars, n = 3) versus when strains are grown liquid
(brown bars, n = 4) media. PTM quantification in each was obtained by normalizing the sums of
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LC-MS/MS PTM peak areas by protein content, and then plotted relative to the PTM production
by strain JV180 grown on solid media. n.d. = not detected. (C) Neighbor-joining tree of PftdA
region sequences extracted from the intergenic region upstream of each strain’s ftdA gene. This
tree indicates that PftdA sequences of JV180-like strains form a separate group from the other
(IFO13350-like) PftdA’s. The analogous PftdA region of Streptomyces albus strain J1074 was used
as an outgroup. These intergenic region sequences were aligned with MUSCLE and the tree was
built using the Kimura substitution model in CLC Main Workbench. Branches supported by less
than 50% of 500 bootstrap simulations were collapsed. (D) PTM production resulting from nonJV180 PftdA regions (source strains on X axis) swapped into JV180 for functional analyses (n =
3). (E) Relative ftdB transcript abundance from JV180 promoter-swapped strains in panel D (n =
6, except JV1178 where n = 3). From these data, a clear trend emerges where strains and their
PftdA-region promoters sourced from the S. griseus group that includes JV180 (green highlights,
panels A-D) yield higher PTM production and transcription compared to the rest of the tested S.
griseus most closely related to IFO13350 (red highlights, panels A-D).

To assess and compare PTM production in these strains, the robust PTM-producing strain JV180
served as an archetype. Strain JV180 PTM production was extensively analyzed using
approaches similar to those reported for clifednamide-type PTM analyses in other Streptomyces
by our group (16). Putative PTM peaks were identified using 13C5-labeled ornithine precursor
incorporation and diagnostic daughter-ion production following collision-induced dissociation in
liquid-chromatography coupled tandem mass spectrometry (LC-MS/MS). These target the
conserved ornithine-derived tetramate region, which has two possible hydroxylation states (see
Fig. S2B-E, S3). As expected, all PTM peaks identified through these methods were absent when
the JV180 PTM BGC was deleted (ΔftdABCDEF; Fig. 1A, S2A), yielding a high-confidence set
of S. griseus clade PTM congeners for quantitative production comparisons.
The remaining S. griseus clade strains were then grown under several growth conditions, and
their extracts were analyzed via LC-MS/MS and UV spectrometry for PTM production (see
Methods). As expected from orthologous PTM BGC’s, all producing strains gave PTM signals
that largely overlapped with those established in JV180, but strain-to-strain differences in
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quantity and relative PTM congener ratios were observed. From these comparative PTM
production data, an interesting trend emerged. Strains JV180, SP18CM02, and JV251-253
displayed robust PTM production while the remaining strains generally showed little production
(Fig. 1B, S4-S6). We noted that these strains belong to a distinct subclade on the S. griseus
phylogenetic tree (Fig. S1, group VI in green), suggesting they might share a conserved genetic
basis for increased PTM production versus the other studied clade-members. Interestingly, these
comparative production analyses revealed a clear bias for higher PTM production on solid media
over shake-flask cultures for all tested strains (Fig. 1B). The strongest PTM producers continued
to have the highest production in liquid media as well. Throughout, to obtain consistent
transcriptional information, liquid media was used. Further, in agreement with prior publications,
PTM production could be detected by UV absorbance in JV180 (10), while strain IFO13350
produced insufficient PTMs for detection using this method (Fig. S7A). In contrast, our PTM
targeted LC-MS/MS analyses revealed detectable production in all tested clade members, but the
amounts varied widely by strain. This suggests prior efforts to characterize weak PTM producers
may have overlooked scant actual production due to inherent UV limitations, overcome here by
MS/MS methodology (Fig. S7B, C).

2.4.2 PTM promoter sequence heterogeneity contributes to differences in
antibiotic production
Because the most robust PTM production was found in strains of the JV180 subclade, we
hypothesized that comparing these genomes against other S. griseus strains could reveal specific
differences that underpin the observed production disparities. PTM BGC transcriptional
differences were immediately targeted as a potential mechanism. While weak transcription is
often implicated in the cryptic biosynthesis literature, this assertion is often speculative or left
without mechanistic investigation (17). The possibility of PTM biosynthetic enzyme defects in
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some strains was ruled out as a potential cause. This is because all tested strains have high PTM
BGC protein-sequence identity (Table S4), and previous transcriptional refactoring experiments
were able to successfully activate the cryptic PTM BGC of strain IFO13350 in heterologous
hosts as a demonstration of BGC functionality (11, 14).
Possible strain-linked differences in PTM BGC transcription were initially explored by
comparing the presumed PTM promoter regions of each strain tested here. S. griseus PTM BGCs
have a simple and conserved gene arrangement with minimal intergenic gaps, suggestive of a
single operon (Fig. S8A). PCR amplification of cDNA intergenic junctions confirmed that the
JV180 PTM BGC is transcribed as a single operon (Fig. S8B).
Phylogenetic analysis of the ~500 nt located upstream of the first gene in each studied PTM
BGC, ftdA, formed two groups: one by JV180-like strains and one by the remaining strains
(these sequences are hereafter referred to as JV180- or IFO13350-like PftdA’s, respectively; Fig.
1C, S9). To test if the sequence differences in PftdA regions are transcriptionally relevant, we
leveraged the strong PTM producer JV180. JV180 represents a uniform background to eliminate
complicating metabolic and genetic variables inherent to strain-to-strain comparisons. After
replacing the native promoter region of JV180 with the corresponding region of the other 10 S.
griseus strains in this study, we observed higher PTM production and ftdB transcription from
JV180-like PftdA’s than IFO13350-like PftdA’s (Fig. 1D, E). This supports the idea that stronger
PTM producers might result from inherently stronger promoters. Surmising that the basic
transcriptional machinery of all S. griseus strains should be highly similar, we also hypothesized
that if JV180-like PftdA’s are stronger than IFO13350-like PftdA’s, then introducing the former
promoter type into strain IFO13350’s PTM BGC should increase PTM production and
transcription. However, exhaustive attempts to introduce the necessary plasmids to engineer
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increased production in IFO13350 (and other group member JV257; Fig. S1) failed by both
conjugation and protoplast transformation. Instead, the effects of PftdA sequence variation were
assayed in strain IFO13350 using a xylE (18) reporter gene chromosomally integrated into the
ΦC31 site. Controls testing the efficacy of colorimetric XylE assays in both strains JV180 and
IFO13350 were successful when using the strong- constitutive promoter PermE*, but both
PftdA_JV180 and PftdA_IFO13350 failed to drive observable XylE in both strains. However, RT-qPCR
assays to detect xylE transcripts were successful in making the desired comparison, confirming
PftdA_JV180 to be stronger than PftdA_IFO13350 in both JV180 and IFO13350 hosts (Fig. S10).
Together, the above data support the initial idea that PftdA sequences from strong and weak PTM
producers determine PTM production.

2.4.3 Mapping promoter regions of the JV180 PTM BGC enables structure
function comparisons
Existing PTM regulatory knowledge is sparse (19, 20), including within the S. griseus clade. Our
above results suggested that S. griseus PTM regulation involves cis-regulatory elements located
directly upstream of ftdA (~500 nt). To define the PTM promoter architecture of these strains, the
transcriptional start site (TSS) of strain JV180 was mapped via circular Rapid Amplification of
cDNA Ends (5’-cRACE). The putative TSS was a cytosine residue 195 nt upstream of the
predicted start codon of ftdA (Fig. S11). Likely −10 and −35 boxes were assigned based upon
established spacing (21, 22) (Fig. 2A). The high sequence conservation between the −35 box and
the TSS (82.4% - 100% pairwise sequence identity) suggested that all examined S. griseus
strains share the same core promoter (−35, −10 and TSS).
To better resolve PftdA promoter architecture and probe for the presence of cis-regulatory
signatures upstream of the predicted −35 boxes, a series of nested deletions in this region were
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created in JV180 (Fig. 2A). PTM transcription and production in these deletions were largely
unaffected, except where the putative −35 box was disrupted (Fig. 2A, Δ−528_−31). This
confirmed the position of the JV180 −35 box, and suggested this region lacks any critical
regulatory residues (Fig. 2B, C). Further, we observed generally low sequence conservation
within this region upstream for all studied S. griseus strains (38.2% - 97.8% pairwise sequence
identity). This contrasts with the high conservation seen for the core promoter region (−35, −10
and TSS).

Figure 2. Mapping of PftdA and identification of cis-regulatory elements by deletion analysis.
(A) Diagram of the JV180 PftdA region, with the zones deleted upstream of PftdA diagrammed
below. Inset: alignment of the core promoter sequence (note: the sequences are identical in
JV180-like PftdA’s). (B) Relative PTM production from JV180 mutants with deletions in the
upstream region of PftdA (n = 3). (C) Relative ftdB transcript abundance from JV180 mutants with
deletions in the upstream region of PftdA (n = 6). (D) Diagram of the PftdA untranslated region
(UTR) downstream of the transcript start site. Regions deleted downstream of PftdA are
diagrammed below. Inset: cartoonized representation of the JV180 PftdA UTR secondary structure
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predicted by mFold. (E) Relative PTM production from PftdA UTR truncation mutants (n = 3). (F)
Relative ftdB transcript abundance from PftdA UTR truncation mutants (n = 6).

The –10 boxes and TSS residues of all examined strains are perfectly conserved, but several
single nucleotide polymorphisms (SNPs) differentiate the −35 boxes of the IFO13350-like PftdA’s
(Fig. 2A, red box) from the strictly conserved −35 boxes of the JV180 group (Fig. 2A, green
box). Because these SNPs could contribute to PftdA strength variations, a panel of JV180 mutants
carrying each observed −35 box SNP in the IFO13350 group was created and tested for PTM
production and transcription (Fig. S12A). These IFO13350 group −35 box SNPs failed to
significantly change PTM production and only slightly decreased transcription in the chimeric
JV180 hosts (Fig. S12B, C). These differences were subtle compared to the far more substantial
ones seen in our ~500 nt replacements upstream of the ftdA gene (Fig. 1D and E), indicating PftdA
strength differences must originate through mechanisms other than −35 box differences.

2.4.4 AdpA positively regulates S. griseus PTM BGCs
Many Streptomyces mRNAs contain long 5’ untranslated regions (5’ UTRs)(21, 22), which can
contribute to regulatory tuning. The DNA regions encoding 5’ UTRs can modulate gene
expression through direct regulator binding (23), and their corresponding mRNAs can further
modulate expression via riboswitches (24) or other RNA secondary structures (25). A series of
~20 nt deletions were constructed (Fig. 2D) across the 195 nt 5’ UTR region of JV180 to probe
contributions to PTM regulation. This revealed multiple lesions with strongly decreased PTM
production and transcript levels, while others had little effect (Fig. 2E, F). mFold (26) modeling
to reveal possible 5’UTR mRNA secondary structures across S. griseus strains yielded several
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energetically favored outputs, and we surmise some of the deleterious mutational effects seen in
JV180 might stem from the disruption of these types of structures (Fig 2D inset, Fig. S13-17).
While S. griseus PftdA 5’ UTR folding remains to be further explored, the above deletions were
particularly useful for identifying a critical region that we subsequently characterized as an
AdpA binding site (Fig. 2D-F; Δ29_48, Fig. S9). AdpA is a global regulator that is well-studied
in strain IFO13350, where it is known to bind >500 chromosomal sites via its weak consensus
sequence TGGCSNGWWY (27). S. griseus AdpA is involved in the hierarchical control of
morphological differentiation, the production of streptomycin and other antibiotics, and several
other important processes (28). Prior ChIP-Seq and RNA-seq data indicated that AdpA might
bind upstream of IFO13350’s PTM BGC (29), but because prior efforts to elicit PTM production
from wild-type IFO13350 were unsuccessful (11, 14), the biological significance of AdpA’s
interaction with the gene cluster was tenuous. Our searches for potential AdpA consensus motifs
within the PftdA regions of the studied S. griseus clade strains revealed an imperfect inverted
repeat 29-48 nt downstream of the TSS in the JV180 PftdA (within the 5’ UTR region) that was
conserved in all S. griseus strains examined. Because our nested deletions revealed that this
sequence is essential for JV180 PTM production (Fig. 2D-F, Δ 29_48, Fig. S9), it renewed the
notion that AdpA might positively regulate PTM expression.
Several experiments were carried out to investigate whether AdpA regulates PftdA, including
adpA deletion and complementation analysis, mutating the putative AdpA binding site in PftdA,
and in vitro binding assays. As expected from prior adpA studies in strain IFO13350 (30),
deletion of the JV180 ortholog (ΔadpA) led to the loss of morphological differentiation and
pigmentation (Fig. S18). PTM production and BGC transcription were also abrogated in JV180,
and these defects were rescued by ectopically expressing either native adpA, its IFO13350
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ortholog (97% amino acid identity vs JV180 AdpA) or by replacing PftdA with the strong
constitutive promoter PermE* to drive PTM BGC expression independent of AdpA (Fig. 3A, B,
S19). These results were consistent with AdpA being a transcriptional activator for PftdA.
However, in bacterial regulation, regulators binding downstream of the RNA polymerase
complex typically cause transcriptional down-shifts. Thus, the location of the putative AdpA
operator site downstream of the conserved –10 box is unusual for a transcriptional activator.
Importantly, another AdpA-activated promoter with a downstream operator site controls S.
griseus IFO13350 adsA, encoding an extracytoplasmic function sigma factor (23). This
precedent thus supports the idea that AdpA could positively regulate PTM expression despite its
atypical putative binding arrangement in PftdA.
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Figure 3. AdpA is required for PTM expression and directly binds PftdA in vivo and in vitro.
(A) Relative PTM production from JV180, its ΔadpA mutant, and complementation of PTM
production by adpA or replacement of PftdA with the constitutive PermE* (n = 3). (B) Relative ftdB
transcript abundance from JV180, its ΔadpA mutant, and complementation of PTM transcription
by adpA or replacement of PftdA with the constitutive PermE* (n = 6). n.d. = not detected. (C)
Alignment of the PftdA AdpA binding sites, with non-conserved nucleotides highlighted in red
(note: the sequences are identical in the JV180-like PftdA’s). (D) Relative PTM production from
JV180 PftdA AdpA binding site mutants (n = 3). (E) Relative ftdB transcript abundance from
JV180 PftdA AdpA binding site mutants (n = 6). EMSA assays for His-tagged JV180 AdpA
interaction with the (F) JV180 PftdA binding site, (G) IFO13350 PftdA binding site, or (H) a JV180
PftdA binding site containing a transversion mutation in one of the nucleotides (red, underlined)
directly interacting with AdpA, which was necessary for protein-DNA interaction. The lane
marked by the + sign is a positive control using wild-type JV180 probe sequence.

AdpA-DNA co-crystallization studies indicate that the protein binds target operators as a
homoduplex that recognizes a highly variable motif, containing four core invariant guanosine
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and cytosine nucleotides (Fig. 3C, bold residues in gray box) (27). In all S. griseus PftdA
promoters studied here, these invariant residues were perfectly conserved, and introducing a
transversion mutation at any one of these nucleotides abrogated JV180 PTM production and
transcription (Fig. 3C-E). This additional evidence further suggests that the identified region acts
as a functional AdpA operator. Exchanging the JV180 AdpA operator site with that from
IFO13350 was PTM proficient although it showed a slight decrease in PTM titer and ftdB
transcription (Fig 3C-E). AdpA-PftdA interactions were further examined via electrophoretic
mobility shift assays (EMSA) using operator sequences from JV180 and IFO13350, plus the
critical point mutants that disrupt essential DNA-AdpA interactions. As expected, recombinant
histidine-tagged AdpA bound the JV180 and IFO13350 PftdA AdpA binding sites (Fig. 3F, G) but
failed to shift operators with the in vivo tested point mutations (Fig. 3H, S20). Together, our in
vivo and in vitro data strongly suggest that AdpA directly binds PftdA in both JV180 and
IFO13350, but also indicate that the native SNPs (Fig. 3C, red residues) in the non-essential
residues of the AdpA operator sites are not the main cause of PTM expression differences seen
between PftdA_JV180 and PftdA_IFO13350 (Fig. 3D,E).

2.4.5 Comparative promoter analyses reveal an indel “switch” that tunes
PftdA strength and PTM production
Aside from the AdpA operator, the JV180 PftdA 5’ UTR truncation experiments revealed that the
28 nucleotides between the TSS and the AdpA binding site are also critical for PTM expression
(Fig. 2B-F, Δ2_28). Nucleotide alignments between promoters in this region revealed generally
high conservation, except for two nucleotides (AG) that are present in all JV180-like PftdA’s but
are missing from IFO13350-like PftdA’s (Fig. 4A, S8). The effects of this indel on PTM regulation
were tested by deleting this AG dinucleotide from JV180, and by introducing the dinucleotide at
the corresponding position in PftdA_IFO13350 (PftdA_IFO13350+AG). PftdA_IFO13350+AG was tested
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heterologously in strain JV180. Strikingly, the dinucleotide deletion led to strongly reduced PTM
production and transcription, while the amended PftdA_IFO13350+AG insertion variant led to a
substantial increase in JV180 PTM production and transcription compared to the wild type
PftdA_IFO13350 sequence (Fig. 4B, C). To test if the indel’s effect was sequence specific, a JV180
transversion (ΔAG::CT) mutant was created, which exhibited reduced PTM production and
transcription compared to wild-type, but was much less deleterious than ΔAG (Fig. 4B,C). This
region is seemingly prone to sequence plasticity within the S. griseus clade; the recently isolated
strain SP18CM02 contains an additional guanosine in this region compared to other JV180-like
PftdA’s (Fig. 4A). Despite having otherwise high overall identity to all other JV180-like PftdA’s,
PftdA_SP18CM02 drove slightly less transcription and resultant PTM production when heterologously
introduced into JV180 (Fig. 1D, E). Together, these data suggest that of the natural sequence
variants in this region, having the AG dinucleotide is important for PTM production. These data
clearly reveal this indel region as a key factor in modulating natural S. griseus PftdA strength.
Further work is necessary to discern how this indel region modulates promoter strength, possibly
via mechanisms such as perturbed AdpA-RNA polymerase interactions or recruitment of another
yet-unknown regulatory component.
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Figure 4. A conserved AG(G) indel tunes strong and weak PftdA’s. (A) Alignment of the PftdA
UTR section containing the conserved AG(G) indel between the TSS and the AdpA binding site.
Non-conserved nucleotides are indicated in red. (B) Relative PTM production from JV180
PftdAΔAG mutants and JV180 ΔPftdA::PftdA_IFO13350±AG mutants (n = 3). (C) Relative ftdB
transcript abundance from JV180 PftdAΔAG mutants and JV180 ΔPftdA::PftdA_IFO13350±AG mutants
(n = 6, except for JV1032 where n = 3).

2.4.6 Discovery of an unexpected griseorhodin biosynthetic interaction that
strengthens PTM production in strain JV180
Our data thus far illustrated how leveraging within-clade comparative metabologenomics can
assist regulatory region mapping, and how small easily overlooked nucleotide changes in these
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regions can tune antibiotic production. The use of comparative genomics to understand
Streptomyces antibiotic production, particularly at the species level, is a relatively recent
development in natural products functional genomics. Studies in this area tend to focus on BGC
conservation and differentiation (e.g. comparison of the S. albus clade, see (31)). From these
comparisons, we anticipated that our S. griseus strains would share several BGCs (beyond
PTMs), and that some antibiotic BGCs in these strains would not be conserved clade-wide. We
found that our S. griseus strains share a core set of 13 conserved BGCs. Some BGCs were found
in only a few strains, and several BGCs were unique by strain (Fig. S21). Strikingly, strain
IFO13350 is one of the oldest known producers of streptomycin (32), but all members of the
JV180 group were found to lack this BGC. Likewise, we noted that JV180 group strains produce
red pigments that are absent from the other studied S. griseus strains (Fig. S22). Through
comparative BGC analysis and subsequent cluster deletion in strain JV180, we attributed this
pigment to the production of griseorhodin polyketide congeners (33) (Fig. 5A; ΔgrhR2-V, S23AC). Unexpectedly, this griseorhodin BGC deletion mutant exhibited several additional
phenotypes, including abrogated PTM production, downregulated PTM BGC transcription, and
reduced sporulation (Fig. 5B-C, S24).
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Figure 5. Deletions in the JV180 griseorhodin (grh) BGC often negatively impact PTM
production and transcription by PftdA. (A) Diagram of the JV180 griseorhodin BGC with gene
ranges deleted in various mutants mapped below as corresponding colored bars. (B) Relative
PTM production from various grh mutants in JV180 rpsL (white background) and JV180
ΔPftdA::PermE* background strains (grey background, n = 3). n.d. = not detected. (C) Relative ftdB
transcript abundance from various grh mutants in JV180 rpsL and JV180 ΔPftdA::PermE*
background strains as noted in panel B, (n = 6).

The loss of PTM production in the JV180 ΔgrhR2-V mutant was wholly unexpected, and the
mutant’s pleiotropic phenotypes suggested griseorhodin might act as a signaling molecule. To
test this, four adjacent genes encoding griseorhodin polyketide synthase (PKS) assembly-line
enzymes were deleted (ΔgrhQSAB) (Fig. 5A). This was done to specifically eliminate
griseorhodin production, while leaving all other grh BGC genes intact. Interestingly, this mutant
was PTM-proficient, arguing against the signaling idea. To further probe how the griseorhodin
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BGC exerts its influence, we tested a griseorhodin-enriched JV180 growth extract (see methods,
Fig. S25A) and authentic γ-rubromycin (34) (a griseorhodin analog) for their ability to
chemically complement the ΔgrhR2-V strain. Neither sample could restore PTM production in
the ΔgrhR2-V mutant in flask cultures (Fig. S25B), and disk diffusion tests on agar plates failed
to restore sporulation in the diffusion zone (Fig. 25C). These experiments together ruled out the
griseorhodin signaling hypothesis.
To continue probing the grh locus for key PTM-influencing genes outside of grhQSAB, multiple
groups of genes were deleted from the BGC (grhR1-E, grhFGH, and grhI-P; Fig. 5A). All three
mutations caused complete loss of red griseorhodin pigmentation and showed reductions in PTM
production and transcription (Fig. 5B, C, S23D, S26B). Homology-based annotations of the
genes in these regions (33) led us to focus on a subset which might affect PTM biosynthesis
through transcriptional or metabolic mechanisms. Genes grhR2 and grhR3 encode transcriptional
regulators, which could influence regulatory crosstalk, grhF encodes a phosphopantetheinyl
transferase (essential for posttranslational modification of NRPS and PKS enzymes), and grhGH
encode β and ε subunits of acetyl-CoA carboxylase (ACC) essential for malonyl-CoA, a
common precursor for fatty acid, griseorhodin, and PTM biosynthesis. PTM production in JV180
ΔgrhR2-V was not complemented by grhR2, grhR3, or grhF, but grhGH was able to restore
some PTM production and transcription (Fig. 5B, C, S26A). Interestingly, expressing either
grhG or grhH alone were sufficient to restore PTM production, similar to grhGH when
expressed together (Fig S26A). A ΔgrhGH mutant was thus created, leading to partial
griseorhodin pigmentation and reduced PTM production comparable to the initial ΔgrhFGH
mutant (Fig. S23D, S26B). How the ΔgrhR1-E and ΔgrhI-P mutations caused decreased PTM
production remains unclear. Because these lesions led to loss of putative regulatory genes (grhR2
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& grhR3, see (33), their phenotypes could be entangled with concomitant grhGH
downregulation.
In addition to the griseorhodin BGC’s grhGH, several other Streptomyces PKS clusters are
known to harbor additional non-housekeeping copies of ACC genes. These include cpkKL in the
coelimycin BGC of S. coelicolor (35) and jadN in the jadomycin BGC of S. venezuelae (36), and
it can be reasoned that these ACC copies likely assist polyketide biosynthesis through increased
malonyl-CoA. Because JV180 PTM production decreased in the ΔgrhR2-V and ΔgrhGH
mutants, but not the ΔgrhQSAB mutant (Fig. 5C), we likewise hypothesized that PTM
downshifts in these mutants might be caused, at least partially, by reduced intracellular malonylCoA concentration. We thus tested several additional S. griseus ACC subunit genes for their
ability to rescue PTM production in the JV180 ΔgrhR2-V strain to discern if these effects were
specific to grhGH or are more broadly attributable across ACC subunit homologs. The tested
ACC genes included housekeeping accBE alleles cloned from JV180 and IFO13350 (whose
functions were assigned by sequence homology and gene neighborhood synteny to the accBE
genes in S. coelicolor (37)) plus the previously-uncharacterized PKS-associated ACC genes
SGR3280-3281 of strain IFO13350, all of which encode ACC β and ε subunits like grhGH. All
of these ACC homologs partially restored PTM production in the ΔgrhR2-V strain (Fig S26A),
further supporting a role for malonyl-CoA in the PTM production defects of the ΔgrhR2-V and
ΔgrhGH mutants.
To test if JV180 could still produce PTMs independent of the griseorhodin BGC, we
constitutively expressed the strain’s PTM BGC by replacing PftdA with PermE*. This ΔPftdA::PermE*
promoter replacement in both of the ΔgrhR2-V or ΔgrhGH backgrounds led to increased PTM
production and PTM BGC transcription, similar to a JV180 ΔPftdA::PermE* control (Fig 5B, C).
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Our data show that PTM transcription and its production is affected by the lack of grhR2-V and
grhGH. It is possible that the griseorhodin BGC may affect the PTM BGC through biosynthetic
malonyl-CoA availability. It is also likely that an as yet-undefined transcriptional regulatory
interaction also connects the two BGCs. Malonyl-CoA responsive regulators are wellcharacterized in other model organisms such B. subtilis (38), but no such regulators are known in
Streptomyces. Further inquiry is underway to characterize this unusual cross-cluster interaction
more fully.
Intrigued by the finding that ectopic expression of just grhG or grhH could rescue PTM
production in the JV180 ΔgrhR2-V mutant, we tested if the PTM BGCs of weak-PTM producing
S. griseus strains might be similarly stimulated for production. This was done by heterologously
expressing grhG in strains IFO13350, JV254, and JV258 (the grhGH construct had low
conjugation efficiency). This resulted in increased PTM production from these natively lowproducing strains on agar media and also increased PTM BGC expression when tested in strain
IFO13350, showing that ACC subunit overexpression can stimulate PTM production in natively
poor producers (Fig. S27A, B). Combined with the above data, these observations support a
model where S. griseus PTM production differences have complex origins. In the case of poor
PTM producers, promoter indels and insufficient positive BGC interactions likely dampen
potential production via low transcription. In contrast, better PTM producers appear to benefit
from cross-BGC interactions that increase transcription from a more active PftdA variant (+AG),
resulting in PTM production. Strain JV180, and possibly other members of its subclade, do not
seem to be bottlenecked for PTM production at the transcriptional level based on several findings
throughout this study. This includes failure of grhG merodiploids to boost WT JV180 PTM
production (Fig. S27A) and evidence from several recombinant strains where PTM BGC
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transcription was significantly upregulated by 2 to 9 fold, but PTM production increased by only
up to 1.4 fold (ΔgrhQSAB, adpA complementation, and ΔPftdA::PermE* strains; Fig. 3A, 3B, 5B,
5C). The above findings also highlight ACC enzyme overexpression as a way to potentially
upregulate certain silent BGCs, adding a new dimension of utility for these genes in synthetic
biology, where they are currently used for increasing fatty acid and polyketide titers via malonylCoA overproduction (39).

2.5 Conclusions
Streptomyces genomes contain many BGCs encoding for drug-like compounds, and to harness
their full biosynthetic capacity for discovery, it is crucial to understand what underpins the
differences between active and silent BGCs (8). Cryptic metabolism is a well-recognized
problem in the field, and poor BGC transcription is often implicated as the predominant
mechanism behind biosynthetic silence. However, this supposition is increasingly challenged by
a growing body of research that suggests all cryptic clusters aren’t necessarily transcriptionally
silent (40). Further, it only addresses how biosynthetic silence could originate in a given
organism but does little towards explaining why affected BGCs show little activity to begin with.
A common but difficult-to-prove hypothesis is that axenic laboratory growth deprives
microorganisms of signals needed to upregulate quiescent BGCs (17). This idea is based on the
complex lifestyles of Streptomyces bacteria, which are known to be heavily influenced by
molecular and environmental cues (41). Indeed, chemical elicitor screening, co-culturing, and
other regulatory manipulation strategies continue to yield new molecules from apparently silent
BGCs, bolstering this idea (7, 41, 42). However, the number and types of molecular signals these
organisms can sense and respond to must have a finite limit, constrained by the characteristics
and capacities of their genetically encoded signal transduction pathways (8). If true, then
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extracellular signals can only explain one part of antibiotic crypticity, highlighting the need to
understand how basic strain-to-strain genetic differences also contribute to the phenomenon.
Towards this, we leveraged the unusual commonality of PTM BGCs in Streptomyces to compare
several highly related S. griseus strains to discover genomic features that differentiate strong and
weak producers. These efforts led to the first sequence-defined PTM promoter in the genus,
confirmation that the global regulator AdpA acts directly on S. griseus PTM production by
binding PftdA promoter regions in an atypical way, and that 2-3 bp lesions between -10 promoter
regions and AdpA operator sites can cause substantial differences in transcription strength and
biosynthetic output. To our knowledge, this type of inquiry is largely absent from the
biosynthetic-regulatory literature, but similar promoter heterogeneity, with resultant tuned
transcription, has been documented to control phase variation in bacterial pathogenicity (43).
Further, because the AG indel discovered here resides in a poly-guanosine rich region, poly-N
strand slippage (43) or a similar mechanism might plausibly explain how these promoter variants
arise in S. griseus populations. As more Streptomyces are sequenced and characterized, it is
likely that additional promoter region sequence variations will emerge as drivers of silent
metabolism in other biosynthetic pathways. In proof, scientists working at WarpDrive Bio, Inc
patented a method for activating silent BGCs encoding rapamycin-like antibiotics by “reversing”
naturally-occurring short indels within LAL-family regulator binding sites (44). Those regulatory
indels were discovered through large-scale actinomycete genome sequence and molecule
production comparisons at that company. Such knowledge is thus highly desirable to streamline
targeted discovery efforts and direct new rational engineering approaches to activate select silent
BGCs.
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Finally, we also found that in strain JV180, a BGC encoding griseorhodin production was
required for both PTM production and transcription. Part of this relationship seems to implicate
malonyl-CoA, whose biosynthesis is encoded for by grhGH, but further research is clearly
needed to reveal a definitive mechanism. The deletion of unwanted BGCs is commonly used to
engineer “clean” chassis strains (45) or to uncover the metabolites of BGCs (35, 46). In light of
this, our discovery of PTM dependence on griseorhodin was surprising and provides a rare
cautionary example of how genome-minimization can have unintended consequences on broader
strain-wide BGC function. Together, our results show that the seemingly simple monocistronic
PTM BGC of strain JV180 appears is under highly complex control, adding to a growing body of
similarly complex BGC regulatory circuits and mechanisms in other Streptomyces (47, 48).
Much remains to be learned about these types of regulatory networks in Streptomyces, and
continued inquiry is required for a more comprehensive understanding to support rational drug
discovery and production.

2.6 Materials and Methods
2.6.1 Strains, Plasmids, Primers, Enzymes, Chemicals and General Methods
Strains, plasmids, and primers are described in Tables S1-3. Strains IFO13350 and JV251-258
were obtained from the Agricultural Research Service Culture Collection (NRRL). All primers
were purchased from Integrated DNA Technologies. All restriction enzymes, Taq polymerase,
and T4 ligase were purchased from New England BioLabs. PCR was generally carried out using
KOD Hot Start DNA Polymerase (EMD Millipore) in FailSafe PCR 2X PreMix G (Epicentre).
Taq polymerase was used for colony PCR to verify cloning and genome editing. Streptomyces
genomic DNA was prepared for PCR by grinding a colony in DMSO as described by Van Dessel
et al (49). Most media components and chemicals were purchased from Sigma Aldrich or Fisher
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Scientific unless specified. γ-rubromycin was purchased from Abcam. 13C5-L-ornithine was
purchased from Cambridge Isotope Laboratories. Standard protocols for manipulating E. coli
were based on those of Sambrook et al (50). Streptomyces cultures were routinely propagated on
ISP2 agar and Trypticase Soy Broth (Difco) at 28˚C. Glass beads were added to liquid cultures to
disrupt mycelial clumps.

2.6.2 Streptomyces conjugations
Conjugations were performed using JV36 as the general E. coli donor as previously described
(51). Streptomyces sp. strain JV180 spores were collected from lawns plated on 8340 agar (1%
Proflo cottonseed meal (ADM); 2% D-mannitol; 0.1% yeast extract; 0.01% KH2PO4; 0.01%
MgSO4-7H2O; 0.002% CaCl2-2H2O; 0.2% (v/v) R2 trace elements solution (52); 2.067% MES
hemi-sodium salt; 2% agar; pH 6.5) using sterile cotton swabs into TX Buffer (53). Strain JV254
and JV258 spores were collected from lawns plated on SFM (52) and ISP-S (1.5% malt extract;
0.5% soluble starch; 0.5% yeast extract; 0.3% CaCO3; 2% agar; pH 7.4; T. A. Voeikova personal
communication, 2007), respectively. Exconjugants were selected with 50 µg/mL colistin and 50
µg/mL apramycin. Successful integrations by ΦC31 integrase-based vectors were verified by
colony PCR as previously described (16).

2.6.3 Marker-less gene deletion/promoter replacement
All gene deletions and PftdA mutants were constructed using double homologous recombination as
previously described (16). To avoid undesired recombination between the wild-type and the
mutant PftdA sequences, an intermediate ΔPftdA::tsr mutant was constructed, with specifics
provided the Supplementary methods. This ΔPftdA::tsr mutant was used as the parent strain for the
construction of most PftdA mutants. Some plasmids for genome editing were cloned using
overlap-extension PCR instead of Gibson assembly as described previously (54) (see Table S2).
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2.6.4 PTM production and analysis
Strains were streaked from −80˚C glycerol stocks onto ISP2 plates and incubated at 28˚C for 2-3
days. A plug was cut from the plate and used to inoculate 3 mL of Trypticase Soy Broth in 24well deep well plates, which were shaken at 300 rpm at 28˚C. One 4 mm glass bead was added
per well to disrupt mycelial clumps. After 2 days of growth, 200 µL of cultures were either
inoculated into 20 mL ATCC-MOPS (adapted from ATCC172: 1% dextrose; 2% soluble starch,
0.5% yeast extract; 0.5% N-Z amine; 0.63% MOPS; pH 7.2) in a 125 mL flask with 6 mm glass
beads for disrupting clumps or plated on 8340 agar overlaid with cellophane and incubated at
28˚C. Flask cultures were shaken at 250 rpm. After 4 days of growth, 1 mL was collected in
RNALater for protein and RNA analyses (see RT-qPCR section below) and the rest of the
cultures were extracted twice with equal volumes of ethyl acetate. Solid media (plate) cultures
were incubated for 6 days and the mycelia and spores were collected from the cellophane for
protein extraction by trichloroacetic acid as described by Bose and Newman (55) and
quantification by Bradford assay. The remaining agar was diced and extracted with ethyl acetate
by soaking overnight.
The ethyl acetate extracts were dried at low pressure and re-suspended in 500 µL of LC-MS
grade methanol and syringe filtered before LC-MS analysis. PTM analysis was performed using
a Phenomenex Luna C18 column (75 x 3 mm, 3 µm pore size) installed on an Agilent 1260
Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer. For each run, 10
µL sample was injected and the chromatography conditions were as follows: T = 0, 5% B; T = 4,
45% B; T = 12, 53% B; T = 16, 100% B, T = 20, 100% B; A: water + 0.1% formic acid, B:
acetonitrile + 0.1% formic acid; 0.8 mL/min. The diode array detector was set to measure
absorbance at 320 nm. The mass spectrometer was set to precursor ion scan mode with the
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precursor ions m/z: 450 – 550, collision energy = 30 V, fragmentor = 70 V, and daughter ions
m/z: 139.2 or 154.2. The resulting data was analyzed offline with Agilent MassHunter
Qualitative Analysis software. Chromatograms were extracted for each parent-daughter ion mass
transition, and the integrated areas for major PTM congeners were used to compare PTM
production. The sums of PTM peak areas were normalized by total protein, and the relative PTM
production was calculated relative to the appropriate control strain, typically JV180 rpsL. PTM
production experiments were generally carried out in triplicates, unless specified. The statistical
significance in the differences observed was calculated by two-tailed Student’s T-test, typically
relative to JV180 or its rpsL mutant, JV307 or otherwise indicated. *p < 0.05, **p < 0.01, ***p <
0.001. Error bars represent standard deviation.
Generally, the PTM production data reported were based on liquid media cultures that were used
to collect the corresponding RT-qPCR data. Relative PTM production trends were consistent
between solid and liquid media. Some figures in the SI show relative PTM production on solid
media, where flask culture/RT-qPCR data was not collected.

2.6.5 RT-qPCR
Strains were cultivated in flasks as described above. After 4 days, 1 mL of culture added to 2 mL
of RNAlater and vortexed to stabilize RNA. The mixture was centrifuged at 3,214 X g for 10
minutes and the supernatant was discarded. The RNA-stabilized pellet was resuspended in 250
µL of 10 mg/mL lysozyme (Sigma) and incubated at 37˚C for 30 minutes. To the lysate, 750 µL
of Trizol reagent (Fisher) was added and protein and RNA were extracted following the
manufacturer’s protocol from this point. Protein concentration was measured by Bradford assay.
The RNA was resuspended in 84 µL of nuclease-free water. DNase treatment was carried out by
adding 10 µL 10X Turbo DNAse buffer, 4 µL Turbo DNase with 2 µL of RNAsin (Promega) for
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approximately 6 hours at 37˚C. Removal of leftover DNA was confirmed by PCR and gel
electrophoresis before the DNase inactivation reagent from the Turbo DNAse kit (Fisher) was
added. RNA concentration was measured with a NanoDrop and 5 µg of RNA was used for
reverse transcription with Superscript II (Thermo) following the manufacturer’s protocol.
Primers for qPCR were designed using the IDT primerquest tool. Real-Time PCR was performed
on a CFX Connect Real-Time PCR Detection System (BioRad) with the following program: 1
cycle at 95°C for 3 min, 40 cycles of 95°C for 10 s and 55°C for 30 s. Each reaction contained 5
µL of iTaq Universal SYBR Green Supermix (BioRad), 2 µL of nuclease free water, 1 µL of 10
µM forward primer, 1 µL of 10 µM reverse primer, and 1 µL of template cDNA. The relative
transcript abundance was calculated using the ΔΔCT method and hrdB was used as the
housekeeping gene (56). The primer efficiency was determined as described by the qPCR
instrument manufacturer for several pairs of PTM BGC probes, and the ftdB primers YQ376180ftdB1153 and YQ377-180ftdB1278 were chosen for subsequent experiments as they had the
highest efficiency and produced the most consistent results. Data shown represent at three
technical replicates each for at two biological replicates. The statistical significance in the
differences observed was calculated by two-tailed Student’s T-test, typically relative to JV180 or
its rpsL mutant, JV307 or otherwise indicated. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars
represent standard deviation.

2.6.6 Expression and purification of His-tagged AdpA
The full-length adpA gene of Streptomyces sp. strain JV180 was amplified by PCR using
primers pET11a-AdpA-F and pET11a-AdpA-R. The PCR product was cloned into the
expression plasmid pET11a. The expression recombinant plasmid, pKN052, contained the
sequence adpA-CTC-GAG-(CAC)6-TGA under the control of the T7 promoter, similar to the
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construct reported by Yamazaki et al (23). E. coli BL21 (DE3) Rosetta harboring pKN052 was
cultured in LB medium with 100 µg/mL ampicillin at 37˚C overnight. 1 mL of seed culture was
transferred to 150 mL of LB medium with 100 µg/mL ampicillin and incubated by shaking at
37˚C at 250 rpm. When OD600 reached 0.6-0.8, the cells were chilled on ice for 1 h. After adding
IPTG to 1 mM, the culture was continued for shaking at 250 rpm for 22 h at 18˚C. The cells were
harvested by centrifugation at 5000 rpm for 30 min, resuspended in Tris-HCl buffer (20 mM
Tris-HCl, 200 mM NaCl and 10% glycerol: pH:8.0) and stored at −80˚C. To purify the protein,
cells were disrupted by sonication (3 min: 10 sec on/10 sec off at 20% amplitude) and His-tagged
AdpA was purified with nickel-nitrilotriacetic acid (Ni-NTA, Qiagen) resin by eluting with 250
mM imidazole. Protein expression was verified with SDS-PAGE before downstream
experiments.

2.6.7 Electrophoretic mobility shift assay
Double-stranded DNA probes containing the 20 bp putative PftdA AdpA binding site plus 15 bp
additional flanking sequences were synthesized by IDT. The DNA was resuspended in TEN
buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl, pH 8.0). For each probe, 50 nM probes were
prepared using the Dig Gel Shift Kit, 2nd generation (version 10, Roche) with the following
conditions: 20 µl DNA (from 100 nM stock), 8 µl 5X labeling buffer (1 M potassium cacodylate;
125 mM Tris-HCl; 1.25 mg/ml bovine serum albumin; pH 6.6), 8 µl CoCl2 (25 mM), 1.5 µl
Digoxigenin-11-DDUTP (1 mM), 1.5 µl terminal transferase, and water up to 40 µl. After brief
mixing and centrifugation, reactions were incubated at 37˚C for 30 min and then chilled on ice.
The reaction was quenched by adding 2 µl of 200 mM EDTA (pH 8.0).
The protein-DNA interaction assay protocol was based on that described by Ming et al(27).
Purified AdpA-His was serially diluted in protein buffer (10 mM Tris-HCl, pH7.5; 100 mM
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NaCl; 2.5% (w/v) glycerol; and 0.25 mM DTT). The reaction mixtures contained 2 µl of binding
buffer (200 mM Tris-HCl, pH 7.5; 1 M KCl; 2.5 mg/mL bovine serum albumin (BSA); and 1%
nonidet P-40), 1.2 µl of 1 ng/µl poly[d(I-C)], 1.8 µl DNA probe (4.5 nM), the desired volume of
purified protein, and water up to 20 µl. Samples were incubated for 1 h on ice. Gel
electrophoresis was performed with a 5% native acrylamide gel (Bio-RAD, mini protein TBE
precast gel) in 0.5X Tris-borate-EDTA buffer (TBE, 10X concentration: 890 mM Tris; 80 mM
boric acid; and 20 mM EDTA, pH 8.3) at 85 V for 145 min. Electro-blotting was performed
using a BioRad Turbo Transfer System (Trans-Blot TurboTM System) on positively charged
nylon membrane (Sigma-Aldrich). Crosslinking was performed by baking the nylon membrane
at 120˚C for 30 min. Subsequently, the chemiluminescent detection was done as mentioned in
the DIG-KIT protocol with very slight modification (overnight blocking, 2 hrs anti-digoxigeninAP treatment, and washing for 30 min each time) and the imaging was done with a LICOR
(ODYSSEY Fc) imaging system (model # 2800).
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Chapter 3: Genetic Variations in PTM
Biosynthetic Genes
3.1 Abstract
Since the discovery of ikarugamycin in 1972, numerous polycyclic tetramate macrolactams
(PTMs) have been discovered and characterized. PTMs show remarkable diversity in their
structures aside from certain eponymous features that define PTMs, which include the tetramatecontaining macrolactam ring and the polycyclic ring system. The structural diversity of PTMs is
reflected by their ability to bind various targets, as PTMs have been reported to inhibit various
organisms and disrupt cellular processes. These results indicate numerous potential applications
for PTMs in healthcare, agriculture, and research. Structural changes in PTMs are the result of
changes in the enzymes encoded for by their biosynthetic gene clusters (BGCs) or off-target
effects by other enzymes encoded in the genomes of PTM-producing strains. Here, I describe my
efforts to document the genetic diversity encoded within PTM BGCs and the functions of various
enzymes which differentiate certain PTM BGCs. A clearer and more comprehensive
understanding of PTM biosynthesis could lay the foundation for engineering PTM BGCs tailored
to produce specific and novel structures.
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3.2 Introduction
Polycyclic tetramate macrolactams (PTMs) are a class of antibiotics produced by numerous
Streptomyces and other bacteria (1). The high conservation of PTM biosynthetic gene clusters
(BGCs), especially in Streptomyces, makes it a suitable model system for comparative studies of
BGC regulation and silencing. In addition, PTMs are also of interest due to their chemical
diversity, which results in the ability of PTMs to inhibit various targets. These properties present
potential applications for PTMs in healthcare, agriculture, and basic research.
One well-characterized PTM is ikarugamycin, which was originally isolated in a screen for
inhibitors of Tetrahymena (2). It and structurally similar PTMs like clifednamides and
capsimycins have recently garnered attention for their cytotoxic properties, which have potential
applications in healthcare (3–5). Recently, ikarugamycin was shown to bind and inhibit hexose
kinase 2 (HK2) to inhibit tumor growth (6), but other glycolysis-independent effects are also
thought to be involved (7). Ikarugamycin also inhibits clathrin-dependent endocytosis in animal
and plant cells, and has been used to study related processes in basic research (8, 9).
Another well-characterized PTM is dihydromaltophilin, which is was originally isolated as heatstable antifungal factor, HSAF (10). The producer of HSAF, Lysobacter enzymogenes strain C3,
inhibits a wide range of phytopathogenic fungi and been tested as an biocontrol agent in several
field experiments (11, 12). The mechanism of function for HSAF is not clearly understood and
may vary in different species. In one study, HSAF was been reported to disrupt ceramide
synthase activity in Aspergillus nidulans (13). Another study reported that HSAF induced ROSmediated apoptosis in Candida albicans, possibly by disrupting β-tubulin polymerization like
another PTM, alteramide B (14, 15).
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These diverse functions are related to the various modifications of PTM molecules, which should
arise from differences in the enzymes encoded for by their BGCs. Better understanding of the
functions of various PTM biosynthetic enzymes lay the foundation for researchers to engineer
PTM BGCs producing novel structures, which could inhibit a wider range of pathogens or have
increased efficacy (16). To date, numerous PTM molecules with diverse structures have been
isolated and characterized. However, the genomes of many of the source organisms have not
been sequenced. Similarly, many Streptomyces and actinomycetes possessing PTM BGCs have
been genome-sequenced, but not evaluated for their ability to produce PTMs.
When I began my thesis project in 2014, three PTM BGCs had been linked to their products: the
HSAF BGC in Lysobacter enzymogenes C3 (17), the frontalamide BGC from Streptomyces sp.
SPB78 (1), and the ikarugamycin BGC of Streptomyces sp. Tü 6239 (18) (Figure 1). Since then,
several other PTM BGCs have been characterized, such as the pactamide BGC of S. pactum
strain SCSIO 02999 (19), the combamide BGC of S. sp. strain S10 (16), and the somamycin
BGC of S. somaliensis strain ZH66 (20).
Thus far, the functions of several enzymes encoded within PTM BGCs have been deduced. PTM
biosynthesis is initiated by the iterative polyketide synthase non-ribosomal peptide synthetase
fusion protein. This protein has been reconstituted in vitro to demonstrate how it uses to use one
L-ornithine and twelve malonyl-CoA precursors to produce the skeleton of PTMs (21).
The cyclization of PTMs have been shown through gene deletions to be dependent on a series of
oxidoreductases. Differences in the polycyclic systems of PTMs are determined by the
oxidoreductases responsible for the first two rings, which are often annotated as phytoene
dehydrogenases (19, 22, 23). The final ring is formed by another NADPH-dependent
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oxidoreductase, which is often annotated as an alcohol dehydrogenase (24). Finally, a commonly
found PTM-tailoring hydroxylase, which is often annotated as a sterol desaturase, has been
shown to be promiscuous for different PTM substrates in vitro (25).

Figure 1. Previously characterized PTM BGCs and their products. The ikaABC BGC of
Streptomyces sp. strain ZJ306 was shown as the ikaABC BGC of Streptomyces sp. Tü 6239 was
not published in its entirety.

As I collected PTM BGC sequences from online databases such as GenBank and IMG for
promoter comparisons, I noticed a greater diversity in the genes encoded by various PTM BGCs
than previously reported. Using homology-based annotations and meta-analysis of known PTM
compounds and PTM-producing strains, I formed several hypotheses on the functions of some
previously uncharacterized PTM BGC genes. Some genes I initiated genetic and metabolomic
studies on include FtdF, which is a cytochrome P450 found in the most widely distributed type
of PTM BGC, and FtdG, which is a Rieske 2Fe-2S domain protein found is some FtdF-less PTM
BGCs. Additionally, I identified an unusual group of PTM BGCs that may be responsible for
producing cylindramide-type PTMs. Finally, I also identified a group of PTM BGCs as being
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likely clifednamide-type PTM BGCs. To support this hypothesis, we sequenced the genome of
the original source organism of clifednamides, Streptomyces sp. strain JV178, which was
published in Genome Announcements (see Chapter 5). We confirmed the identity of the
clifednamide PTM BGC and the role of novel cytochrome P450, CftA, which we published in
ACS Synthetic Biology (see Chapter 6).
In addition, the Blodgett lab has also conducted selective isolation of actinomycetes from local
soil samples. Dr. Blodgett’s BIO3493 class at WUSTL also conducts selective isolation of
actinomycetes each year. The majority of these strains have been screened via LC-MS/MS or
PTM biosynthesis or via PCR for key PTM BGC genes. We had the opportunity to sequence the
genomes of 96 strains, of which roughly half contained PTM BGCs. Two of these strains were
Streptomyces sp. strains JV180 and SP18CM02, which were used in comparative studies of PTM
regulation (see chapter 7). Preliminary analyses of the PTM BGCs encoded in these genomes
reveals striking diversity in PTM BGCs is readily obtainable, even among isolates from local soil
samples.
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3.3 Results
3.3.1 FtdF, a CYP450 found in the most common type of PTM BGC
A majority of PTM biosynthetic gene clusters have a similar genetic content as the frontalamide
biosynthetic gene cluster. These clusters contain ftdA, encoding the sterol desaturase; ftdB,
encoding the iPKS-NRPS; ftdCD, encoding two phytoene dehydrogenases; ftdE, encoding an
alcohol dehydrogenase; and ftdF, encoding a cytochrome P450. By sequence similarity, FtdF
would be considered a member of a different subfamily of cytochrome P450 enzymes than CftA.
Additionally, frontalamides do not bear a ketone group at the same site as clifednamides. These
observations suggested a different role for FtdF. To investigate the function of FtdF, I deleted the
ftdF gene from Streptomyces sp. strain JV180, whose PTM BGC has the same gene content as
the ftd cluster, through markerless homologous recombination. The resulting strain, JV1171, was
grown on 8340 agar along with the parent strain JV307 (JV180 rpsL), extracted with ethyl
acetate, and analyzed for PTM production by LC-MS/MS (Figure 2). Compared to JV307, the
extract from JV1171 was missing the peaks for compounds 1, 4, 5, 6, and 7. Conversely, the
peaks for compounds 2, 3, and 8 were either unaffected or grew larger, suggesting that these
were intermediate compounds that accumulated due to the absence of FtdF. The lost peaks could
be complemented by ectopic expression of ftdF under the constitutive promoter PermE*. However,
the relative ratios of the PTM peaks was still different from wild-type JV180. Additionally,
overexpressing ftdF from the same construct in wild-type JV180 also caused a skew in the
relative ratios of the various peaks. More of compounds 1 and 7 appeared to be produced than in
wild-type JV180, while less of compounds 4 and 5 appeared to be produced.
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Figure 2. The production of some PTM peaks in strain JV180 is ftdF-dependent.

Table 1. List of PTM compounds produced by strain JV180 and their mass transitions.
compound # RT (min) m/z1
m/z2
ftdF dependent?
1
7.1
511
139
Y
2
7.8
513
154
N
3
8.8
497
139
N
4
10.5
495
139
Y
5
9.1
511
154
Y
6
6.2
509
139
Y
7
6.5
511
154
N

97

As the JV180 PTM BGC contained two phytoene dehydrogenases, FtdC and FtdD, I predicted
that JV180 would produce PTMs with 5-5-6 carbon ring systems. Additionally, the as the JV180
PTM BGC contained the sterol desaturase, FtdA, I predicted that some of its products would
have the commonly found tetramate-adjacent hydroxylation. These hydroxylated PTMs are
distinguishable from non-hydroxylated PTMs by their fragmentation. I obtained authentic
maltophilin isolated from Stenotrophomonas maltophilia, a Gram-negative bacterium, from
EMC microcollections GmbH. I was able to match compound 5 in the extracts from JV180 to the
maltophilin standard by retention time, m/z, and collision-induced dissociation (Figure 3). These
data strongly indicated that JV180 produced maltophilin or a stereoisomer, which could not be
distinguished by the employed liquid chromatography conditions.
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Figure 3. Strain JV180 produces maltophilin. (A) LC-MS/MS chromatograms of JV180 extract,
the extracted ion chromatogram of the 511.2 → 154.2 mass transition, and a maltophilin
standard. (B) Product ion spectra of maltophilin and compound 5 in the extract of JV180
produced by collision-induced dissociation at 20 V.
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A few compounds could be identified as FtdA-hydroxylated PTMs due to their fragmentation
into a m/z 154 daughter ion. Using these observations, I proposed a role for FtdF as well as
possible structures for compounds 1-5 based on structures of previously characterized PTMs. I
hypothesize that FtdF oxidizes a pre-existing hydroxyl group on carbon 12 to a ketone group.
This hydroxyl group appears to be originally added by FtdC and there are homologs of FtdC
such as PtmB1 that do not appear to add this hydroxylation (23). I also predicted that FtdF can
carry out a subsequent addition of a hydroxyl group at carbon 14. I predicted that FtdF carried
out multiple rounds of oxidation on its substrates due to the number of peaks that were lost when
ftdF was deleted, and the skewed distribution of ftdF-dependent peaks when ftdF was
overexpressed. A similar model was recently proposed by researchers studying the PTM BGC of
Streptomyces sp. strain SCSIO 40010, which has a similar BGC (20). Multiple PTM-associated
cytochrome P450 enzymes appear to carry out multiple rounds of oxidation, including IkaD,
CftA, and CbmD (4, 26, 16). Additionally, I was unable to predict a structure for compounds 6
and 7. Based on their mass transitions, they may be derivatives of compounds 1 and 2,
respectively, where a bond was oxidized into a double bond. Additionally, there should likely be
a FtdA-hydroxylated product of compound 1, but this compound appears to be barely produced
under the culturing conditions used, if at all.
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Figure 4. Proposed role of FtdF and the structures of PTM compounds 1-6 produced by strain
JV180.
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Spencer Stumpf, a former technician in the Blodgett lab, generated a ftdA deletion in JV307 as
well as JV1171. This eliminated a widely conserved and characterized sterol desaturase, which
adds a hydroxyl group adjacent to the tetramic acid. The loss of peaks in these mutants further
supported my proposed PTM tailoring pathway in JV180. The ΔftdA ΔftdF double mutant
predominantly produces compound 3, which should also help in the purification of this
compound for structural elucidation experiments.
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Figure 5. JV180 ΔftdA mutants support the proposed PTM tailoring pathway.
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15

3.3.2 FtdG, a 2Fe-2S Rieske domain protein
Through bioinformatic analyses, I discovered a clade of PTM BGCs which contained ftdABCDE,
but not ftdF. Instead of the cytochrome P450 enzyme, these PTM BGCs encoded a 2Fe-2S
Rieske domain protein, which I will refer to as ftdG (Figure 6). Since a 2Fe-2S Rieske domain
could function as an electron carrier, I reasoned that this enzyme could have a redox-related
function. Interestingly, in S. pactum SCSIO 02999, this gene was considered to be part of the
adjacent xiamycin BGC and named xiaA (27). However, the authors reported that they were
unable to delete xiaA and could not investigate whether it affected xiamycin production. Based
on the start-stop codon overlap of ftdE-ftdG in S. olivaceus strain NRRL B-3009, I determined
that this gene should actually be part of the PTM BGC. To investigate the function of FtdG, I
obtained several genome-sequenced Streptomyces strains with ftdG-containing PTM BGCs from
the NRRL collection (Table 2). I grew each strain on several different media and their extracts
were analyzed via LC-MS/MS. JV820 seemed to be the only strain that naturally produced
PTMs on the media tested.

Figure 6. S. olivaceus strain NRRL B-3009 (JV820) contains a PTM BGC with a novel Rieske
2Fe-2S domain protein.
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Table 2. List of obtained strains containing FtdG-type PTM BGCs.
Strain Description
Media tested (underlined: PTM+)
JV819 Streptomyces griseus subsp. griseus NRRL BISP2, YMS, SMMS, HT, 8340,
2621
JBFM1
JV820 Streptomyces olivaceus NRRL B-3009
ISP2, ISP4, YMS, SMMS, HT,
8340, JBFM1, ATCC172, SFM
JV823 Streptomyces atroolivaceus NRRL ISP-5137
ISP2, YMS, SMMS, JBFM1

Compared to JV180, the extract of JV820 appeared to contain many identical peaks (Figure 7).
The JV820 extract also contains putative PTM peaks which are novel and not present in the
JV180 extract. Two peaks eluting at 15.8 minutes (m/z 479) and 16.4 minutes (m/z 481) may
correspond to compounds similar to lysobacterene A or a 5-carbon ring intermediate. The JV820
extract also contained several novel PTM-like peaks do not appear in the extract of JV180
(Figure 8A, 8B). Two of these peaks eluting at 5.5 minutes and 6.4 minutes had similar UV
absorbance spectra as known PTM compounds, with absorbance maxima at approximately 222
nm and 322 nm (Figure 8C). The peak eluting at 6.4 minutes had an additional absorbance
maximum at approximately 404 nm, but this may have been due to a co-eluting compound.
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Figure 7. Strain JV820 produces some PTMs also produced by JV180. LC-MS/MS
chromatograms of extracts of JV180 and JV820.

To further verify if these compounds were PTMs, Edward Ding, a former undergraduate student
in the Blodgett lab, grew JV820 on YMS media supplemented with 50 μg/mL d7-L-ornithine,
which could be directly taken up and incorporated into PTMs. As expected, a +7 m/z shift was
observed in the mass transition for the peak eluting at 6.4 minutes (Figure 8D). However, at the
point when this experiment was carried out, I had an incorrect model for how PTMs fragmented
to produce a m/z 154.2 daughter ion. Therefore, I looked for the wrong m/z shift in the mass
transition for the peak eluting at 5.5 minutes. LC-MS/MS analysis of these novel peaks by their
product ion spectra or deletion of ftdB could be used to further verify their identity as PTMs.
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Figure 8. Strain JV820 may produce novel PTMs. Novel PTM-like peaks can be seen in the
extracted ion chromatograms for the (A) 495.2 -> 139.2 and (B) 511.2 -> 154.2 mass transitions.
(C) Absorbance spectra at 5.5 minutes and 6.4 minutes. (D) Precursor ion spectra at 6.4 minutes
for JV820 grown on YMS supplemented with 50 μg/mL L-ornithine (blue) or d7-L-ornithine
(red).

To investigate whether FtdG was responsible for modifying PTMs into these novel compounds,
Edward set out to delete the ftdG gene from JV820 (Table 3). Edward also ectopically expressed
ftdG in the parent rpsL mutant (JV1047), the ΔftdG mutant (JV1208), as well as the JV180 ΔftdF
mutant (JV1171) to test if he could complement loss of novel PTM compounds or cause JV180
to produce novel PTM compounds.
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Table 3. List of JV820 mutants and ftdG-expression strains
Strain
Genotype
Strain
Genotype
JV1047 JV820 rpsL_K43R
JV1171 JV180 rpsL_K43R ΔftdF colony a
JV1048 JV820 rpsL_K43M
JV1201 JV1171 + pJMD2-ftdG_819 colony
2
JV1049 JV820 rpsL_K88R
JV1202 JV1171 + pJMD2-ftdG_820 colony
1
JV1208 JV1047 ΔftdG colony #1
JV1203 JV1171 + pJMD2-ftdG_820 colony
2
JV1227 JV1047 + pJMD2-ftdG_820 colony JV1204 JV1171 + pJMD3-ftdG_820 colony
#1
1
JV1228 JV1047 + pJMD2-ftdG_820 colony JV1206 JV1171 + pJMD2-ftdG_823 colony
#2
1
JV1229 JV1047 + pJMD3-ftdG_820 colony JV1207 JV1171 + pJMD2-ftdG_823 colony
#1
2
JV1230 JV1047 + pJMD3-ftdG_820 colony
#2
JV1231 JV1208 + pJMD2-ftdG_820 colony
#1
JV1232 JV1208 + pJMD2-ftdG_820 colony
#2
JV1233 JV1208 + pJMD3-ftdG_820 colony
#1
JV1234 JV1208 + pJMD3-ftdG_820 colony
#2

Interestingly, no PTM peaks seemed to be lost when ftdG was deleted in JV820, but the sizes of
various PTM peaks increased or decreased (Figure 9A). Similarly, when ftdG was heterologously
expressed in JV1171, no new PTM peaks were added, but the relative amounts of PTM peaks
changed. After closer analysis, I noticed a pattern where FtdA-hydroxylated compounds
increased in peak area while non-hydroxylated compounds decreased in peak area (Figure 9B).
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Figure 9. FtdG does not create new PTM compounds but changes the amount of ratio of
hydroxylated and non-hydroxylated compounds. (A) LC-MS/MS chromatograms of JV1047
(JV820 rpsL_K43R) and JV1208 (JV1047 ΔftdG) and (B) PTM production by JV1171
expressing ftdGJV820 (n = 3, p values calculated by Student’s T-test relative to JV1171).

Therefore, I hypothesize that FtdG may somehow interact with FtdA and improve its catalytic
efficiency. In a similar case, a ferrodoxin reductase gene (FNR) encoded upstream of the HSAF
BGC in Lysobacter enzymogenes C3 appears to have a similar function, as its deletion caused a
similar reduction in HSAF (dihydromaltophilin) and accumulation of the precursor 3-deOH
HSAF (17). The FtdA-catalyzed hydroxylation appears to be necessary for the ability of HSAF
to inhibit some fungal targets, which may explain why mechanisms to increase its catalytic
efficiency may be selected for. To further test this hypothesis, Spencer Stumpf, a former
technician in the Blodgett lab, deleted ftdA from several strains. We hypothesized that if FtdG’s
function is to increase FtdA’s activity, then the JV820 ΔftdA (JV1521) and ΔftdA ΔftdG (JV1559)
double mutants should have the same PTM production profiles. While the mutants were
constructed, they were not analyzed in the same experiment, and may have been affected by
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batch-to-batch variation in PTM production profiles. These strains should be re-grown on the
same batch on media in triplicates to
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Figure 10. Preliminary LC-MS/MS analysis of JV820 ΔftdA and ΔftdA ΔftdG mutants.

3.3.3 Sea-sponge associated PTMs
In 1991, a novel PTM compound named discodermide was isolated from the marine sponge
Discodermia dissoluta (28). Since then, the PTMs cylindramide A and geodin A were also
isolated from sea sponges (29, 30). If a marine sponge was able to produce PTMs, this could
have been an interesting example of horizontal gene transfer. However, I hypothesized that it
may be more likely that these PTMs were produced by symbiotic bacteria, similar to how the
Altermonas sp. strain that was isolated from the sea sponge Halichondria okadai produces
alteramide A (31). These sponge-derived PTM molecules are structurally interesting as they
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contain two fewer carbon atoms (Figure 11). Due to their cytotoxic properties, these molecules
became the subject of numerous synthetic chemistry studies (32, 33).

Figure 11. Sponge-derived PTMs have two less carbon atoms. Atoms highlighted in red in
alteramide A and HSAF are missing in discodermide and cylindramide A.

I noticed that several PTM BGC sequences collected during bioinformatic analyses contained
several different open reading frames, including one predicted to encode a thioesterase (Figure
12). This was unusual as the iPKS-NRPS gene already encodes a thioesterase domain. I also
noticed that many of the strains containing these PTM BGCs were sea-sponge associated Gramnegative bacteria. Therefore, I hypothesize that these could be the BGCs responsible for
producing discodermide-like PTMs. It may be possible that the additional thioesterase enzyme
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prematurely terminates the elongation of the second polyketide chain, resulting in the omission
of two carbons. As these thioesterase genes are short, it may be possible to synthesize codonoptimized versions of these genes for ectopic expression in PTM-producing Streptomyces strains
in the future to test whether discodermide-like PTMs can be produced. The Pseudoalteromonas
flavipulchra strain JG1 PTM BGC also contains additional ORFs which may be involved in
PTM production (Figure 12). In place of the commonly found ftdA, the first ORF encodes an
acetylornithine deacetylase. This enzyme may help to supply additional ornithine precursor for
PTM production, similar to the arginase found upstream of the HSAF BGC in Lysobacter
enzymogenes strain C3. Two ORFs encoding a transmembrane protein and an efflux protein
likely help to provide self-resistance by exporting PTMs into the environment. A short ORF
encoding a flavodoxin may provide a redox partner for the phytoene dehydrogenases that are
responsible for the cyclization of the PTM.

Figure 12. Sponge-associated bacteria contain unusual PTM BGCs, which may produce
cylindramide-type PTMs.
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3.3.4 Genome sequencing of 96 Actinomycetes
The Blodgett lab has two ever-growing collections of environmentally isolated Actinomycetes.
The BE (Blodgett Environmental) strain collection contains strains isolated from enrichment
cultures of local soil samples by undergraduate students, technicians, and rotating graduate
students, while the BIOL3493 strain collection contains strains isolated by WUSTL students in
the BIOL3493: Bacterial Prospecting and Biotechnology course. A large proportion of the BE
strain collection were screened for their ability to inhibit the growth of Pseudogymnoascus
destructans, the causative agent of bat white-nose syndrome (WNS) (34). Many strains which
produced strong inhibitory activity were PCR-screened with degenerate primers for signatures of
ftdB, the PTM iPKS-NRPS, or pzbB, which produces the non-proteinogenic amino acid Lpiperazate (26, 35). All strains in the BIOL3493 collection also undergo the ftdB degenerate PCR
screen as part of the coursework. The Blodgett lab received funding to sequence the genomes of
96 strains with 2 x 150 bp Illumina sequencing and to complete the genomes of 10-15 strains
with 2 x 300 bp Illumina sequencing and long-read PacBio sequencing. Of the strains chosen for
sequencing, 56 strains originated from the BE collection, 23 originated from the BIOL3493
collection, and 14 strains originated from a collection of strains (JV176, JV177, JV179-JV190)
isolated by Dr. Blodgett at Harvard in 2010 (Table 4). Additionally, 3 strains (S. jamaicaensis
NCIMB 10166, Kutzneria buriramensis DSM 45791, and S. malaysiense DSM 100712)
originated from public culture collections and were chosen for sequencing in an attempt to close
the gaps of BGCs of interest in the original draft genomes.

112

Table 4. List of strains chosen for 2 x 150 bp Illumina sequencing and assembly results
Strain

Reason for sequencing

Length (bp)

Contig #

N50 (bp)

AL04

BIOL3493, rare species, strong broad-spectrum inhibitor

11,301,112

782

164,142

BAT2

BE strain, Tyler isolate

contaminated (2 Streptomyces)

BAT24

BE strain, Tyler isolate, PzbB positive

9,486,057

357

256,527

BAT26

BE strain, Tyler isolate, PzbB positive

9,506,583

411

281,640

BAT42

BE strain, Tyler isolate, PzbB positive

9,492,239

375

256,527

BB07

BIOL3493, PTM-positive

10,676,817

376

183,423

BB09

BIOL3493, PTM-positive

10,395,563

501

203,602

BE10

Pamamycin

9,603,600

301

348,969

BE12

Pamamycin

9,580,770

237

356,864

BE121

PzbB positive

10,610,326

608

230,468

BE128

PTM producing

8,918,868

326

183,478

BE13

PTM producing

8,533,920

305

264,667

BE132

WNS inhibitor F

8,064,299

341

436,993

BE133

PzbB positive, WNS inhibitor J

9,930,516

746

105,986

BE137

PTM producing

7,763,681

343

153,795

BE147

WNS inhibitor A1

9,284,533

405

277,560

BE148

PTM producing

9,218,342

305

215,089

BE174

PTM producing

9,739,818

390

285,901

BE185

PTM producing

9,793,097

584

131,456

BE188

PTM producing

8,076,758

285

266,673

BE20

PTM producing, WNS inhibitor A2

10,271,073

1,260

105,095

BE206

PTM producing, WNS inhibitor A2

9,914,897

943

121,580

BE225

PTM producing

10,031,912

1,066

116,972

BE227

PzbB positive

9,049,326

335

263,218

BE228

WNS inhibitor C2,

9,820,179

254

315,646

BE230

PzbB positive

9,001,909

307

254,675

BE237

PzbB positive

contaminated (Streptomyces + Kocuria)

BE24

PTM producing

7,971,324

798

141,216

BE277

Strongly anti-C. neoformans

9,017,290

302

277,108

BE28

PTM producing

8,043,392

272

457,457

BE282

PzbB positive, WNS inhibitor F

8,598,617

306

370,259

BE284

WNS inhibitor

9,833,168

481

288,600

BE29

PTM producing

8,075,161

370

376,521

BE303

PTM producing

9,891,409

970

116,825

BE304

PzbB positive

contaminated (2 Streptomyces)

BE308

WNS inhibitor B1

9,261,303

423

215,089

BE313

PTM producing

8,724,148

419

174,959

113

BE315

PzbB positive

9,562,638

372

280,975

BE319

PTM producing

8,558,901

263

331,196

BE32

PTM producing

8,219,217

250

284,361

BE320

PTM producing

8,493,263

498

170,937

BE323

broadly anti-fungal

9,756,673

391

387,221

BE327

PTM producing

8,500,088

246

404,390

BE33

PTM producing

10,217,343

936

100,891

BE34

PTM producing

10,166,712

1,023

117,209

BE345

anti-C. neoformans

8,744,333

664

157,290

BE350

PTM producing

8,066,878

344

374,272

BE356

PzbB positive, WNS inhibitor O

9,304,540

768

123,559

BE38

WNS inhibitor

10,012,355

366

290,019

BE39

PzbB positive

10,003,645

334

286,490

BE42

WNS inhibitor B2

9,195,459

396

234,316

BE45

PTM producing

9,454,890

1,019

110,999

BE48

WNS inhibitor

10,015,493

369

290,003

BE54

WNS inhibitor

9,979,542

264

351,252

BE76

WNS inhibitor

9,931,428

349

281,144

BE78

WNS inhibitor

9,876,433

391

285,745

BE83

PTM producing

7,831,504

403

152,811

BE87

PTM producing

10,934,189

1,349

105,073

BM10

BIOL3493, rare species, possible PTM

8,907,934

693

206,289

BM11

BIOL3493, rare species

contaminated (E. coli)

BM12

BIOL3493, rare species

8,368,232

113

718,560

CM02

BIOL3493, PTM producer

8,032,753

362

431,047

CM03

BIOL3493, PTM-positive

9,441,162

523

192,487

CS02

BIOL3493, PTM-positive

7,792,961

309

344,841

CS05

BIOL3493, PzbB positive

9,946,654

356

301,199

CS06

BIOL3493, PzbB positive

8,682,499

361

238,624

EM04

BIOL3493, PTM-positive

7,423,092

715

167,922

EM07

BIOL3493, PzbB positive

8,347,011

420

162,775

EM08

BIOL3493, PTM-positive

7,102,563

485

288,813

ENG2

BE strain, Tyler isolate

7,437,980

197

285,969

ENG35

BE strain, Tyler isolate

7,437,360

198

285,834

ES09

BIOL3493, PTM-positive

8,004,884

384

350,916

JA06

BIOL3493, possible PTM

10,251,260

434

168,112

JA07

BIOL3493, rare species

7,602,102

229

550,036

JA12

BIOL3493, possible PTM

8,628,358

387

263,986

JA17

BIOL3493, possible PTM

8,242,768

569

166,691
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JG07

BIOL3493, PzbB positive

8,697,082

403

291,113

JV176

HSAF screen #8

9,180,255

297

395,164

JV177

HSAF screen #23

9,094,990

685

252,002

JV179

HSAF screen #33

9,158,385

234

413,960

JV180

HSAF screen #38

8,082,789

391

385,067

JV181

HSAF screen #42

7,826,196

256

355,395

JV182

HSAF screen #44

10,924,231

3,819

240,575

JV183

HSAF screen #45

9,210,398

447

164,957

JV184

HSAF screen #69

9,471,885

470

206,890

JV185

HSAF screen #71

8,952,695

458

210,935

JV186

HSAF screen #75

7,236,288

397

223,038

JV187

HSAF screen #32

11,784,417

441

149,906

JV188

HSAF screen #47

9,392,901

504

254,039

JV189

HSAF screen #60

9,429,214

611

211,373

JV190

HSAF screen #65

8,992,785

507

343,451

JV974

S. jamaicensis

10,325,532

765

208,728

JV995

Kutzneria buriramensis

8,125,896

662

156,601

JV996

Streptomyces malaysiense

8,094,488

570

156,601

KL33

BIOL3493, strong clifednamide A producer

10,339,804

482

189,496

MRY08

BIOL3493, PzbB positive

9,339,871

708

92,810

Jennifer Greif, a former undergraduate student in the Blodgett lab, extracted the genomes of 95
of these strains with a Qiagen DNeasy UltraClear microbial kit. Spencer Stumpf and I extracted
the genomes of the strains chosen for PacBio sequencing using a phenol-chloroform protocol.
The library preparation, sequencing, and genome assembly were carried out by a team at the
McDonnell Genome Institute (WUSTL). Based on research relevance and draft genome
assembly, roughly 20 strains were chosen to receive additional 2 x 300 bp Illumina sequencing
or long-read PacBio sequencing. Out of these strains, the 10 strains which yielded abundant
genomic DNA sample by phenol-chloroform extraction were chosen for PacBio sequencing,
while another subset of 15 strains received additional 2 x 300 bp Illumina sequencing (Tables 5
and 6). The genomes of two strains, which underwent the original 2 x 150 bp Illumina
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sequencing and PacBio sequencing, were published with details on library preparation,
sequencing, and assembly (see Chapter 7).
The 15 TruSeq PCR-free libraries which were chosen for additional Illumina sequencing were
PCR amplified with KAPA Hi-Fi for 5 cycles. The final libraries were assessed on a
BioAnalyzer (Agilent) for size and a Qubit Fluorometer (Invitrogen) for mass. The concentration
of each final library was determined through qPCR (Kapa Biosystems). The libraries were
normalized and pooled. The pool of libraries was loaded on a MiSeq 600 cycle v3 flow cell
generating 2 x 300 paired end sequence data targeting an additional 100x coverage per sample.
Draft genomes were assembled using MEGAHIT as with the original 96 assemblies.
Interestingly, the additional 2 x 300 bp sequencing did not seem to greatly improve the quality of
the draft genomes, as evidenced by the contig counts and N50 lengths. This discrepancy may be
partly due to the original 2 x 150 sequencing producing enough read data for approximately 200x
fold coverage the additional while the 2 x 300 sequencing only resulted in roughly 50x fold
coverage for each genome.
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Table 5. List of strains chosen for 2 x 300 bp Illumina sequencing and assembly results
Original (2 x 150)
Original + Miseq (2 x 301)
Sample

Total
Contig
bases (Kb) #

Length
(bp)

N50
(bp)

Total
Contig
bases (Kb) #

Length
(bp)

N50
(bp)

AL04
BAT24
BE277
BE282
BE356
BM10
EM04
ES09
JA06
JG07
JV180
JV186
JV974
JV995
JV996

2,036,885

782

11,301,112

164,142

391,201

821

11,458,582

193,646

1,729,231

357

9,486,057

256,527

404,482

383

9,494,737

277,984

2,148,815

302

9,017,290

277,108

498,118

290

8,694,361

277,108

2,489,907

306

8,598,617

370,259

581,536

305

7,892,733

357,090

2,424,424

768

9,304,540

123,559

618,654

795

9,316,203

183,166

2,414,060

693

8,907,934

206,289

567,420

701

8,913,205

206,289

2,845,561

715

7,423,092

167,922

587,621

772

7,445,144

165,518

1,974,693

384

8,004,884

350,916

683,659

359

7,998,661

415,023

2,235,084

434

10,251,260

168,112

457,259

442

10,254,302

213,176

1,948,056

403

8,697,082

291,113

525,690

428

8,705,345

291,113

3,402,599

391

8,082,789

385,067

707,881

454

8,104,256

444,161

1,870,266

397

7,236,288

223,038

892,132

471

7,262,953

245,626

2,156,619

765

10,325,532

208,728

714,113

814

10,235,916

259,587

2,280,918

662

8,125,896

156,601

490,565

650

8,122,922

158,799

1,718,066

570

8,094,488

156,601

536,857

599

8,107,249

158,799

As compared to the Illumina sequencing, PacBio sequencing allowed for the genomes to be
assembled on much fewer genomes. In one case (BE327), a full genome was assembled. These
high-quality assemblies allowed for fragmented biosynthetic gene clusters in the Illumina
assemblies to be joined, providing a clearer view of the biosynthetic potentials of these strains.
Preliminary analysis of the draft genomes revealed that one strain (BM11) was actually an E. coli
contaminant. Additionally, 3 strains (BAT2, BE237, and BE304) contained a mixture of two
strains. Finally, four strains (BE28, BE29, BE132, and BE350) proved to be re-isolates of JV180,
which was probably accidentally introduced into the isolation plates.
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Table 6. List of strains chosen for PacBio sequencing and assembly results
Original (2 x 150)
PacBio
Sample

Contig #

Length
(bp)

N50
(bp)

Total bases
(Kb)

Contig #

Length
(bp)

Largest
contig (bp)

BE133
BE277
BE308
BE319
BE327
BE356
CS06
JV180
JV184
JV974

746

9,930,516

105,986

2,550,310,971

5

9,791,935

9,306,862

302

9,017,290

277,108

3,702,241,109

2

8,644,767

8,641,032

423

9,261,303

215,089

3,751,302,636

6

9,210,507

7,647,761

263

8,558,901

331,196

3,239,280,775

4

8,575,992

4,785,636

246

8,500,088

404,390

5,692,994,945

1

8,476,695

8,476,695

768

9,304,540

123,559

2,779,481,931

3

6,616,652

6,569,312

361

8,682,499

238,624

4,814,006,921

4

8,567,140

7,192,574

391

8,082,789

385,067

2,597,107,056

5

8,006,517

7,244,875

470

9,471,885

206,890

4,738,490,877

2

9,405,146

8,599,015

765

10,325,532

208,728

6,375,991,040

4

10,211,859

9,614,926

Although many of the sequenced strains originated from the same few soil samples, preliminary
analysis of the 88 remaining draft genomes reveals a large diversity of Streptomyces, with 16S
sequences ranging from 94.7% - 100% identity (Figure 13). Furthermore, two strains, JA07 and
BM12, belong to the actinomycete genera Nocardia and Kribella, respectively. A tBLASTn
search with the FtdB amino acid sequence of JV180 as the query revealed that 42 strains had
PTM BGCs. In addition, I found 38 pzbB homologs and 5 pzbAB homologs.
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Figure 13. The genome-sequenced strains represent a diverse collection of Streptomyces. The
16S sequence of S. coelicolor strain A(3) was used as the query of a BLASTn search to extract
the 16S sequences from the 88 genome-sequenced strains (indicated in blue). Sequences which
did not have close matches in my in-house 16S sequence list were used as queries in BLASTn
searches against the nr database in GenBank to identify their closest relatives. Where possible,
the sequences of type strains were used for the phylogeny. Sequences were aligned with
MUSCLE, degapped, and used to build a neighbor-joining tree with the Kimura80 nucleotide
substitution model in CLC Main Workbench. A root was set above the node containing several
non-Streptomyces actinomycetes. Branches which supported by less than 25% of 500 bootstrap
simulations were collapsed.
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The PTM BGCs showed remarkable diversity in gene content (Figure 14 and 15). Of the 42
PTM BGCs, 23 of them have the same ftdABCDEF gene arrangement as the frontalamide BGC
of Streptomyces. sp. strain SPB78. Based on bioinformatic searches in other published genome
sequences, this type of PTM BGC appears to be the most commonly found. In addition, 11 of the
isolates have clifednamide-type PTM BGCs and 3 strains had ftdG-containing BGCs. I also
noticed that 3 strains had ftdE-less PTM BGCs. Based on the established role of FtdE, these
strains should produce alteramide-like PTMs with 5-5 carbon ring systems. Interestingly, these
strains appear to have a novel CYP450 enzyme, which is more like CftA and IkaD than FtdF,
based on amino acid sequence alignments. These novel CYP450 enzymes may produce PTMs
with novel modifications. Additionally, two other strains, BM10 and CS02 have PTM BGCs
with unique contents, which could produce novel molecules.
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Figure 14. The genome-sequenced strains encode diverse FtdB enzymes, reflecting diverse PTM
BGCs. The FtdB amino acid sequence of Streptomyces sp. strain JV180 was used as the query of
a BLASTx search to extract the FtdB sequences from the 88 genome-sequenced strains
(indicated in blue). Sequences were aligned with ClustalOmega against an in-house collection of
FtdB sequences, degapped, and used to build a neighbor-joining tree with the Jukes-Cantor
substitution model in CLC Main Workbench. A root was set above the node containing FtdB
sequences from Gram-negative proteobacterial strains. Branches which supported by less than
25% of 500 bootstrap simulations were collapsed. FtdB sequences belonging to strains that have
been characterized for PTM production were indicated in red.
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A more detailed and comprehensive phylogenetic analysis of all available PTM BGCs is being
conducted by Blodgett lab members Anna Day, an undergraduate student, and Chris Harper, a
PMB student. In summary, in this chapter I have detailed bioinformatic and experimental work
undertaken to study diversity in PTM BGC gene content and how they cause PTM structural
differences. Bioinformatic analyses of our data and other publicly available bacterial genomes
reveals a large diversity in the gene contents of PTM BGCs. Further characterization of the
products of these clusters should reveal diverse PTMs, which may have novel or improved
antibiotic or cytotoxic properties. Furthermore, deducing the functions of PTM tailoring enzymes
will open the door for combinatorial biosynthesis of even more PTM chemical structures through
synthetic biology. Finally, comparative metabolomic and genomic analyses of these strains could
reveal novel mechanisms that cause differences in the regulation of strong and weakly expressed
PTM BGCs, similar to the work described in chapters 2 and 3.
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Figure 15. Diversity of PTM BGCs encoded by the genome-sequenced strains.
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3.4 Discussion
PTMs demonstrate remarkable chemical and functional diversity despite the genetic simplicity of
their biosynthetic gene clusters. These chemical modifications can result in major changes in the
binding targets and affinities of these molecules, which may also translate to increased efficacy
or reduced side effects for antibiotics and other drugs. Structural changes in natural products are
often the result of changes in the enzymes encoded for by biosynthetic gene clusters, or off-target
effects by other enzymes encoded in the host strains.
By collecting the sequences of PTM BGCs, I was discovered a large diversity of PTM BGCs. I
predicted several correlations between the predicted enzymes and previously isolated PTM
molecules without cognate BGCs. This resulted in the discovery of the clifednamide BGC and
the novel PTM-tailoring cytochrome P450, CftA (see Chapter 6). I also predicted and tested the
functions of FtdF and FtdG. I also predicted that an unusual type of PTM BGC found in sea
sponge-associated bacteria may be responsible for producing the cylindramide-type PTMs.
Finally, I was also involved in the sequencing of numerous Actinomycete isolates obtained by
the Blodgett lab as well as WUSTL undergraduate students in the BIOL3493 class. The genomes
of these bacteria and others deposited on GenBank reveal an even greater diversity of PTM
BGCs than described in this chapter.
As whole-genome sequencing technologies continue to improve and become more accessible, it
is reasonable to predict that even more types of PTM BGCs may be discovered. Studying these
PTM BGCs should result in the discovery of novel PTM molecules, which may have improved
inhibitory activity, or novel targets. Even if certain PTM BGCs may not be readily expressed, the
wide distribution of PTM BGCs makes it likely that another strain could be isolated that actively
expresses the same BGC. The distribution of PTM BGCs is likely related to its genetic
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simplicity, which also makes simplifies engineering approaches that seek to activate expression
by regulatory manipulation, if such a route is chosen. In summary, PTMs have numerous
potential applications, and study of PTM biosynthesis offers potential for numerous useful
discoveries. As the functions of more PTM biosynthetic enzymes are further characterized, novel
PTMs could be produced through combinatorial BGCs with biosynthetic genes originating from
different PTM BGCs.
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Chapter 4: Draft Genome Sequence of
Streptomyces sp. strain JV178, a Producer of
Clifednamide-Type Polycyclic Tetramate
Macrolactams
This chapter was previously published in the journal Genome Announcements as:
Qi Y, D’Alessandro JM, Blodgett JAV. 2018. Draft genome sequence of Streptomyces sp. strain
JV178, a Producer of Clifednamide-Type Polycyclic Tetramate Macrolactams. Genome
Announc. 6:e01401-17. https://doi.org/10.1128/genomeA.01401-17.

4.1 Personal contributions
I performed bioinformatic analyses to hypothesize that Streptomyces sp. strain JV178 likely had
a novel polycyclic tetramate macrolactam (PTM) biosynthetic gene cluster (BGC). In particular,
I hypothesized that the JV178 PTM BGC may be similar to that of Streptomyces torulosus strain
NRRL B-3889, based on sequence homology to the fragment of the JV178 PTM BGC that had
been PCR-amplified and sequenced by Dr. Joshua Blodgett. I provided the phenol-chloroform
DNA extract protocol that was used by John D’Alessandro, a former technician in the Blodgett
lab, to extract genomic DNA. The genomic DNA of strain JV178 was submitted for Illumina
sequencing by the McDonnell Genome Institute (WUSTL), along with actinophage genome
samples from the BIOL 191 undergraduate Phage Hunters course, by Dr. Chris Shaffer, an
instructor for the course. I performed the quality control, adaptor trimming, de novo assembly,
and annotation of the JV178 genome. Dr. Blodgett and I wrote the manuscript.
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4.2 Abstract
Here, we report the draft genome sequence of Streptomyces sp. JV178, a strain originating from
Connecticut (USA) garden soil. This strain produces the polycyclic tetramate macrolactam
compounds clifednamides A and B. The draft genome contains 10.65 Mb, 9,045 predicted
protein coding sequences, and several natural product biosynthetic loci.

4.3 Genome Announcement
Members of the Streptomyces genus of Gram-positive filamentous bacteria produce diverse
secondary metabolites, including two-thirds of clinical antibiotics (1). Streptomyces genomes
have been shown to contain a rich repertoire of small-molecule-encoding biosynthetic loci (2). A
high proportion of sequenced Streptomyces strains encode the biosynthesis of polycyclic
tetramate macrolactams (PTMs) (3). Streptomyces sp. strain JV178 was isolated from a
Connecticut (USA) garden soil sample during a screen to discover new PTM compounds (4). We
have sequenced its genome to further understand clifednamide-type PTM biogenesis.
Strain JV178 was grown in Trypticase soy broth supplemented with 0.6% glycine at 28°C.
Genomic DNA was extracted by phenol-chloroform extraction as described elsewhere (5).
Sequencing was performed on a MiSeq platform (2 × 301-bp reads [Illumina, Inc., San Diego,
CA, USA]) on a paired-end library prepared using a high-throughput library preparation kit
(Kapa Biosystems). Adapter sequences and low-quality reads (quality score 0.05) were removed
using CLC Genomics Workbench (CLC Bio-Qiagen, Aarhus, Denmark). The trimmed reads
totaled 3,064 Mb, corresponding to approximately 287-fold coverage. De novo genome assembly
was performed in CLC Genomics Workbench, and resulting contigs having less than 200 bp or 3
average coverage were discarded. The resulting draft genome contains 10,650,097 bp in 759
contigs (N50, 540,451 bp), with a G+C content of 71.0%. Gene prediction and annotation by the
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Rapid Annotations using Subsystems Technology version 2.0 pipeline (6, 7) predicted 9,045
protein coding sequences and 126 RNA genes.
Automated secondary metabolism analysis using antiSMASH version 4.0 (8) and PRISM version
3.0 (9) predicted 39 biosynthetic gene clusters. Six of these matched known clusters for
concanamycin (10), coronafacic acid (11), marineosins (12), melanin, ectoine, and anticapsin
(13). Using this sequence, the clifednamide biosynthetic cluster was also found (14), along with
clusters predicted to encode five terpenes, three polyketides, three non-ribosomal peptides, eight
hybrid polyketide/non-ribosomal peptides, four siderophores, five lantipeptides, a single lasso
peptide, and three bacteriocins. Multi-locus sequence alignment using atpD, gyrB, recA, rpoB,
and trpB concatenates (15) identified the closest sequenced relative of strain JV178 as
Streptomyces torulosus strain NRRL B-3889, consistent with prior 16s rRNA gene analysis (3).
These results place this strain in the S. scabiei clade (16), which contains several plant-associated
Streptomyces species, including the potato pathogen S. scabiei 87.22 (17). While we failed to
detect homologs of known pathogenicity loci, such as txtAB (18), eight genes were predicted to
encode the plant-growth hormone auxin. The absence of recognizable pathogenicity loci and the
predicted ability to produce the plant modulators concanamycin (10), coronafacic acid (11), and
auxin suggest a plant-associated but nonpathogenic lifestyle. These observations suggest
potential roles for the clifednamides, whose targets are still unknown.

4.3.1 Accession number(s)
The draft genome sequence of Streptomyces sp. strain JV178 was deposited in
DDBJ/ENA/GenBank under the accession number PEKU00000000. The version described in
this paper is the first version, PEKU01000000.
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Chapter 5: Native and Engineered
Clifednamide Biosynthesis in Multiple
Streptomyces spp.
This chapter was previously published in the journal ACS Synthetic Biology as:
Qi Y., Ding E., and Blodgett J., Native and Engineered Clifednamide Biosynthesis in Multiple
Streptomyces spp., ACS Synthetic Biology 7, 357-362 (2017). DOI: 10.1021/acssynbio.7b00349

5.1 Personal contributions
I identified putative clifednamide-type PTM BGCs in the genomes of several Streptomyces
strains previously deposited on GenBank. I obtained four genome-sequenced strains with
putative clifednamide-type PTM BGCs and one genome-sequenced strain with an ikarugamycintype PTM BGC from the Agricultural Research Service culture collection (NRRL – Northern
Regional Research Laboratory). In addition, an undergraduate student in Dr. Joshua Blodgett’s
BIOL3493 class isolated another clifednamide-producing strain, KL33. I characterized these
strains for PTM production and genetic tractability and generated a ΔcftA mutant of
Streptomyces sp. strain NRRL F-6131. Edward Ding, a former undergraduate student in the
Blodgett lab, cloned the cftA expression plasmids and conjugated the strains into the
ikarugamycin producer Streptomyces sp. strain NRRL F-2890. I characterized the PTM
production from these strains and identified clifednamide C as a novel congener through MS/MS
fragmentation and d7-L-ornithine incorporation. Dr. Blodgett and I wrote the manuscript.
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5.2 Abstract
Polycyclic tetramate macrolactam (PTM) natural products are produced by actinomycetes and
other bacteria. PTMs are often bioactive, and the simplicity of their biosynthetic clusters make
them attractive for bioengineering. Clifednamide-type PTMs from Streptomyces sp. strain JV178
contain a distinctive ketone group, suggesting the existence of a novel PTM oxidizing enzyme.
Here, we report the new cytochrome P450 enzyme (CftA) is required for clifednamide
production. Genome mining was used to identify several new clifednamide producers, some
having improved clifednamide yields. Using a parallel synthetic biology approach, CftA
isozymes were used to engineer the ikarugamycin pathway of Streptomyces sp. strain NRRL F2890 to yield clifednamides. Further, we observed that strong CftA expression leads to the
production of a new PTM, clifednamide C. We demonstrate the utility of both genome mining
and synthetic biology to rapidly increase clifednamide production.

5.3 Letter
Actinomycete bacteria are widely studied for their ability to produce diverse bioactive secondary
metabolites. Already the source of nearly two-thirds of clinical antibiotics,1 actinomycete
genome sequencing has revealed a wealth of previously unrecognized biosynthetic gene
clusters.2−4 With many of these clusters apparently encoding drug-like molecules, these
organisms remain as promising sources of much-needed future antibiotics and other
therapeutics.5,6
An unusually high proportion of sequenced actinomycete genomes contain polycyclic tetramate
macrolactam (PTM) biosynthetic clusters.7 PTMs are of therapeutic interest, with family
members having documented activity against bacteria, protozoa, fungi, plants, and cancer cell
lines.8−11 In addition to their bioactivity, the relative simplicity and commonality of PTM
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biosynthetic loci has made them attractive targets for genomics-based discovery and engineering
via synthetic biology approaches.12−14 Despite containing only 3−6 genes, these small clusters
encode diverse structures15 (Figure 1).

Figure 1. Representative PTM biosynthetic clusters and their products. (A) the Streptomyces sp.
strain JV178 clifednamide cluster (A: R = H, B: R = OH); (B) the Streptomyces sp. strain ZJ306
ikarugamycin cluster; (C) The Lysobacter enzymogenes C3 HSAF cluster; (D) the Streptomyces
sp. strain SPB78 frontalamide cluster (A: R = OH, B: R = H). Orange ORFs encode for sterol
desaturases, red for iterative polyketide synthase nonribosomal peptide synthase fusion proteins,
green for FAD-dependent oxidoreductases, blue for zincdependent alcohol dehydrogenases, and
yellow for cytochrome P450s. ORFs in black are not conserved between PTM biosynthetic
clusters

The clifednamides are a family of PTMs discovered from Streptomyces sp. strain JV178, an
environmental isolate from Connecticut garden soil.16 The clifednamides have therapeutic
potential due to their structural similarity with ikarugamycin, which is active against a wide
range of organisms.8,10,11 The clifednamides are distinguished from ikarugamycin by a ketone
group on carbon 29 (Figure 1A). However, efforts to extensively profile clifednamide
bioactivities have been limited by low yields from strain JV178 (Table 1).
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Table 1. PTM Titers from Strains in This Study a,b
Strain
S. sp. strain JV178
S. purpeofuscus
S. sp. strain NRRL F-6131
S. sp. strain F-6131 rpsL
(K43N)
S. torulosus
S. neyagawaensis
S. sp. strain KL33
S. sp. strain NRRL F-2890
S. sp. strain F-2890
PermE*pDA1652-cftAJV178
S. sp. strain F-2890
PermE*pHM11a-cftAJV178
S. sp. strain F-2890
PermE*pDA1652-cftApurpeofuscus
S. sp. strain F-2890
PermE*pHM11a-cftApurpeofuscus
S. sp. strain F-2890
PermE*pDA1652-cftAF-6131
S. sp. strain F-2890
PermE*pHM11a-cftAF-6131
S. sp. strain F-2890
PermE*pDA1652-cftAtorulosus
S. sp. strain F-2890
PermE*pHM11a-cftAtorulosus

Ikarugamycin

Clifednamide A

Clifednamide B

Clifednamide C

Trace
Trace*
Trace*
Trace*

0.94 μM
Trace
Trace*
Trace*

1.87 μM
0.10 μM
Trace*
Trace*

N.D.
N.D.
N.D.
N.D.

N.D.
N.D.
N.D.
28.2 ± 5.27 μM
1.10 ± 0.68 μM

0.30 μM
19.53 μM
3.23 μM
N.D.
13.7 ± 1.04 μM

0.91 μM
6.46 μM
N.D.
N.D.
N.D.

N.D.
7.20 μM
0.55 μM
N.D.
2.62 ± 0.70 μM

N.D.

19.8 ± 4.86 μM

N.D.

16.6 ± 0.01 μM

12.7 ± 2.08 μM

15.8 ± 2.79 μM

N.D.

Trace*

3.20 ± 0.34 μM

13.5 ± 3.02 μM

N.D.

0.87 ± 0.06 μM

12.9 ± 0.96 μM

18.0 ± 1.13 μM

N.D.

Trace*

1.95 ± 0.47 μM

15.2 ± 1.58 μM

N.D.

3.96 ± 0.80 μM

3.03 ± 0.14 μM

17.8 ± 4.37 μM

N.D.

1.03 ± 0.15 μM

0.99 ± 1.14 μM

17.4 ± 1.73 μM

N.D.

4.27 ± 2.31 μM

*

a

N.D.: Not detected. b Trace*: A credible MS/MS signal is found at the expected retention time,
but the corresponding UV peak area was below the threshold for reliable quantification (>83
nM).

To understand clifednamide biosynthesis toward engineering its production, strain JV178 was
genome-sequenced (see Methods). Due to the structural similarity of ikarugamycin and
clifednamides, we expected strain JV178 would encode an ikarugamycin-like PTM cluster.
Using BLAST, we identified a 5-gene PTM locus that likely encodes the clifednamides.
Homology analysis of these genes allowed us to propose a plausible clifednamide biosynthetic
pathway (Figure S1).
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Three of the genes, ikaA, ikaB and ikaC, recapitulate the ikarugamycin cluster.12 As such,
clifednamide biosynthesis likely begins with IkaA, an iterative polyketide synthase/
nonribosomal peptide synthase fusion protein. Biochemical studies of its ortholog in HSAF
biosynthesis17 indicate the protein initiates PTM biosynthesis by ligating two polyketide chains,
built from six malonyl-CoA precursor units each, to the nonproteinogenic amino acid L-ornithine
(Figure S1).18 The resulting tetramate-polyene product is reductively cyclized by IkaB and IkaC
to produce the 5−6−5 carbon ring system shared by ikarugamycin and clifednamides.19 A ftdA
homologue was also found in the cluster. A PTM hydroxylase common to a number of PTM
pathways,7,20,21 ftdA is likely responsible for the C25 hydroxyl group of clifednamide B. The
remaining open reading frame is encoded between ikaA and ikaB (Figure 1A). Predicted to
encode a novel cytochrome P450, we reasoned its cognate enzyme (designated CftA, for
clifednamide tailoring A) may install the C29 ketone of the clifednamides. No additional PTM
genes were detected in the genome of strain JV178, further suggesting the cftA-containing cluster
encodes the clifednamides.
Strain JV178 was poorly transformed with plasmids having a pSG5 origin of replication,
confounding gene deletion analyses in this strain. Toward experimentally verifying our
clifednamide biosynthetic model, we thus used a genome mining approach to identify additional
producers. Several actinomycetes having publicly available genome sequences were found to
harbor PTM clusters syntenic with the strain JV178 locus (Figure S2).
Four such strains were obtained from the USDA NRRL strain collection. Each strain was grown
on a panel of solid media and extracted with ethyl acetate for LC−MS/MS analysis.
Clifednamide production was determined by comparison with extracts containing clifednamides
A and B from strain JV178. All four strains appear to produce both compounds based on product
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retention times, UV absorbance spectra, and mass fragmentation patterns (Figure 2). Notably,
Streptomyces neyagawaensis strain NRRL B-3092 produced approximately 26 μM of
clifednamides A and B combined, about 10-fold greater than Streptomyces sp. strain JV178
(Figure 2E, Table 1). The other three strains, Streptomyces purpeofuscus strain NRRL B-1817,
Streptomyces sp. strain NRRL F-6131, and Streptomyces torulosus strain NRRL B-3889
produced considerably lower amounts (Figure 2B−D, Table 1). Interestingly, a local PTMproducing soil isolate (Streptomyces sp. strain KL33, Supporting Information) also produced
significant clifednamide A titers, but no clifednamide B was detected (Figure 2F).

Figure 2. LC-MS/MS chromatograms of clifednamide production by (A) Streptomyces sp. strain
JV178, (B) Streptomyces purpeofuscus strain NRRL B-1817, (C) Streptomyces sp. strain NRRL
F-6131, (D) Streptomyces torulosus strain NRRL B-3889, (E) Streptomyces neyagawaensis strain
NRRL B-3092, and (F) Streptomyces sp. strain KL33. The retention times for clifednamides A and
B (cfA and cfB) are indicated by grey bars.

Of the newly obtained clifednamide producers, Streptomyces sp. strain NRRL F-6131 proved to
be the most amenable to intergeneric conjugation. This strain was thus used to interrogate
clifednamide biosynthesis. A rpsL(K43N) mutant was isolated for streptomycin
counterselection.22 As noted for other Streptomyces metabolites, this lesion also increased PTM
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production23 (Figure 3A,B). Markerless cftA deletion resulted in the loss of clifednamide
production. However, the strain produced increased amounts of a previously minor compound
(m/z 479) (Figure 3C). This peak was confirmed to be ikarugamycin by comparison with an
authentic standard, and its apparent accumulation is consistent with it being a clifednamide
biosynthetic precursor. An additional peak of interest (m/z 495) was detected in the ΔcftA
mutant. This was tentatively identified as butremycin, a known C25-hydroxyl derivative of
ikarugamycin (Figure S1).24 The experimental mass matches the compound and its UV profile is
consistent with other PTMs. MS/MS analysis revealed a daughter ion with a m/z of 154,
consistent with C25-hydroxylated PTMs such as clifednamide B. Because butremycin is
structurally equivalent to clifednamide B lacking the C29 ketone, it is an expected biosynthetic
precursor.

Figure 3. Deletion of cftA in Streptomyces sp. strain NRRL F-6131. LC-MS/MS chromatograms
of extracts from (A) the wild-type strain, (B) the rpsL (K43N) mutant, and (C) the rpsL ΔcftA
double mutant. The peaks for ikarugamycin (ika), butremycin (but), clifednamide A (cfA), and
clifednamide B (cfB) are indicated with dotted lines.
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Our biosynthetic model suggested an ikarugamycin-producing microbe could be engineered to
produce clifednamide via cftA expression. BLAST searches using sequences from the
characterized ika cluster of Streptomyces sp. strain ZJ30619 identified Streptomyces sp. strain
NRRL F-2890 (hereafter referred to as strain F-2890) as a candidate ikarugamycin producer.
Characterization of the strain revealed it produced up to 28 μM (13.6 mg/L) of ikarugamycin
(Figure 4A), rivaling S. neyagawaensis clifednamide production. A genetic system was
established in strain F-2890 to further verify our biosynthetic model and systematically evaluate
the activities of a panel of CftA isozymes. To do this, four cftA orthologs were cloned under two
versions of the strong constitutive PermE* promoter. While the original ermE promoter in
Saccharopolyspora erythraea begins transcription at the start codon,25 a short 5′- UTR
containing a ribosome binding site is often added to PermE* expression plasmids. The two
PermE* promoters used in this study contain different 5′-UTR sequences (see Supporting
Information), and our plasmids harboring pHM11a26-derived PermE* drive higher xylE reporter
expression than identical constructs having pDA165227-derived PermE* instead (Figure S3).28
The resulting panel of PermE*-cftA constructs was chromosomally integrated in strain F-2890 at
the ΦC31 attB site29 following intergeneric conjugation. As expected, the resulting strains all
produced clifednamide A, which was confirmed by HRMS (C29H36N2O5 [M + H]+ m/z
493.2696 found, calculated 493.2696; Figures 4, S4, S6, and Table 1). Interestingly, CftA
homologues from different strains produced varying amounts of clifednamide A, with the strain
JV178 homologue producing the most (20 μM). No clifednamide B or butremycin was observed
in any of these strains due to ftdA being absent in the host. In general, constructs driven by the
stronger pHM11a-derived PermE* promoter converted more ikarugamycin precursor to
clifednamide A than those derived from pDA1652.
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Figure 4. Production of PTMs in Streptomyces sp. strain NRRL F-2890 expressing CftA from
Streptomyces sp. strain JV178. (A) Wild-type strain F-2890, (B) strain F-2890
attBΦC31::PermE*pDA1652-cftAJV178, and (C) strain F-2890 attBΦC31::PermE*pHM11a-cftAJV178.
Strains were grown in triplicate and extracted at days 2, 4, and 6.

143

Additionally, all four pHM11a constructs and two pDA1652 constructs resulted in a new product
(m/z 509) having a characteristic PTM UV profile (Figures 4, S4, and S5). MS/MS
fragmentation produced a daughter ion with m/z of 139, a diagnostic daughter ion shared among
PTM molecules lacking C25 hydroxylation such as clifednamide A, ikarugamycin, and
capsimycin30 (Figures S7 and S8). Furthermore, metabolic labeling with 2 H7-L-ornithine
resulted in a correspondingly heavier mass (m/z 516) and daughter ion (m/z 146; Figure S7B,D).
These results parallel those following 2 H7-L-ornithine labeling of clifednamide A (Figure
S7A,C). With multiple lines of data together establishing this new mass as a PTM family
molecule, this molecule was named clifednamide C. HRMS molecular formula determination
(C29H36N2O6, m/z 509.2645 found for [M + H]+ , calculated 509.2646, Figure S6) suggests
clifednamide C is a hydroxylation or epoxidation product of clifednamide A. In comparing
MS/MS fragmentation patterns of clifednamide C against ikarugamycin, clifednamide A, and
literature values for capsimycin, all four molecules gave expected m/z 139.1 and 181.1 daughter
ions that likely map to the ornithine-tetramate regions conserved among the molecules. In
contrast, few other fragments match between the compounds, confirming each PTM has unique
5-6-5 carbocycle oxidation patterns. Due to fragmentation complexity (Figure S8), further
analyses are required to completely solve the clifednamide C structure. While we first identified
clifednamide C following heterologous CftA expression, we also detected it in S. neyagawaensis
extracts, confirming its production in native clifednamide producers.
The tandem oxidation of ikarugamycin by CftA to produce both clifednamides A and C is
analogous to the activity of the recently characterized IkaD.30 A cytochrome P450 associated
with some ikarugamycin biosynthetic clusters, IkaD primarily installs an epoxide across carbons
7 and 8. However, it can also hydroxylate C29, the same position targeted for keto insertion by
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CftA (Figure S1). We noted that strain F-2890, the ikarugamycin-producing host strain, also
contains an IkaD homologue. However, ikarugamycin was the major observed PTM product in
the F-2890 parent strain, indicating IkaD activity is minimal in this strain.
The putative CftA orthologs identified in this study share at least 80% amino acid sequence
identity, but have less than 57% amino acid sequence identity with IkaD and presumed IkaD
orthologs. Thus, under the cytochrome P450 naming convention,31 CftA and IkaD are members
of distinct subfamilies within the CYP107 clade. Aside from IkaD and CftA, additional PTMassociated P450 enzymes also fall within the CYP107 group (Figure S9, S10). Beyond CYP107
family P450s, our data also indicates the existence of three other distinct CYP families (<40%
identity with CYP107) associated with PTM loci. The largest group is comprised of FtdF
homologues (as found in the frontalamide cluster), but no role has yet been established for these
enzymes. Together, our analyses suggest further investigations into PTM-associated CYPs will
continue to reveal enzymes with varied PTM scaffold specificity, oxidative activities and
regioselectivity.
In conclusion, we used a combination of comparative genomics, genetics, and genome mining to
reveal the novel cytochrome P450 CftA is responsible for clifednamide production. We engaged
in a synthetic biology approach to engineer clifednamide production by utilizing cftA orthologs
sourced from newly identified clifednamide producing strains. Increased availability of
clifednamides will enable increased throughput in bioactivity assays, with the eventual goal of
identifying the molecular targets of PTMs. In addition to increased clifednamide production over
Streptomyces sp. strain JV178, we noted substantial differences from cftA homologues. As such,
this work demonstrates the value of leveraging bioinformatically identified panels of isozymes in
a plug-and-play fashion to rapidly identify efficient biocatalysts. Further, we show CftA belongs
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to an expanding family of PTM cytochrome P450 enzymes with the apparent capability to carry
out multiple oxidation events. These enzymes may be useful to engineer diversity-oriented
panels of PTMs for future bioactivity and structure−function analyses.
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5.4 Methods
5.4.1 Strains, Plasmids, Primers, Enzymes, Chemicals and General Methods.
Strains, plasmids, and primers are described in Tables S1−S3. Several strains were obtained from
the Agricultural Research Service Culture Collection (NRRL). All primers were purchased from
Integrated DNA Technologies. All restriction enzymes and Taq polymerase were purchased from
New England BioLabs. T4 ligase was purchased from New England BioLabs and ThermoFisher.
KOD Hot Start DNA Polymerase (EMD Millipore) in FailSafe PCR 2X PreMix (Epicentre) was
used to amplify DNA sequences for cloning from Streptomyces genomic DNA. Taq polymerase
was used for colony PCR. Ikarugamycin (>99%) was purchased from Santa Cruz Biotechnology.
L-Ornithine2,3,3,4,4,5,5-d7 HCl (>98% atom D) was purchased from CDN Isotopes. All other
chemicals were obtained from Sigma-Aldrich or Fisher Scientific. Streptomyces genomic DNA
was prepared for PCR by grinding a colony in 100 μL DMSO as described by Van Dessel et al.32
Standard protocols for manipulating E. coli were based on those of Sambrook et al.33
Streptomycetes were routinely propagated on ISP2 agar34 and Trypticase Soy Broth (Difco) at 28
°C. Glass beads were added to liquid cultures to disrupt mycelial clumps.

5.4.2 Genome Sequencing of JV178.
Genomic DNA was extracted from TSB-grown mycelia as previously described.35 An Illumina
301-bp paired-end sequencing library was prepared using a High-Throughput Library
Preparation Kit (Kapa Biosystems) and was sequenced on an Illumina MiSeq platform (Illumina,
Inc., San Diego, CA, USA) by the Washington University in St Louis McDonnell Genome
Institute. Sequencing reads were trimmed and de novo assembled using CLC Genomics
Workbench (CLC Bio-Qiagen, Aarhus, Denmark). An annotated sequence for the Streptomyces
sp. strain JV178 clifednamide cluster was deposited to GenBank (accession no. MF89327).
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5.4.3 Streptomycete Conjugations.
Streptomyces sp. strain NRRL F-6131 spores were collected from ISP4 agar,34 while
Streptomyces sp. strain NRRL F-2890 spores were collected from ISP2 agar. Spores were
harvested using TX Buffer.36 Conjugations were performed using JV36 as the general E. coli
donor as previously described.7 Exconjugants were selected with 50 μg/mL colistin and 25 or 50
μg/mL apramycin. Successful conjugations were verified by colony PCR.

5.4.4 cftA Markerless Gene Disruption.
The cftA coding sequence of Streptomyces sp. strain NRRL F-6131 was replaced with a
truncated gene containing the first nine codons and the last ten codons of the wild-type coding
sequence with homologous recombination as previously described.37 Streptomycin-resistant
(StrR) mutants were isolated on ISP2 + Str25 agar. The rpsL genes were amplified and
sequenced. Strain JV739 bearing the rpsL (K43N) mutation was chosen for subsequent
experiments as the mutation did not interfere in clifednamide production. The 990 bp upstream
flanking region of cftA was amplified using primers YQ273 and YQ274 (introduced a XbaI site
and homology to pUC19). The 1079 bp downstream flanking region of cftA was amplified using
primers YQ275 (introduced homology to the upstream flanking region) and YQ276 (introduced a
HindIII site and homology to pUC19). The 2668 bp fragment of pUC19 was amplified
withprimers YQ268 and YQ269. PCR amplicons were assembled using the NEBuilder HiFi
Assembly kit (New England BioLabs). The resulting pUC19-ΔcftA was digested with XbaI and
HindIII and the 1956 bp fragment was ligated into pJVD52.1 digested with XbaI/HindIII. The
resulting pJVD52.1-ΔcftA was introduced into strain JV739 by intergeneric conjugation, and
apramycin-resistant (AprR) exconjugants were selected. Exconjugants were grown in TSB
nonselectively at 37 °C and double-recombinants were selected for on ISP2 + Str100. The ΔcftA
mutants were confirmed by PCR with primers YQ277−280.
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5.4.5 cftA Heterologous Expression.
The cftA homologues were amplified using primers ED9−16 (introduced NdeI and XbaI sites).
The PCR products were digested with NdeI and XbaI and ligated into pJMD2 or pJMD3 to
generate plasmids pED1−8. After confirming the inserts by Sanger sequencing (Genewiz) with
primers PermE*-fw and PXS6, the constructs were introduced into Streptomyces sp. strain
NRRL F-2890 by intergeneric conjugation. Integration at the ΦC31 attB site was confirmed with
primers R2NJ, F3NJ, Int 7NJ, and Int 8NJ.

5.4.6 PTM Detection by HPLC−MS/MS.
Strains were cultivated in 15 mL of TSB liquid medium in 125 mL Erlenmeyer flasks shaken in
1-in. orbitals at 250 rpm at 28 °C. Six mm glass beads were added to disrupt mycelial clumps.
After 2 days of growth, 200 μL of cultures were plated on HT,38 ISP4, ATCC172, or JBFM1
(adapted from Medium 2:39 2% D-fructose; 5% D(+)Mannose; 0.167% Na-L-aspartate; 0.06% Larginine HCl; 0.05% L-histidine HCl; 0.2% K2HPO4; 0.2% KH2PO4; 0.5% NaCl; 0.006%
ZnSO4-7H2O; 0.0256% MgSO4-7H2O; 0.051% MgCl2-6H2O; 0.001% CoCl2-6H2O; 0.036%
NaSO4; 2.13% MES free acid; 1.5% agar; 2% R2 Trace elements; 1.5% Agar; pH 6.0) and
incubated at 28 °C. After 6 days, the agar was diced and immersed in ethyl acetate overnight.
The ethyl acetate was evaporated at low pressure and the extract was suspended in 400 μL of
HPLC-grade methanol and syringe filtered. Analysis was performed using a Phenomenex Luna
C18 column (75 × 3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected
to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T = 0, 5% B; T
= 3, 40% B; T = 13, 60% B; T = 17, 100% B, T = 20, 100% B; A: water +0.1% formic acid, B:
acetonitrile +0.1% formic acid; 0.9 mL/min. Ten μL of the methanol-dissolved extract was
injected per run. The precursor ion scan mode was used to identify molecules that fragmented
(collision energy, 30 V) into daughter ions with m/z of 139.2 or 154.2. The resulting data was
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analyzed offline with Agilent MassHunter Qualitative Analysis software. We quantified PTM
production in native and recombinant strains by integrating UV absorbance values at 320 nm,
detected with an HPLC in-line diode array detector (DAD). Because the PTMs in this work have
identical UV chromophores arising from their conserved ornithine-tetramate substructures
(Figures 1, S5, S7, and S8), an ikarugamycin standard curve (R2 = 0.9947, 5−200 μM) was used
to calculate both ikarugamycin and clifednamide production titers throughout this work.
However, we acknowledge minor differences might exist in the molar extinction coefficients of
these PTMs, leading to subtle differences between our reported and actual concentration values.
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Chapter 6: Draft Genome Sequences of Two
Polycyclic Tetramate Macrolactam
Producers, Streptomyces sp. Strains JV180
and SP18CM02
This chapter was previously published in the journal ACS Synthetic Biology as:
Qi Y*, Nepal KK*, Greif J, Martini C, Tomlinson C, Markovic C, Fronick C, Blodgett JAV.
2020. Draft Genome Sequences of Two Polycyclic Tetramate Macrolactam Producers,
Streptomyces sp. strains JV180 and SP18CM02. Microbiol Resour. Announc. 9:e01066-20.
https://doi.org/10.1128/MRA.01066-20
*These authors contributed equally

6.1 Personal contributions
Streptomyces sp. strain JV180 was previously isolated by Dr. Blodgett. Cole Martini, a former
WUSTL undergraduate student, isolated Streptomyces sp. strain SP18CM02 in Dr. Blodgett’s
BIO3493 class. I extracted the genomic DNA for Streptomyces sp. strain JV180. Jennifer Greif, a
former undergraduate student in the Blodgett lab, extracted the genomic DNA for Streptomyces
sp. strain SP18CM02. Library preparation, sequencing, quality control, and genome assembly
were performed by McDonnell Genome Institute (WUSTL) scientists Chad Tomlinson,
Christopher Markovic, and Catrina Fronick. Dr. Blodgett, Dr. Keshav Nepal, a postdoc in the
Blodgett lab, and I wrote the manuscript.
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6.2 Abstract
Here, we report the draft genome sequences of two related Streptomyces sp. strains, JV180 and
SP18CM02. Despite their isolation from soils in Connecticut and Missouri (USA), respectively,
they are strikingly similar in gene content. Both belong to the Streptomyces griseus clade and
harbor several secondary metabolite biosynthetic gene clusters.

6.3 Microbial Resource Announcement
Streptomyces species produce many diverse secondary metabolites that are medicinally relevant
(1). Recent advancements in genome sequencing have revealed Streptomyces as a reservoir of
diverse biosynthetic gene clusters (BGCs). A high proportion of Streptomyces harbor BGCs
encoding polycyclic tetramate macrolactams (PTMs), molecules of interest due to their structural
complexity, atypical biosyntheses, and biomedical significance (2–4). Streptomyces sp. strain
JV180 and Streptomyces sp. strain SP18CM02 are soil isolates found to carry PTM BGCs. The
isolation of strain JV180 was previously reported (3), while strain SP18CM02 was recently
isolated using identical methods from calcium carbonate-treated soil collected at Tyson Research
Center in Eureka, MO, using low-tryptone-yeast extract (LTY) medium supplemented with
nalidixic acid.
Both strains were grown in Trypticase soy broth supplemented with 0.6% glycine at 28°C, and
genomic DNA was extracted with the Qiagen DNeasy UltraClear microbial kit for Illumina
sequencing or phenol-chloroform (5) for PacBio sequencing. For PacBio sequencing, genomic
DNA was sheared to approximately 15 kb using Covaris g-TUBEs. The PacBio SMRTbell
Express template prep kit 2.0, barcoded overhang adapter kit 8A, and barcoded overhang adapter
kit 8B were used for library construction. Final library pools were assessed on an Agilent 2100
Bioanalyzer using a DNA 12000 kit. DNA polymerase binding complex was processed using the
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PacBio Sequel binding kit 3.0 and sequencing primer 4. The PacBio Sequel sequencing plate 3.0
and a single-molecule real-time (SMRT) cell (1M v3 Tray) were used for the sequencing run.
The resulting reads were evaluated based on mean read length, which was 27,869 bp. PacBio
read error correction, adapter trimming, and assembly were done in Hierarchical Genome
Assembly Process 4 (HGAP4). Default parameters were used with the exception of the advanced
parameter, “aggressive mode.” The assembly was polished in Pilon 1.23 with Illumina reads,
which were obtained as described below (6, 7).
For Illumina sequencing, dual-indexed libraries were constructed with 2 mg of genomic DNA
(gDNA) utilizing the TruSeq PCR-free library prep kit (Illumina) on the SciClone nextgeneration sequencing (NGS) instrument (Perkin Elmer) targeting 550- bp inserts. Then, 50 ml
of gDNA was fragmented on an LE200 Covaris instrument, and the library was evaluated on a
LabChip GX system (Perkin Elmer). The library was sequenced on a NovaSeq 6000 (Illumina)
S4 300 cycle flow cell for 2 × 150-bp paired-end reads, and NovaSeq Real Time Analysis 3.3.3
software (Illumina) was used to ensure that $80% of resulting bases had a quality score of $Q30.
FLEXBAR 3.4 (8) was used for adapter trimming, and MEGAHIT (9) was used for genome
assembly with default parameters. Genomic features were annotated with Rapid Annotations
using Subsystems Technology 2.0 (10) and antiSMASH (11) (Table 1).

Table 1. Genomic features of Streptomyces sp. strains JV180 and SP18CM02
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Strains JV180 and SP18CM02 share 100% identical 16S rRNA sequences, and their closest
match in GenBank was Streptomyces californicus strain NRRL B-3320 (99.93%), a strain that
has a similar genome size (8,023,053 bp) and belongs to the Streptomyces griseus clade (12).
MUSCLE pairwise alignments (13) revealed that strains JV180 and SP18CM02 share 99.93,
99.76, 99.29, 99.91, and 99.53% nucleotide identities for atpD, gyrB, recA, rpoB, and trpB,
respectively. Strains JV180 and SP18CM02 possess 34 and 35 BGCs, respectively, and all strain
JV180 BGCs are conserved in strain SP18CM02.

6.3.1 Data availability
The draft genome sequences of strains JV180 and SP18CM02 were deposited in
DDBJ/ENA/GenBank under accession numbers JACGMP000000000 and JACGMQ000000000,
respectively. The SRA accession numbers for strain JV180 are SRR12430886 and
SRR12430887 for Illumina and PacBio sequencing, respectively, and that for strain SP18CM02
is SRR12430885. The versions described in this paper are the first versions.
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Chapter 7: Conclusions and Future
Directions
7.1 Abstract
Bacterial whole-genome sequencing and automated genome annotation is now commonplace.
Advances in these technologies coupled with lower experiment costs have led to an explosion of
Streptomyces genomes for analysis. One major consequence from this is the realization that the
genomes of Streptomyces and other closely related actinobacteria contain many more
biosynthetic gene clusters (BGCs) for drug-like compounds than previously thought. However,
the products of many of these BGCs are undetectable in laboratory cultures, which poses a major
roadblock for genomics-based drug discovery. It is commonly hypothesized that such BGCs are
transcriptionally downregulated, possibly due to a lack of chemical signals in standard growth
media that are normally present in native growth environs. In my thesis work, I used comparative
genomics and metabolomics to study polycyclic tetramate macrolactam (PTM) biosynthesis. The
genetic simplicity and widespread conservation of PTM BGCs in Streptomyces strains enabled
me to directly compare actively expressed and apparently silent PTM BGCs. Leveraging these
features, I was able to examine how genetic variations resulted in differences in the expression of
PTM BGCs as well as differences in the structures of PTMs produced by different BGCs.
Herein, I briefly highlight some of my key findings and discuss potential future research
questions that arise from them.

7.2 Genetic variations in the regulation of PTM
biosynthesis
One of my major thesis goals was to address a long-standing question in Streptomyces genomemining: why are some BGCs highly expressed and why are the products of other BGCs
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undetectable in laboratory cultures? Streptomyces genomes can encode upward of 30 BGCs for
specialized metabolites (1). These are important because it is widely thought that they may
encode for much needed novel antibiotics or other useful compounds. However, the apparent
silence of many BGCs hinders the genome-mining of Streptomyces BGCs for new drugs (2).
Focusing on a group of 11 closely related Streptomyces griseus clade strains carrying PTM
BGCs, I demonstrated how PTM production could vary widely between individual strains, from
being robustly expressed under most culturing conditions to being almost undetectable in other
strains. By examining the regions upstream of the first open reading frame in the PTM BGC
(PftdA), I found conserved patterns in promoter sequence variations that correlated with robust and
weak PTM production. This suggested that weak PTM producers had downregulated PftdA
promoters. When the PftdA regions of various strains were used to replace the native PftdA region
of a robust PTM producer, PftdA regions of other robust PTM producers resulted in robust BGC
expression and PTM production, while PftdA regions of weak PTM producers resulted in
decreased BGC expression and PTM production. These results supported the long-held belief
that silent BGCs are transcriptionally downregulated, by directly comparing the promoters of
active and silent PTM BGCs. To my knowledge, this is the first comparative metabologenomics
study to understand the effects of native promoter variation on BGC expression across different
Streptomyces. This contrasts with a recent study that examined several strains from the marine
actinomycete genus Salinispora, where the authors highlighted changes in cluster-situated
regulators as possible causes of observed differences in BGC expression (3).
Through detailed mapping of the PftdA region in strain JV180, a genetically tractable S. griseus
PTM-producer, I found a dinucleotide ‘AG’ indel whose presence or absence strongly affected
PftdA strength. I also mapped the transcript start site, −10 box, and −35 box of PftdA and showed
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that AdpA likely directly regulates PftdA, which was also supported by EMSA experiments
performed by Keshav Nepal, a postdoc in the Blodgett lab. I found that although there were some
differences in the sequences of the −35 boxes and binding sites of the AdpA transcriptional
regulator in the PftdA regions S. griseus clade strains, these SNPs had much weaker effects on PftdA
strength than the ‘AG’ indel. The ‘AG’ indel’s apparent ability to tune PftdA strength strongly
suggests an evolutionary divergence between PTM-expressing and PTM-silent S. griseus clade
members.
It is commonly thought that the products of BGCs that are highly expressed in across various
conditions without any exogenous triggers are produced by Streptomyces strains to prevent other
organisms from stealing nutrients released when they undergo lysis during morphological
differentiation (4). In this model, most other BGCs are repressed and only expressed under
specific conditions when they are needed. I interpret our results to suggest that different strains
may have diverged BGC regulatory networks that lead to differences in which BGCs are
preemptively expressed and which are downregulated in the absence of specific stimuli. This
finding challenges the notion that all silent BGCs should be activated through synthetic
regulatory manipulation or rewiring; learning to recognize weak promoters from genomic
sequences will allow researchers to avoid poorer producers a priori and focus discovery efforts
on strains that are likely to produce the desired molecules.
In future experiments, the promoters of other PTM BGCs could be systematically interrogated
using the approach I pioneered for S. griseus above in order to discover new signatures that
differentiate strong and weak promoters. One group of PTM BGCs which could be examined are
the clifednamide-type PTM BGCs. When I characterized several clifednamide-type PTM BGCs,
I noticed dramatic differences in PTM production between these strains. While the strongest
162

producer, S. neyagawaensis, produced over 30 μM of clifednamide PTMs in total, weaker
producers such as S. torulosus and S. sp. strain NRRL F-6131 produced less than 83 nM
(minimum quantifiable threshold). Subsequent to this, during a large-scale genome sequencing
project in the lab, I identified 11 additional isolates with clifednamide BGCs that could be
studied. Preliminary characterization of these strains showed that one strain, BE34, produced
little to no PTMs, while others produced varying amounts of PTMs. Eight of these BE strains
appear to be especially closely related by 16S rDNA and iPKS-NRPS (IkaA) sequence
homology, providing a similar study cohort as the S. griseus strains that I extensively
characterized in my thesis. One area to be cautious of when examining transcriptional regulation
of clifednamide-type PTM BGCs is the possibility that these BGCs contain two promoters, PftdA
and PikaA. This appears to be likely given the larger intergenic space between ftdA and ikaA
(approximately 250 nucleotides) and the fact that several strains have ftdA-less clifednamide
BGCs. This would add additional complexity to the experiments needed to understand
clifednamide regulation in comparison to the S. griseus clade strains, which only have a single
PTM promoter, PftdA.
Additionally, the PftdA regions of the S. griseus clade strains can be studied in further detail, as
these promoters and UTRs have several interesting features yet to be characterized. First, it
remains unclear how AdpA can bind downstream of the transcript start site in promoters like
PftdA and PadsA without downregulating transcription. To fully understand this, it may be
necessary to carry out in vitro transcription experiments. However, to my knowledge, such
methodology has not been widely used in studying Streptomyces transcriptional regulation. This
may be due to the fact that many Streptomyces promoters of interest control specialized
metabolism and are therefore not transcribed using the housekeeping σ70. Aside from hrdB
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encoding σ70, Streptomyces genomes encode for dozens of additional σ factors that enable
exquisite regulatory control. As a result, the complex relationship between numerous σ factors
and their target promoters is yet to be well-understood.
Another feature of the PftdA regions of the S. griseus clade strains that bears further study is the
highly conserved region containing the AG indel, which appears to be a key factor in controlling
the strengths of these PftdA’s. It is possible that this region acts as a binding site for another
transcription factor or is involved in the formation of mRNA secondary structures. Based on my
RT-qPCR analysis of grh BGC mutants, PftdA could be controlled by multiple regulators, and a
pull-down experiment to identify other proteins which bind the PftdA region could reveal other
regulators of PftdA in addition to AdpA. Alternatively, mRNA folding of the PftdA UTR could be
studied through more detailed in silico analysis and mutational studies. As UTR secondary
structures can often control mRNA degradation and translation dynamics, the effects of UTR
variations could be studied through transcriptomic and proteomic analyses as well as ribosomal
occupancy in in vitro translation experiments. Through these experiments, it may be possible to
discover novel regulators of PTM expression, such as a new transcription factor or riboswitch.
The widespread presence of PTM BGCs in Streptomyces and other bacteria could mean that any
mechanisms controlling PTM BGCs are also equally widespread, raising the potential impact of
such research.
Another related research goal is to demonstrate that these findings can be leveraged to activate a
silent PTM BGC. Although I indirectly showed that restoring the ‘AG’ indel could increase the
strength of the PftdA of IFO13350 and that PftdA_JV180 was stronger than PftdA_IFO13350 in both JV180
and IFO13350 host strains, I was unable to activate PTM production in IFO13350 or any other S.
griseus strain with a weak PTM BGC. Further experiments could attempt to develop genetic
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tools for these strains or identify a genetically tractable S. griseus clade strain with a silent BGC
to be engineered.
With the growing body of research on the regulation of Streptomyces BGCs and the promoters
controlling these BGCs, it may become possible to predict a priori whether a given BGC should
be expressed or not. This would greatly streamline genome-mining efforts to discover novel drug
candidates. Additionally, well-characterized BGC promoters with complex regulation could be
used in place of constitutive promoters when regulatory rewiring is necessary, as constitutive
expression of antibiotic BGCs during exponential growth could negatively impact cell growth
rates, maximum cell density, and ultimately drug production titers.

7.3 Metabolomic variations affecting PTM biosynthesis
The crosstalk between the griseorhodin and PTM biosynthetic gene clusters was an unexpected
finding. One original motivation for deleting the grh BGC was that PTM production could be
increased by eliminating an unneeded pathway that competed for a shared precursor pool.
Instead, I observed almost complete loss of PTM production in the ΔgrhR2-V mutant. These
results contradicted a popular strategy for increasing production titers in Streptomyces (5) and
also suggested that another PftdA transcriptional regulator existed.
Further experiments showed that PTM production and BGC transcription were reduced by the
deletion of certain grh BGC genes. However, this interaction did not actually involve the
production of griseorhodin molecules, as evidenced by the fact that deletion of grhQSAB had no
effect on PTM production and that a griseorhodin-enriched fraction and a griseorhodin analog, γrubromycin, were unable to chemically complement the loss of PTM production in the ΔgrhR2-V
mutant. Instead, genetic complementation studies pointed to grhGH, a two-gene operon encoding
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for production of the shared precursor unit malonyl-CoA, as a key player. While regulatory
crosstalk between BGCs has been previously documented, the most-well documented
mechanisms of BGC crosstalk involved pleiotropic cluster situated regulators (CSRs) (6). Based
on complementation studies, the grh CSRs, GrhR2 and GrhR3, do not appear to have any effect
on PftdA, and there is no PTM CSR which could explain how griseorhodin production decreased
in a ΔftdA-F mutant.
Due to these results, I hypothesize that the PTM BGC could be regulated, either directly or
indirectly, by a malonyl-CoA or long chain acyl-CoA dependent mechanism. While
actinomycetes lack homologs of other well-characterized regulators of lipid metabolism such as
FapR (7) and FadR (8), a novel global regulator of lipid metabolism, FasR, has been
characterized in several actinomycetes, including Streptomyces coelicolor (9), Corynebacterium
glutamicum (10), and Mycobacterium tuberculosis (11). Data from C. glutamicum suggests that
FasR regulates its target promoters in a long chain acyl-CoA responsive manner, but this result
has not been reproduced in Streptomyces yet, to my knowledge. The grh-PTM interaction
presents an opportunity for the potential role of FasR in Streptomyces secondary metabolism to
be investigated. Further genetic and transcriptomic analyses of grh BGC mutants, acetyl-CoA
carboxylase mutants, and fasR mutants could be used to probe this relationship.
Another significant finding was that S. griseus strain IFO13350 and other poor PTM producers
in the S. griseus clade lack grh BGCs. This suggests that other factors besides differences in PfftdA
sequences contribute to difference in PTM production. The interdependence of the PTM and
griseorhodin BGCs on each other goes against the commonly held notion that BGCs compete for
precursor units. Instead, it is likely that the malonyl-CoA produced by GrhGH help to support
both PTM and griseorhodin production, as well as other polyketides encoded for by S. sp. strain
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JV180. These findings also raise a caution towards the frequently used strain engineering
strategy of eliminating unwanted BGCs in order to create a metabolic chassis strain. Rather than
wholesale deletion of entire BGCs, which can contain pleiotropic CSRs and precursor
biosynthetic genes, it may be better to selectively inactivate key biosynthetic genes in unwanted
biosynthetic pathways.
Interestingly, although S. griseus strain IFO13350 and other poor PTM producers in this clade
lack grh BGCs, these strains have other polyketide BGCs which contain grhGH homologs. How
these BGCs influence PTM biosynthesis could be explored by genetic, transcriptomic, and
metabolomic studies. One challenge in this area is that I was unable to make gene knockouts in
strain IFO13350 due to its strong DNA restriction system. We have recently sequenced the
genomes of 3 environmental isolates, BE277, BE319, and BE327, which also belong to the S.
griseus clade. Based on phylogenetic analyses, these strains clade with poor PTM producers in
the S. griseus clade, and replacement of JV180 PftdA sequence with those of BE277, BE319, and
BE327 confirmed that these strains have weak PftdA’s. However, unusually, BE319 and BE327
were able to produce a similar amount of PTMs as JV180. One possible cause of this is the fact
that these two strains possess two polyketide BGCs with grhGH homologs, which help boost
their ability to produce PTMs. If these strains prove to be genetically tractable, this relationship
should be further explored.

7.4 Genetic variations in PTM biosynthetic genes
Another type of genetic variations affecting PTM biosynthesis that I was interested in exploring
was the genetic diversity in biosynthetic enzymes encoded within PTM BGCs. When I began
working on my thesis project, only three PTM BGCs had been completely characterized, which
were the HSAF BGC in Lysobacter enzymogenes C3 (12), the frontalamide BGC from
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Streptomyces sp. SPB78 (13), and the ikarugamycin BGC of Streptomyces sp. Tü 6239 (14). In
addition, a few frontalamide-type BGCs had been studied in promoter-rewiring experiments (15,
16). At the time, it was poorly understood how these PTM BGCs could produce the diverse PTM
structures that had been published over the previous few decades. These structural differences
are important because they contribute to the ability of these PTM molecules to bind and inhibit
different targets. Better knowledge of PTM biosynthetic enzymes could be used to create
engineered PTM BGCs to produce novel chemicals using prior knowledge of PTM enzymes
(17).
As I began to collect BGC sequences for comparative studies of promoter sequence variation, I
started to notice that PTM BGCs could contain a larger diversity of genes than previously
reported. Through phylogenetic analyses, I realized that the fragment of the iPKS-NRPS that had
been sequenced in the original clifednamide producer, Streptomyces sp. strain JV178 (18), had
high homology to the iPKS-NRPS enzymes encoded for by one group of unusual PTM BGCs.
Further studies into these BGCs resulted in the identification of the clifednamide-type PTM
BGCs and the novel cytochrome P450 enzyme, CftA (19). These results gave me confidence that
novel PTM biochemistry could be identified and studied through similar comparative genomics
and metabolomics approaches. Currently, we are collaborating with the Wencewicz lab to
elucidate the structure of clifednamide C, the novel clifednamide congener that I identified by
LC-MS/MS, and to verify the ability of CftA to carry out two rounds of oxidation in vitro.
Recently, another research group has identified and published the structures of seven novel
clifednamide congeners obtained through promoter rewiring and heterologous expression of a
clifednamide-type PTM BGC (20).
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Based on similar genetic and metabolomic data, I have also proposed the functions for the
commonly found cytochrome P450 enzyme, FtdF, and a Rieske 2Fe-2S domain protein, which I
have named FtdG. These models are based on genetic and metabolomic evidence we have
collected in laboratory experiments so far, but the function of FtdF needs to be verified by
structural elucidation of PTMs produced by ftdF-null and ftdF-overexpressing strains as well as
in vitro enzymatic assays with purified PTMs and FtdF enzymes. Recently, a similar model for
FtdF activity was postulated by another group by structural elucidation of the PTMs produced by
Streptomyces sp. strain SCSIO 40010, which has a similar ftdABCDEF BGC as JV180 (21).
Similarly, the function of FtdG as a redox partner for FtdA needs to be verified in coupled in
vitro assays. In addition, I have proposed that PTM BGCs found in sea-sponge associated
bacteria, which contain an unusual thioesterase gene, could produce cylindramide-type PTMs
that contain two less carbon atoms than typical PTMs. Many of the strains encoding these PTM
BGCs are not actinomyces and also may not be easily obtainable. However, the thioesterase gene
has a short coding sequence and a codon-optimized version could be synthesized for relatively
low cost, allowing for the function of this enzyme to be studied by heterologous expression in
PTM producing Streptomyces strains.
Bioinformatic analyses of PTM BGCs suggests that further genetic diversity exists within more
unusual PTM BGCs. The sequencing of 96 Blodgett lab strains and the bioinformatic analysis of
their encoded PTM BGCs showed that it was possible to obtain strains with diverse PTM BGCs
from just a few local soil samples, which could enable the study of novel PTM BGCs and their
products. These studies could also help to connect PTM BGCs to previously published PTM
molecules without cognate BGCs. However, one caveat to this is that some chemical
modifications could be carried out by non-BGC enzymes. For example, while the frontalamide169

type BGC (ftdABCDEF) is the most commonly found type of PTM BGC, the terminal olefin
moiety found in the frontalamides has not been reported from any other sources. This suggests
that the terminal olefin moiety could be the result of a non-PTM BGC enzyme encoded
elsewhere in the genome of Streptomyces sp. strain SPB78. A more comprehensive analysis of
PTM BGCs found in these draft genomes and other publicly available genome sequences is
currently being carried out in the Blodgett lab by undergraduate students Anna Day, Maya
Tsingos, and PMB student Chris Harper.
Another potential research topic for PTMs is their ecological significance. The frequency of
PTM BGCs being found in the genomes of Streptomyces and other bacteria from various sources
clearly points to a selective advantage for the ability to produce these molecules. Based on
phylogenetic analysis of all PTM BGCs, it seems that certain types of PTM BGCs are specific to
strains found in specific niches. For example, clifednamide-type PTM BGCs tend to be found in
plant-associated Streptomyces strains, and the putative cylindramide-type PTM BGCs tend to be
found in sea sponge-associated Streptomyces strains. These specialized PTMs may be involved
in host-microbe interactions in addition to having anti-bacterial or anti-fungal properties like
other PTMs.

7.4 Conclusions
The goal of my thesis was to use comparative genomics and metabolomics to study polycyclic
tetramate macrolactam biosynthesis to try to understand the long-standing question in the field of
genome mining for antibiotic discovery: Why are many BGCs in Streptomyces genomes
apparently silent? The high conservation of PTM BGCs provided a uniquely suitable system to
study this question by comparing naturally occurring genetic variations and their effects on PTM
expression. I was able to show that for S. griseus clade strains with PTM BGCs, mutations in the
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promoter resulted in reduced PTM expression. This confirmed the commonly held belief that
silent BGCs are transcriptionally downregulated. How the mutations I identified, such as the key
‘AG’ indel, caused these differences in expression and how widespread such mechanisms are in
silencing BGCs remains to be further explored.
Another key finding from my thesis was that PTM production in Streptomyces sp. strain JV180
is dependent on the presence of the griseorhodin BGC. It is also possible that differences in the
BGCs encoded by S. griseus clade strains contributes to differences in PTM production, as grh
BGCs were only found in the genomes of robust PTM producers. Further studies may reveal
several interesting findings, such a potential malonyl-CoA responsive regulator or other forms of
metabolic and regulatory crosstalk between antibiotics BGCs. These results were completely
unexpected at the time I began my thesis work and showed that complex factors control
antibiotic production.
Recent technical advances have turned genomics and other ‘-omics’ tools into an accessible
discovery suite that enables many researchers to study non-model organisms in a manner that
would have been cost-prohibitive even a decade ago. As cellular processes are recognized to be
increasingly complex and interdependent, such ‘-omics’ tools may often be needed for
researchers to study biology with a more holistic view of what is occurring in a cell. When
applied in comparative studies, these powerful tools can allow researchers to study how naturally
occurring minor genetic variations cause phenotypic differences. In the future, I believe that
similar comparative approaches can be applied to study the BGCs of PTMs and other pathways
to reveal important regulatory mechanisms and discover potential new drugs.
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Appendix I: Supplementary Information for
Chapter 2: A comparative metabologenomic
approach reveals new mechanistic insights
into Streptomyces antibiotic crypticity
Supplementary methods
Marker-less gene deletion/promoter replacement
All gene deletions and PftdA mutants were constructed using double homologous recombination as
previously described (1). To avoid undesired recombination between the wild-type and the
mutant PftdA sequences, an intermediate ΔPftdA::tsr mutant was constructed, and the steps will be
described as an example for all mutants:
Streptomycin-resistant (StrR) mutants of Streptomyces sp. strain JV180 were isolated on ISP2 +
Str100 agar. The rpsL genes were amplified with primers (YQ4-Sg_rpsL_f and YQ5-Sg_rpsL_r)
and sequenced. JV307 bearing the rpsL_K43R mutation was chosen for subsequent experiments
as no phenotypic changes were observed, including PTM production. The upstream and
downstream homology regions flanking PftdA were amplified from JV180 (primers YQ211180DPro-us-f and YQ212-180DPro-us-r; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r). The
tsr gene was amplified from pJVD53 (primers YQ215-tsr-f and YQ216-tsr-r). The vector pUC19
was linearized by PCR-amplification (primers YQ268-pUC19-us and YQ269-pUC19-ds) and
digested by DpnI. PCR products were assembled using the NEBuilder HiFi Assembly kit (NEB).
Correct cloning was confirmed by restriction digest and Sanger sequencing. The resulting
pUC19-ΔPftdA::tsr and were digested with XbaI and HindIII and ligated into pJVD52.1 using the
same restriction sites. The resulting pJVD52.1-ΔPftdA::tsr was introduced into JV307 by
conjugation, and apramycin-resistant (AprR) exconjugants were selected. Exconjugants were
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grown in TSB non-selectively at 37˚C and recombinants were selected for on ISP2 + Apr50. AprR
colonies were grown TSB non-selectively at 37˚C and double recombinants were selected for on
ISP2 + Str100. The resulting ΔPftdA::tsr mutant was confirmed by colony PCR.

Circular Rapid Amplification of cDNA Ends
Streptomyces sp. strain JV180 was cultured on solid ATCC172 medium overlaid with a
cellophane film. After six days, mycelia were harvested from three plates and pooled in 5 mL
RNAlater with 4 mm diameter beads. The mycelia were homogenized by vortexing for about 1
minute and allowed to settle for 5 minutes. The cell suspension was transferred to a clean tube
and pelleted by centrifugation at 3,214 × g for 10 minutes. The supernatant was discarded the
pellet was frozen at −20°C. The following day, approximately 100 mg of the frozen pellet was
powdered by grinding with mortar and pestle in liquid nitrogen and resuspended in 450 µL of
buffer RLT (QIAGEN). The suspension was lysed with a Fisherbrand model 120 sonic
dismembrator at 30% amplitude with 4 cycles of 15 seconds of sonication followed by 30 second
of resting. Total RNA was extracted with the QIAGEN RNeasy kit following the manufacturer’s
protocol after this point and its integrity was verified by gel electrophoresis.
The cRACE protocol was adapted from that of Bose and Newman (2). Genomic DNA was
removed with Turbo DNase (Ambion). Superscript II Reverse Transcriptase (Invitrogen) was
used to generate cDNA with random hexamers. Leftover RNA was removed with RNase H and
cDNA was purified with Wizard SV Gel and PCR clean-up kit (Promega) and eluted in
nuclease-free water. Adaptor ligation was performed in a buffer containing 1X RNA ligase
buffer, 25% PEG 8000, 10 µg/mL BSA, 1 mM hexamine cobalt (III) chloride, 100 pmol
WNp213, and 25 Units of T4 RNA (Ambion) ligase. The reaction was carried out at room
temperature overnight and purified with the Wizard SV Gel and PCR clean-up kit. The eluate
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was used for PCR amplification with Taq DNA polymerase (NEB) using Failsafe Premix G
(Epicentre) with primers WNp210 and YQ186. PCR products were amplified in a second
reaction using 1.5 µL of the first reaction as template with nested primers YQ188 and YQ185 as
reverse primers. PCR products were cloned into pCR2.1-TOPO using the TOPO-TA cloning kit
(Invitrogen) and the inserts were Sanger sequenced by Genewiz to map the transcript start site.

Griseorhodin enrichment
A griseorhodin-enriched fraction was obtained using a modified Kupchan scheme (3, 4) and
solid phase extraction column. Strain JV180 was plated on approximately 1 L worth of 8340 agar
plates. After 6 days, the agar plates were diced and collected in a large 2 L flask and the agar was
submerged with acetonitrile overnight. The acetonitrile was collected and evaporated under low
pressure and the agar was extracted with acetonitrile again. The dried extract was resuspended in
9:1 (v/v) methanol/water. The solution was extracted with equal volume of petroleum ether
followed by equal volume of ethyl acetate, which extracted the red pigment from the aqueous
solution. The ethyl acetate was evaporated under low pressure and resuspended with 1:1
methanol/water. A Bond Elut C18-OH (Agilent) solid phase extraction column was used to
further purify the extract. The column was primed with water before the extract was loaded. The
column was washed with water, and 1:3 acetonitrile /water. The red pigments were eluted by 1:1
acetonitrile/water. This fraction was dried under low pressure and resuspended in 500 µL 1:1
acetonitrile/water and filtered before LC-MS analysis.
The griseorhodin-enriched fraction was analyzed using a Phenomenex Luna C18 column (75 x 3
mm, 3 µm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420
Triple-Quad mass spectrometer. For each run, 10 µL sample was injected and the
chromatography conditions were as follows: T = 0, 5% B; T = 2, 5% B; T = 16, 100% B, T = 20,
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100% B; A: water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid; 0.7 mL/min. The
diode array detector was set to measure absorbance at 488 nm. The mass spectrometer was set to
mass scan mode with m/z ranges 100 – 1000 for positive and negative ions and the fragmentor
voltage was set to = 70 V.
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Supplementary Tables and Figures
Table S1. List of strains used in this study
Strain
Relevant characteristics / Genotype
Escherichia coli
DH5α
BL21(DE3) +
Rosetta2
JV36

Source

cloning host, F– φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 (rK–,
mK+) phoA supE44 λ– thi-1 gyrA96 relA1
plasmid expression host, F– ompT hsdSB (rB–, mB–) gal dcm (DE3)

NEB

conjugal donor strain, dam-3 dcm-6 metB1 galK2 galT27 lacY1 tsx-78 supE44 thi1 mel-1 tonA31 ΔhsdRMS-mrr::FRT(rK- mK-) attHK::pJK202 (ΔoriR6KaadA::FRT bla::pir) (Tra+, AmpS)

Blodgett
et al (5)

Novagen

Streptomyces strains
Streptomyces
griseus subsp.
griseus
IFO13350
Streptomyces
sp. strain JV180
JV251

model Streptomyces griseus strain, aka strain ISP-5235

NRRL

environmental isolate, PTM producer
Streptomyces californicus strain NRRL B-3320

Blodgett
et al (6)
NRRL

JV252

Streptomyces floridae strain NRRL 2423

NRRL

JV253

Streptomyces puniceus strain NRRL B-2895

NRRL

JV254

Streptomyces griseus subsp. griseus strain NRRL F-5144

NRRL

JV255

Streptomyces globisporus subsp. globisporus strain NRRL B-2709

NRRL

JV256

Streptomyces albus subsp. albus strain NRRL B-2445

NRRL

JV257

Streptomyces griseus subsp. griseus strain NRRL WC-3480

NRRL

JV258

Streptomyces baarnensis strain NRRL B-2842

NRRL

Streptomyces
sp. strain
SP18CM02
JV307

environmental isolate, PTM producer

Qi et
al(7)

JV180 rpsL_K43R

JV352

JV307 ΔftdA-F

JV631

JV307 ΔPftdA::tsr

JV1851

JV307 ΔPftdA::PermE*_pHM11a

JV847

JV307 ΔPftdA::PftdA_IFO13350

JV1961

JV307 ΔPftdA::PftdA_SP18CM02

JV1176

JV307 ΔPftdA::PftdA_JV251

This
study
This
study
This
study
This
study
This
study
This
study
This
study
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JV1178

JV307 ΔPftdA::PftdA_JV252

JV1673

JV307 ΔPftdA::PftdA_JV253

JV898

JV307 ΔPftdA::PftdA_JV254

JV1186

JV307 ΔPftdA::PftdA_JV255

JV1182

JV307 ΔPftdA::PftdA_JV256

JV1184

JV307 ΔPftdA::PftdA_JV257

JV1188

JV307 ΔPftdA::PftdA_JV258

JV503

JV180 attBΦC31::pJMD1-PftdA_IFO13350-xylE

JV505

JV180 attBΦC31::pJMD1-PftdA_JV180-xylE

JV527

JV180 attBΦC31::pJMD1-PermE*_pHM11a

JV1871

JV180 attBΦC31::pJMD1-PftdA_JV180-ftdA-xylE

JV1873

JV180 attBΦC31::pJMD1-PftdA_IFO13350-ftdA-xylE

JV1743

IFO13350 attBΦC31::pJMD1-PftdA_IFO13350-xylE

JV1745

IFO13350 attBΦC31::pJMD1-PftdA_JV180-xylE

JV1747

IFO13350 attBΦC31::pJMD1-PermE*_pHM11a

JV1875

IFO13350 attBΦC31::pJMD1-PftdA_JV180-ftdA-xylE

JV1877

IFO13350 attBΦC31::pJMD1-PftdA_IFO13350-ftdA-xylE

JV712

JV307 PftdAΔ−528_−207

JV716

JV307 PftdAΔ−528_−57

JV1933

JV307 PftdAΔ−528_−38

JV1836

JV307 PftdAΔ−528_−31

JV1986

JV307 PftdAΔ2_28

JV936

JV307 PftdAΔ29_48
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This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study

JV1675

JV307 PftdAΔ49_68

JV1655

JV307 PftdAΔ69_88

JV1680

JV307 PftdAΔ89_108

JV1688

JV307 PftdAΔ109_128

JV1697

JV307 PftdAΔ129_148

JV1693

JV307 PftdAΔ149_181

JV2084

JV307 PftdAΔ−528_−31:: −35boxJV254

JV2088

JV307 PftdAΔ−528_−31:: −35boxJV255

JV2090

JV307 PftdAΔ−528_−31:: −35boxJV256

JV2100

JV307 PftdAΔ−528_−31:: −35boxJV257

JV556

JV307 ΔadpA

JV623

JV556 attBΦC31::pSET152-adpA_JV180

JV664

JV556 attBΦC31::pSET152-adpA_IFO13350

JV629

JV556 attBΦC31::pJMD3-adpA_JV180

JV618

JV556 attBΦC31::pJMD3-adpA_IFO13350

JV2111

JV1851 ΔadpA

JV938

JV307 PftdAΔ29_48::IFO13350

JV1553

JV307 PftdA_35G/T

JV1565

JV307 PftdA_37C/A

JV1555

JV307 PftdA_40G/T

JV1567

JV307 PftdA_42C/A

JV894

JV307 PftdAΔAG

JV1673

JV307 PftdAΔAG::CT
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This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study

JV1032

JV307 ΔPftdA::PftdA_IFO13350+AG

JV564

JV307 ΔgrhR2-V

JV1832

JV307 ΔgrhR1-E

JV1898

JV307 ΔgrhFGH

JV1698

JV307 ΔgrhGH

JV1892

JV307 ΔgrhI-P

JV1706

JV307 ΔgrhQSAB

JV1854

JV1851 ΔgrhGH

JV2108

JV1851 ΔgrhR2-V

JV671

JV564 attBΦC31::pJMD2-grhR2

JV669

JV564 attBΦC31::pJMD2-grhR3

JV919

JV564 attBΦC31::pJMD2-grhF

JV921

JV564 attBΦC31::pJMD2-grhG

JV923

JV564 attBΦC31::pJMD2-grhH

JV1070

JV564 attBΦC31::pJMD2-grhGH

JV1054

JV564 attBΦC31::pJMD2-accBE_JV180

JV1060

JV564 attBΦC31::pJMD2-SGR1943-44

JV1066

JV564 attBΦC31::pJMD2-SGR3280-81

JV1018

JV180 attBΦC31::pJMD2-grhG

JV978

JV254 attBΦC31::pJMD2-grhG

JV982

JV258 attBΦC31::pJMD2-grhG

JV986

IFO13350 attBΦC31::pJMD2-grhG
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This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study
This
study

Table S2. List of plasmids used in this study.
plasmid
description
pUC19
pCR2.1TOPO
pET11a

bla

oripUC
R

source

cloning vector

NEB

pBR322

Invitrogen

Amp ori

TOPO-TA cloning vector

AmpR oripBR322 lacI T7 promoter protein expression vector
pBR322

R

pCM130

ori

pSET152

aac(3)IV oriT oripUC intΦC31 attPΦC31 self-integrating vector

pJMD2

AprR oriT oricolE1 intΦC31 attPΦC31 PermE* sequence from pDA1652

pJMD3

pJMD2 variant with PermE* sequence from pHM11a

pJVD52.1

AprR oriT oripSG5(ts) reppUC rpsL+ shuttle vector

pJVD53

TsrR AmpR oriT oripIJ101 oriR6K nitR protein expression vector

pJMD1

ligation of PCR product of pSET152 (primers PXPX2 and PXPF2) digested with
BamHI, SpeI and overlap extension PCR product of [pJVD53 (primers Fd-pSET and
Fd-xylE) and pCM130 (primers xylE-pSET and xylE-fd)] amplified with primers
PXFP2 and PXXP2, digested with BglII and XbaI
ligation of pJVD52.1 and overlap extension PCR products of JV180 (primers YQ82180PTM_us_f and YQ91-180PTM_us_o_v2; YQ84-180PTM_ds_f and YQ85180PTM_ds_r), both digested with XbaI and HindIII
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and pJVD53 (primers YQ215-tsr-f
and YQ216-tsr-r)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and pJMD2 (primers YQ243DPro-ermEh-r and YQ258-DPro-ermEh-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and IFO13350 (primers YQ249DPro-158-r and YQ259-DPro-158-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV251 (primers YQ231-DPro180-r and YQ260-Dpro-25123-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV252 (primers YQ231-DPro180-r and YQ260-Dpro-25123-f-v2)

pJVD52.1ΔftdA-F
pUC19ΔPftdA::tsr

pUC19ΔPftdA::Pe
rmE*
pUC19ΔPftdA::P1
3350
pUC19ΔPftdA::P2
51
pUC19ΔPftdA::P2
52

Tet xylE reporter gene vector

182

Novagen
Marx et al
(8)
Bierman
et al (9)
Ko et al
(10)
Ko et al
(10)
Blodgett
et al (5)
Blodgett
et al (5)
This study

This study

This study

This study

This study

This study

This study

pUC19ΔPftdA::P2
53
pUC19ΔPftdA::P2
54
pUC19ΔPftdA::P2
55
pUC19ΔPftdA::P2
56
pUC19ΔPftdA::P2
57
pUC19ΔPftdA::P2
58
pJVD52.1ΔPftdA::tsr
pJVD52.1ΔPftdA::Pe
rmE*
pJVD52.1ΔPftdA::P1
3350
pJVD52.1ΔPftdA::P2
51
pJVD52.1ΔPftdA::P2
52
pJVD52.1ΔPftdA::P2
53
pJVD52.1ΔPftdA::P2
54
pJVD52.1ΔPftdA::P2
55

gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV253 (primers YQ231-DPro180-r and YQ260-Dpro-25123-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV254 (primers YQ252-DPro254-r and YQ261-DPro-254-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV255 (primers YQ254-DPro255-r and YQ262-DPro-255-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV256 (primers YQ256-DPro2568-r and YQ263-DPro-2568-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV257 (primers YQ249-DPro158-r and YQ264-DPro-257-f-v2)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), JV180 (primers YQ211-180DPro-us-f and YQ212-180DPro-us-r;
YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and JV258 (primers YQ256-DPro2568-r and YQ263-DPro-2568-f-v2)
ligation of pJVD52.1 and pUC19-ΔPftdA::tsr, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::PermE*, both digested with XbaI and
HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P13350, both digested with XbaI and
HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P251, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P252, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P253, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P254, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P255, both digested with XbaI and HindIII

This study
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This study

This study

This study

This study

This study

This study

pJVD52.1ΔPftdA::P2
56
pJVD52.1ΔPftdA::P2
57
pJVD52.1ΔPftdA::P2
58
pJMD1PermE*_p
HM11axylE
pJMD1PftdA_JV1
80-xylE
pJMD1PftdA_IFO
13350-xylE
pJMD1PftdA_JV1
80-ftdAxylE
pJMD1PftdA_IFO
13350ftdA-xylE
pUC19ΔadpA
pJVD52.1ΔadpA
pSET152adpA_1335
0
pSET152adpA_180
pJMD3adpA_1335
0
pJMD3adpA_180
pUC19PftdA-Δ528_-307

ligation of pJVD52.1 and pUC19-ΔPftdA::P256, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P257, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P258, both digested with XbaI and HindIII

This study

Qi et
al(11)

ligation of pJMD1 and overlap extension PCR product of [pJMD1 (primers YQ67XylE-fw and xylE-REV) and JV180 (primers YQ50-P180-overlap-r and YQ51-P180overlap-f)], both digested with AscI and HpaI
ligation of pJMD1 and overlap extension PCR product of [pJMD1 (primers YQ67XylE-fw and xylE-REV) and JV180 (primers YQ69-P13350-overlap-r and YQ70P13350-overlap-f)], both digested with AscI and HpaI
gibson assembly of PCR products of pJMD1 (primers YQ67-XylE-f and YQ177pXylE-r) and JV180 (YQ501-P180-ftdA-xylE-f and YQ502-PftdA-ftdA-xylE-r)

This study

gibson assembly of PCR products of pJMD1 (primers YQ67-XylE-f and YQ177pXylE-r) and pUC19-ΔPftdA::P13350 (YQ503-P13350-ftdA-xylE-f and YQ502PftdA-ftdA-xylE-r)

This study

ligation of pUC19 and overlap extension PCR product of JV180 (primers YQ180DadpA-u-f-xbaI and YQ189-DadpA-us-r-2; YQ190-DadpA-d-f-o-3 and YQ169DadpA-d-r-h-2), both digested with XbaI and HindIII
ligation of pJVD52.1 and pUC19-ΔadpA, both digested with XbaI and HindIII, for
the construction of the ΔadpA mutant
ligation of pSET152 and the PCR product of IFO13350 (primers YQ225-adpA-f-xbaI
and YQ226-adpA-r-bamHI), both digested with BamHI and XbaI

This study

ligation of pSET152 and the PCR product of JV180 (primers YQ225-adpA-f-xbaI
and YQ226-adpA-r-bamHI), both digested with BamHI and XbaI
ligation of pJMD3 and the PCR product of IFO13350 (primers YQ119-AdpA_fw_n
and YQ120-AdpA_rv1_x), both digested with NdeI and XbaI

This study

ligation of pJMD3 and the PCR product of JV180 (primers YQ119-AdpA_fw_n and
YQ121-AdpA_rv2_x), both digested with NdeI and XbaI
gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265Dpro-us-r-v2; YQ231-DPro-180-r and YQ229-Dpro-D500-f; YQ213-180DPro-ds-f
and YQ214-180DPro-ds-r)

This study

184

This study

This study

This study
This study

This study

This study

pJVD52.1PftdA-Δ528_-307
pJVD52.1PftdA-Δ528_-207
pJVD52.1PftdA-Δ528_-57
pUC19PftdAΔAG

pUC19PftdAΔAG::CT
pUC19PftdA-Δ2948

pUC19PftdA-Δ2948::IFO133
50
pUC19ΔPftdA::P1
3350+AG
pJVD52.1PftdAΔAG
pJVD52.1PftdAΔAG::CT
pJVD52.1PftdAΔ29_48
pJVD52.1PftdAΔ29_48::IF
O13350
pUC19ΔPftdA::P1
3350+AG

ligation of pJVD52.1 and pUC19-PftdA-Δ-528_-307, both digested with XbaI and
HindIII

This study

ligation of pJVD52.1-PftdA-Δ-528_-307 and PCR product of JV180 (primers
YQ237-Dpro-ds-ncoI-r and YQ232-Dpro-D400-f), both digested with SpeI and NcoI

This study

ligation of pJVD52.1-PftdA-Δ-528_-307 and PCR product of JV180 (primers
YQ237-Dpro-ds-ncoI-r and YQ234-Dpro-D250-f), both digested with SpeI and NcoI

This study

gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap
extension PCR product of JV180 (primers YQ238-Dpro-DAG-r and YQ260-Dpro25123-f-v2; YQ231-DPro-180-r and YQ229-Dpro-D500-f)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds) and JV180 (primers YQ211-180DPro-us-f and YQ390-180PTM-dAGCT-r; YQ389-180PTM-dAG-CT-f and YQ214-180DPro-ds-r)
gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap
extension PCR product of JV180 (primers YQ239-Dpro-DadpA-r and YQ260-Dpro25123-f-v2; YQ231-DPro-180-r and YQ229-Dpro-D500-f)
gibson assembly of PCR product of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds), PCR products of JV180 (primers YQ211-180DPro-us-f and YQ265Dpro-us-r-v2; YQ213-180DPro-ds-f and YQ214-180DPro-ds-r), and overlap
extension PCR product of JV180 (primers YQ240-Dpro-DadpA158-r and YQ260Dpro-25123-f-v2; YQ231-DPro-180-r and YQ229-Dpro-D500-f)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds) and pUC19-ΔPftdA::P13350 (primers YQ211-180DPro-us-f and YQ407P158+AG-us-r; YQ340-P254+AG-ds-f and YQ214-180DPro-ds-r)
ligation of pJVD52.1 and pUC19-PftdA-ΔAG, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-PftdA-ΔAG::CT, both digested with XbaI and
HindIII

This study

ligation of pJVD52.1 and pUC19-PftdA-Δ29-48, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-PftdA-Δ29-48::IFO13350, both digested with XbaI
and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔPftdA::P13350+AG, both digested with XbaI and
HindIII

This study
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This study

This study

This study

This study

This study

pUC19ΔgrhR2-V
pJVD52.1ΔgrhR2-V
pUC19ΔgrhGH
pUC19ΔgrhQSAB
pJVD52.1ΔgrhGH
pJVD52.1ΔgrhQSAB
pJMD2grhR2
pJMD2grhR3
pJMD2grhF
pJMD2grhG
pJMD2grhH
pJMD2grhGH
pJMD2accBE-180
pJMD2SGR194344
pJMD2SGR328180
pKN001

pKN002

pKN003

pKN004

ligation of pUC19 and overlap extension PCR product of JV180 (primers YQ183Dgrh-us-r-3 and YQ191-Dgrh-us-f-x-4; YQ184-Dgrh-ds-f-o-2 and YQ163-Dgrh-dsr-hindIII), both digested with XbaI and HindIII
ligation of pJVD52.1 and pUC19-ΔgrhR2-V, both digested with XbaI and HindIII

This study

gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds) and JV180 (primers YQ466-grhGdel-u-f and YQ467-grhGdel-u-r;
YQ469-grhGHdel-d-r and YQ473-grhGHdel-d-f)
gibson assembly of PCR products of pUC19 (primers YQ268-pUC19-us and YQ269pUC19-ds) and JV180 (primers YQ485-grhQdel-u-f and YQ486-grhQdel-u-r;
YQ487-grhBdel-d-f and YQ488-grhBdel-d-r)
ligation of pJVD52.1 and pUC19-ΔgrhGH, both digested with XbaI and HindIII

This study

ligation of pJVD52.1 and pUC19-ΔgrhQSAB, both digested with XbaI and HindIII

This study

ligation of pJMD2 and the PCR product of JV180 (primers YQ244-grhR2-f-n and
YQ245-grhR2-r-x), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ246-grhR3-f-n and
YQ247-grhR3-f-r), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ286-grhF-f-n and
YQ287-grhF-r-x), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ288-grhG-f-n and
YQ289-grhG-r-x), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ294-grhH-f-n and
YQ295-grhH-r-x), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ288-grhG-f-n and
YQ295-grhH-r-x), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of JV180 (primers YQ351-180accB-f and
YQ354-180accE-r), both digested with NdeI and XbaI
ligation of pJMD2 and the PCR product of IFO13350 (primers YQ355-158accB-f and
YQ358-158accE-r), both digested with NdeI and XbaI

This study

ligation of pJMD2 and the PCR product of IFO13350 (primers YQ359-3281-f and
YQ362-3280-r), both digested with NdeI and XbaI

This study

gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers G35T-us-F and G35T-us-R; G35T-ds-F and G35T-ds-R) for
construction of the PftdA-AdpAo::G35T point mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers G40T-us-F and G40T-us-R; G40T-ds-F and G40T-ds-R) for
construction of the PftdA-AdpAo::G40T point mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers C37A-us-F and C37A-us-R; C37A-ds-F and C37A-ds-R) for
construction of the PftdA-AdpAo::C37A point mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers C42A-us-F and C42A-us-R; C42A-ds-F and C42A-ds-R) for
construction of the PftdA-AdpAo::C42A point mutant

This study
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This study

This study

This study

This study
This study
This study
This study
This study
This study
This study

This study

This study

This study

pKN012

pKN015

pKN016

pKN017

pKN018

pKN019

pKN027

pKN028

pKN029

pKN030

pKN031

pUC19JV180ΔPftdA::P
CM02
pKN038
pKN040

pKN047

gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 69-88-us-F and 69-88-us-R; 69-88-ds-F and 69-88-ds-R) for
construction of the PftdA∆(69_88) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 49-68-us-F and 49-68-us-R; 49-68-ds-F and 49-68-ds-R) for
construction of the PftdA∆(49_68) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 89-108-us-F and 89-108-us-R; 89-108-ds-F and 89-108-ds-R) for
construction of the PftdA∆(89_108) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 129-148-us-F and 129-148-us-R; 129-148-ds-F and 129-148-ds-R)
for construction of the PftdA∆(129_148) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 109-128-us-F and 109-128-us-R; 109-128-ds-F and 109-128-ds-R)
for construction of the PftdA∆(109_128) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers 149-181-us-F and 149-181-us-R; 149-181-ds-F and 149-181-ds-R)
for construction of the PftdA∆(149_181) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers grhR1-grhE-us-F and grhR1-grhE-us-R; grhR1-grhE-ds-F and
grhR1-grhE-ds-R) for construction of the ∆grhR1-E mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers -528--31-us-F and -528--31-us-R; -528--31-ds-F and -528--31-ds-R)
for construction of the PftdA∆(−528_−31) mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers grhF-grhH-us-F and grhF-grhH-us-R; grhF-grhH-ds-F and grhFgrhH-ds-R) for construction of the ∆grhFGH mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers grhI-grhP-us-F and grhI-grhP-us-R; grhI-grhP-ds-F and grhI-grhP-dsR) for construction of the ∆grhI-P mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR product of
JV180 (primers -528--38-us-F and -528--38-us-R; -528--38-ds-F and -528--38-ds-R)
for construction of the PftdA∆(−528_−38) point mutant
gibson assembly of the PCR products of pUC19-JV180-ΔPftdA::tsr (primers BE277PftdA500 bp-F and BE277-PftdA500 bp-R1) and SP18CM02 (primers CM02PftdA500 bp-F and CM02-PftdA500 bp-R)

This study

ligation of pJVD52.1 and pUC19-JV180-ΔPftdA::PCM02, both digested with HindIII
and XbaI
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers 2-28-us-F and 2-28-us-R; 2-28-ds-F and 2-28-ds-R) for construction
of the PftdA∆(2-28) point mutant
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers -35JV254-us-F and-35JV254-us-R; -35JV254-ds-F and-35JV254-dsR) for insertion of -35 box from JV254 in JV1836

This study
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This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

This study

pKN048

pKN049

pKN050

pKN052

gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers -35JV255-us-F and-35JV255-us-R; -35JV255-ds-F and-35JV255-dsR) for insertion of -35 box from JV255 in JV1836
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers -35JV256-us-F and-35JV256-us-R; -35JV256-ds-F and-35JV256-dsR) for insertion of -35 box from JV256 in JV1836
gibson assembly of pJVD52.1 digested with BamHI and HindIII and PCR products of
JV180 (primers -35JV257-us-F and-35JV257-us-R; -35JV257-ds-F and-35JV257-dsR) for insertion of -35 box from JV257 in JV1836
ligation of pET11a and the PCR product of JV180 (primers pET11a-AdpA-F and
pET11a-AdpA-R), both digested with NdeI and NheI

188

This study

This study

This study

This study

Table S3. List of oligonucleotides used in this study.
name
Sequence (5’ to 3’)
PXPX2
PXPF2
Fd-pSET
Fd-xylE
xylE-pSET
xylE-fd
PXFP2
PXXP2
YQ4Sg_rpsL_f
YQ5Sg_rpsL_r
YQ82180PTM_us_f
YQ91180PTM_us_r
_v2
YQ84180PTM_ds_f
YQ85180PTM_ds_r
YQ38180PTM_us_f
1153
YQ42180PTM_ds_r
1155
YQ113180PTM_us_f
326
YQ114180PTM_ds_r
203
YQ268pUC19-us
YQ269pUC19-ds
YQ211180DPro_us_f

AGATTACAACTAGTGATTACACGCTCACTGCCCGCT
TTCC
AGATTACAGGATCCGATTACATTACCCGCAGGACAT
ATCCACGC
AGATCTAAGCGGCCTTTGACTCCC

description
Construction of pJMD1

CTTTGTTCATGGCGCGCCTCGTCTTTCCAGACGTTA
GTAAATGAATTTTCT
TCTAGAGTTAACTCAGGTGAGCACGGTCATGAATC
GGAAAGACGAGGCGCGCCATGAACAAAGGTGTAAT
GCGACCGG
AGATTACAGGATCCGATTACATTACCCGCAGGACAT
ATCCACGC
AGATTACAACTAGTGATTACACGCTCACTGCCCGCT
TTCC
CACGAACGGCACACAGAAAC

sequencing rpsL mutation

GATGATGACCGGGCGCTTC
ATGTTGGCGTCGTGGTCCAGC

PCR upstream homology
region (us) for ΔftdA-F

TCAACCGGCTGCACGACGGGACCGTGCACGACTGG
TGAGACCCCATCGGCCCAGATCATC
TCACCAGTCGTGCACGGTCCC

PCR downstream homology
region (ds) for ΔftdA-F

GTCGCTGTACCGGGGCGCGTA
verify ΔftdA-F plasmid and
mutant

TCTCCGGTCACCGSGTCGAA

GRGARCTGGCSGTCGTCAGC

ACTAAGGAATGTCCCGCCCAG

CACGCCTACACCTTCACCGAC

TCTAGAGGATCCCCGGGTAC

amplify pUC19 for gibson
assembly

AAGCTTGGCGTAATCATGGTC
GGCCAGTGAATTCGAGCTCGGTACCCGGGGATCCTC
TAGAGGGCCGAAGAACTTGTACG
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PCR us for JV180 PftdA
replacement

YQ265Dpro_us_r_v2
YQ213180DPro_ds_f
YQ214180DPro_ds_r
YQ215-tsr_f
YQ216-tsr_r
YQ217tsr_int_f
YQ218tsr_int_r
YQ219180DPro_us_
out
YQ36180PTM_us_f
738
YQ221180DPro_ds_
out
YQ222180DPro_ds_i
nt
YQ229Dpro_D500_f
YQ232Dpro_D400_f
YQ234Dpro_D250_f
YQ237Dpro_ds_r
YQ260Dpro_25123_f
_v2
YQ231DPro_25123_r
YQ258DPro_ermEh_
f_v2
YQ243DPro_ermEh_
r

CACCCCGCGGTTCCCCGTCGAG
ATGAACGAGCGCGAACCATC

PCR ds for JV180 PftdA
replacement

TCACACAGGAAACAGCTATGACCATGATTACGCCA
AGCTTGGTTGTTCACGTCGGCCATG
GGCCGGTGGAGGGCTCCGGCGAAGGGCTCTGGCGA
AGCTCATCAAGGCGAATACTTCATATGC
AATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGT
TCATCGAGGAACAGAGGCGCTTATC
TCATTCGGGACAGCGGTATG

PCR tsr for JV180 PftdA
replacement plasmid

verify Δ PftdA::tsr replacement

GACCTCGATGAACTCCACCC
CCATCATCTCGTAGGGCAGC

verify JV180 PftdA replacement

GGACGTCGTACGACAAGGRGG

GAAGCCGTCGATGTATCCGC

AGCAGAAGAACGGGATAGGC

GGAACTGTGCGCGCACCGCGCGGACGTCGTACGAC
AAACTAGTCCGTCGGGCCGGTGGAG
GAGAGAACTAGTTGCGTGCGCCTCCGCGCTC

PCR truncated JV180 PftdA

GAGAGAACTAGTCGGATATTTTGATGAGCAAG
ACCGCTACGAGGAGCTGTG
GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTCCGTCGGGCCGGTGGAGGGCTC

PCR JV251-JV253 PftdA for
JV180 PftdA replacement

AATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGT
TCATCGGTGACCCTCCACGAGAGT
GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTAGCCCGACCCGAGCACGC

PCR PermE* for JV180 PftdA
replacement

AATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGT
TCATATGGGTCCTCCTGTGGAGTG
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YQ261DPro_254_f_v
2
YQ252DPro_254_r
YQ262DPro_255_f_v
2
YQ254DPro_255_r
YQ263DPro_2568_f_
v2
YQ256DPro_2568_r
YQ259DPro_13350_f
_v2
YQ264DPro_257_f_v
2
YQ249DPro_13350_r
YQ238Dpro_DAG_r
YQ389180PTMdAG_CT-f
YQ390180PTMdAG_CT-r
YQ239Δ29_48_r
YQ240Δ29_48_1335
0_r
YQ67-XylE-f

GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTGGCGGAAGGAGCCCGGAGTC

PCR JV254 PftdA for JV180 PftdA
replacement

ATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGTT
CATAGGTGACCCCCACAAGGGAAC
GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTGGGCGGAGCCCTCCGGCGGAAG

PCR JV255 PftdA for JV180 PftdA
replacement

ATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGTT
CATACGTGACCCCCACAAGGGAAC
GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTAGGCGTGGGGCCGGTCGGG

PCR JV256, JV258 PftdA for
JV180 PftdA replacement

ATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGTT
CATCCGTGACCCTCCGCAAGTGAC
GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTACTCCCCGGCCCGGGAGGCG

PCR IFO13350 PftdA for JV180
PftdA replacement

GGCGCGGGCCGGGGGCGGCTCGACGGGGAACCGCG
GGGTGACTAGTCACTTGCCGGCACGGGAGGC

PCR JV257 PftdA for JV180 PftdA
replacement

AATGGTTTTCGCCATCGGCGGATGGTTCGCGCTCGT
TCATCCGTGACCCTCCACAAGTG
TTCGGATCATTCCGGCCGTGACGTGAACCGATGCCC
CCGACCCCATCGGCCCAGATCATC
GGGCATCGGTTCACGTCACG

PCR IFO13350 and JV257 PftdA
for JV180 PftdA replacement
PCR PftdA ΔAG for PftdA editing
plasmid
PCR PftdA ΔAG::CT for PftdA
editing plasmid

xylE-REV

CAGTGAGCTGTTAACCAGGTGAGCACGGTCATGAA
TCG
TCGTCTTTCCAGACGTTAG

YQ177pXylE-rv
YQ123pXylE-MCS-f
YQ371-PXS6
YQ50-P180overlap-r

CTTCGGATCATTCCGGCCGTGACGTGAACCGATGCC
CCCAGGACCCCATCGGCCCAGATC
GCACCACACTGACCGATTCCCGACGCCCGGCTTCGG
ATCCGATGCCCCCCTGACCCCATC
ACTGACCGATTCCCGACGCCCGGCTTCGGATCAATG
CGGCCGTGGCGTGAACCGATGCCC

PCR PftdA Δ29_48 for PftdA
editing plasmid
PCR PftdA Δ29_48::13350 for
PftdA editing plasmid

ATGAACAAAGGTGTAATGCG

Amplification of xylE, xylE
reporter plasmid
Amplification of xylE

TCTCACTCCGCTGAAACTGT

Amplification of xylE reporter
plasmid
checking clone into xylE
reporter plasmid

GGCCGATTCATTAATGCAGC
ATGGCCCGGTCGCATTACACCTTTGTTCATCGGTGA
CCCTCCACGAGAGTTC
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PCR JV180 PftdA for xylE
reporter plasmid

YQ51-P180overlap-f
YQ69P13350overlap-r
YQ70P13350overlap-f
YQ501-P180ftdA-xylE-f
YQ503P13350-ftdAxylE-f
YQ502PftdA-ftdAxylE-r
YQ495-xylEq-507
YQ496-xylEq-625
YQ178WNp213
YQ179WNp210
YQ185180PTM_r_115
YQ186180PTM_r_227
YQ188180PTM_r_46
YQ193180FtdA_f_75
4
YQ196180FtdB_r_23
4
YQ203180FtdB_f_20
3
YQ204180FtdC_r_14
6

GAGGCGCGCCGAGAAGGGTTCTGGCGAAGCTC
ATGGCCCGGTCGCATTACACCTTTGTTCATCCGTGA
CCCTCCACAAGTG

PCR IFO13350 PftdA for xylE
reporter plasmid

GAGGCGCGCCGAGGCTTCGGGGGCGCTATTC

CATACAGAAAATTCATTTACTAACGTCTGGAAAGAC
GACCGTCGGGCCGGTGGAGGGCTC
CATACAGAAAATTCATTTACTAACGTCTGGAAAGAC
GAACTCCCCGGCCCGGGAGGCG

PCR JV180 PftdA-ftdA for xylE
reporter plasmid
PCR IFO13350 PftdA-ftdA for
xylE reporter plasmid

ACGCAGCTGCACATGGCCCGGTCGCATTACACCTTT
GTTCATGCGAACTCCTAGATCGTC

PCR PftdA-ftdA for xylE reporter
plasmid

CAAGGTGCTCGGTTTCTATCT

qPCR primers for xylE

TTCCGGATGGTGAATGAAGG
GTCTCGTTAGCTCGCTGGATCCTA/3InvdT/

cRACE - adapter

TAGGATCCAGCGAGCTAACGAGAC

cRACE - forward primer

GATAGGCCAGGAAACGGAGG

cRACE - nested reverse
primers

AGAGCGAGATAGGAGATGACC

CGGCCGAATGGTTTTCGCCATCGG

CAGCACCGATCTGTCCGAAG

ftdA-B junction PCR

GAAGCCGTCGATGTATCCGC

AGGTCACCGTCATCACCGAC

ftdB-C junction PCR

TCGAAGATCCGGGTCCTGG
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YQ205180FtdC_f_13
4
YQ206180FtdD_r_25
4
YQ207180FtdD_f_24
4
YQ208180FtdE_r_21
8
YQ209180FtdE_f_11
3
YQ210180FtdF_r_24
9
YQ180DadpA_u_f_x
YQ189DadpA_us_r
YQ190DadpA_d_f_o
YQ169DadpA_d_r_h
YQ117adpA_seq_f_i
nt
YQ118adpA_seq_r_i
nt
YQ164DadpA_out_f
YQ165DadpA_out_r
YQ119AdpA_fw_n
YQ120AdpA_rv1_x
YQ121AdpA_rv2_x
YQ225adpA_f_x
YQ226adpA_r_b

AGTACCTCTGCCGTGAACTC

ftdC-D junction PCR

CAGATCTGGTGCATCTCGTTG

GGAACTGATCAAGAAGCACGG

ftdD-E junction PCR

ACCACCTCCATGATCGAGTC

AGATCACCTTCGACCACACC

ftdE-F junction PCR

CTGGTTGAACATGAGGTCGG

ACTAGTGATCTAGAGCGTCTGG

us for JV180 ΔadpA plasmid

CCAGCTCAATGTCGATAAGGG
GAACGCTTCACGCCACGTCCCCTTATCGACATTGAG
CTGGGAGGCGTTCGTTCCCGGAC
ACTAGTGAAAGCTTGTTCTACGC

ds for JV180 ΔadpA plasmid

TCGAACTCACCGCGCCGTACG

verify ΔadpA plasmid and
mutant

TCGACGTGCACCGACGGATAG

ATGGACGATGATCAGACCGG
TTCCGGTACTACGTCACCAAG
ACTAGTGACATATGAGCCAGGACTCCGCC

clone adpA into pJMD3

ACTAGTGATCTAGACTACGGGGCGCTCCGCTGTC

clone adpA_JV180 into pJMD3

ACTAGTGATCTAGACTACGGGGCACTCCGCTGTC

clone adpA_IFO13350 into
pJMD3
clone adpA into pSET152

ACTAGTGATCTAGAGTGACCGGATTCAGCACAC
ACTAGTGAGGATCCAGTCGATCCACACCATGCG

193

YQ191Dgrh_us_f_x_
4
YQ183Dgrh_us_r_3
YQ184Dgrh_ds_f_o_
2
YQ163Dgrh_ds_r_h
YQ146grh_ds_seq_f
YQ147grh_ds_seq_r
YQ152grh_ds_seq_f_
2
YQ153grh_ds_seq_r_
2
YQ166Dgrh_int_f
YQ167Dgrh_out_f
YQ168Dgrh_out_r
YQ244grhR2-f-n
YQ245grhR2-r-x
YQ246grhR3-f-n
YQ247grhR3-r-x
YQ286-grhFf-n
YQ287-grhFr-x
YQ288-grhGf-n
YQ289-grhGr-x
YQ294-grhHf-n
YQ295-grhHr-x

ACTAGTGATCTAGAGTGGACATCGAAATACTGGG

PCR us for JV180 ΔgrhR2-V
plasmid

GTTCGGACGTCATGCGCAC
GATCACCGCAGGTGGGAAGGGGTGCGCATGACGTC
CGAACCCCCGGAGAGAAGGAGCAAG

PCR ds for JV180 ΔgrhR2-V
plasmid

ACTAGTGAAAGCTTCGAAGATCATCCAGAACGCG
verify ΔgrhR2-V plasmid and
mutant

GTTCGAGATCTACCGGGTGC
CATCCCGAAGAAGCTGAACC
GAGAACACCATGGCCAAGAG

CCTGGCACCTCGGCTTCG

CCAGTTCATCATCGACCACC
TTCGGACCAGTCGATGATGC
CATGACGACGAAGCTCAGCC
ACTAGTGACATATGAGGATCCGGGTTCTGGG

clone JV180 grhR2

ACTAGTGATCTAGAGGGACGCACGTTCATGGCAC
ACTAGTGACATATGGACCCGCTCGACGCGGTG

clone JV180 grhR3

ACTAGTGATCTAGAGGTCAGGCGTCGAGGGCGCC
ACTAGTGACATATGCCGCGCCTCGCGCCGC

clone JV180 grhF

ACTAGTGATCTAGATCAAGGGCGGTCGGAAGAAG
ACTAGTGACATATGACCACCGAGACCGCCG

clone JV180 grhG

ACTAGTGATCTAGATCGTCGTCGGTGTCATCGTC
ACTAGTGACATATGACACCGACGACGACCGG
ACTAGTGATCTAGATCATCTGCCGCGCCACGTAC
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clone JV180 grhH

YQ298-grhGr-int
YQ351180accB-f
YQ354180accE-r
YQ35513350accB-f
YQ35813350accE-r
YQ359-3281-f

TACGGGCGTTTGTTCTCCAG

verify JV180 grhG clone

ACTAGTGACATATGACCGTTGTGGACGAAAC

clone JV180 accBE

YQ362-3280-r

ACTAGTGATCTAGACTAGCTGCCGGGCACGGGCTC

YQ363180accB-int
YQ36413350accB-int
YQ36513350grhG-int
YQ372grihrdBF
YQ373grihrdBR
YQ376180ftdB1153
YQ377180ftdB1278
YQ466grhGHdel-u-f
YQ467grhGHdel-u-r
YQ469grhGHdel-d-r
YQ473grhGHdel-d-f
YQ477grhGHdel-f-i
YQ478grhGHdel-f-o
YQ480grhGHdel-r-o
YQ483grhGHdel-r-i
YQ485grhQdel-u-f
YQ486grhQdel-u-r

CAGATGTTCATCACCGGCCC

verify JV180 accBE clone

CCAGAAGGGTGATGATCGGG

verify SGR1943-44 clone

AGCGGAATGTTGAAGGCGTC

verify SGR3280-3281 clone

CACCAAGGGCTACAAGTTCT

qPCR primers for hrdB, from
Claesen and Bibb(12)

ACTAGTGATCTAGATCTCAGCCCTGCCAGCTGTG
ACTAGTGACATATGACCGTTGTGGACGAAAC

clone SGR1943-44 (IFO13350
accB)

ACTAGTGATCTAGATGGTCAGCCCTGCCAGCTGTG
ACTAGTGACATATGCATGACCGGGTGGGCGAAC

clone SGR3280-3281

CGAGCTTGTTGATGACCTC
ATCAACCTGGAGAACCTCAAC

qPCR primers for ftdB

GAAGCCGAAGGAGTTGACC
GGCCAGTGAATTCGAGCTCGGTACCCGGGGATCCTC
TAGAGAGCTGGACCTCGCCTACC
GTCGGATGCGGCGGCGGTCTC

PCR us for JV180 ΔgrhGH
plasmid

TCACACAGGAAACAGCTATGACCATGATTACGCCA
AGCTTCGGGCGTCTACTTGTCGATG
AGGAGATCGCGTGACCACCGAGACCGCCGCCGCAT
CCGACCCCTCCCCCGGTACGTGGCG
TTCTTCCGACCGCCCTTGAG

PCR ds for JV180 ΔgrhGH
plasmid

verify JV180 ΔgrhGH plasmid
and mutant

GAACCAGCTCCACCGGCAG
GCGGAGGCGTGGTTCATCC
CCGATGTTCTTGGCGTTGAC
GCCAGTGAATTCGAGCTCGGTACCCGGGGATCCTCT
AGATCTCCCTCCTGCGGTTCTTC
CTCGGGCGGCTCAGGCGGTGTGGTCGGTTCGGTCGC
CCCCCATCCTGGCCACGATCAGGG
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PCR us for JV180 ΔgrhQSAB
plasmid

YQ487grhBdel-d-f
YQ488grhBdel-d-r
YQ489grhQdel-f-i
YQ490grhQdel-f-o
YQ491grhBdel-r-i
YQ492grhBdel-r-o
CM02PftdA500bp-F
CM02PftdA500bp-R
2-28-us-F
2-28-us-F
2-28-ds-F
2-28-ds-F
49_68-us-F
49_68-us-R
49_68-ds-F
49_68-ds-R
69_88-us-F
69_88-us-R
69_88-ds-F
69_88-ds-R
89_108-us-F
89_108-us-R
89_108-ds-F

PCR ds for JV180 ΔgrhQSAB
plasmid

GGGGGCGACCGAACCGACCAC
TCACACAGGAAACAGCTATGACCATGATTACGCCA
AGCTTTGGAGCCGAGGTTGACGATC
AGACAGCTTTGAGAACCGCC

verify JV180 ΔgrhQSAB
plasmid and mutant

TTCTCGGTCAACTTCACGGG
CATCAGAATCGGGCCTCCTC
GATGTAGGAGGACTGGTCGC
CGGCTCGACGGGGAACCGCGGGGTGCGTCGTGCCG
GTGGAGGGCTCCGGCGA
TCGGCGGATGGTTCGCGCTCGTTCATCGGTGACCCT
CCACGAGAGTTCCTG
GTTGTAAAACGACGGCCAGTGCCAGTCGAAGTCGG
CCATGCGCACGT
CGGATCATTCCGGCCGTGACGTGAACGATCATCTAT
TTCCCGATCGCCAGGCT
AGCCTGGCGATCGGGAAATAGATGATCGTTCACGT
CACGGCCGGAATGATCCG
CGATATCGCGCGCGGCCGCGGATCAGGTGAAGCTG
CCGAAGAGGT
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
GGTCAGGGGCACCACACTGACCGATTCATTCCGGCC
GTGACGTGAACCGAT
GCATCGGTTCACGTCACGGCCGGAATGAATCGGTC
AGTGTGGTGCCCCTGACCG
ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
AGACGATGTCCGGCACGGCGGTCAGGCCGACGCCC
GGCTTCGGATCATTCCGG
CCGGAATGATCCGAAGCCGGGCGTCGGCCTGACCG
CCGTGCCGGACATCGTCTCT
ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
GGTCATACCTGTTGGTGAGAGACGAGGCACCACAC
TGACCGATTCCCGA
GTCGGGAATCGGTCAGTGTGGTGCCTCGTCTCTCAC
CAACAGGTATGACCT
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clone PftdA from strain
SP18CM02 to construct
pKN038
PCR us for pKN040

PCR ds for pKN040

PCR us for pKN015

PCR ds for pKN015

PCR us for pKN012

PCR ds for pKN012

PCR us for pKN016

PCR ds for pKN016

89_108-ds-R
109_128-us-F
109_128-us-R
109_128-ds-F
109_128-ds-R
129_148-us-F
129_148-us-R
129_148-ds-F
129_148-ds-R
149_181-us-F
149_181-us-R
149_181-ds-F
149_181-ds-R
-528_-31-us-F
-528_-31-us-R
-528_-31-ds-F
-528_-31-ds-F
-528_-38-us-F
-528_-38-us-R
-528_-38-ds-F
-528_-38-ds-F
-528_-31sequs-F
-528_-31sequs-R

ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
CCGCCGCATCGCGTCACCGCAGGTCATGTCCGGCAC
GGCGGTCAGGGGCA
TGCCCCTGACCGCCGTGCCGGACATGACCTGCGGTG
ACGCGATGCGGC
ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
TCCTGCCTGGGGGAGAGAGGCCGCCGTACCTGTTG
GTGAGAGACGATGTCCGG
GACATCGTCTCTCACCAACAGGTACGGCGGCCTCTC
TCCCCCAGGCAGGA
ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
CGCTCGTTCATCGGTGACCCTCCACATCGCGTCACC
GCAGGTCATACCTGT
AGGTATGACCTGCGGTGACGCGATGTGGAGGGTCA
CCGATGAACGAGCGCG
ATATCGCGCGCGGCCGCGGATCCGTGATGCAGTCCT
TGCCCGCCACCAG
GTTGTAAAACGACGGCCAGTGCCAACGCGGACAGT
CCCACGCGCA
TATTTCCCGATCGCCAGGCTTTAATTGTCGTACGAC
GTCCGCGCGGTG
CACCGCGCGGACGTCGTACGACAATTAAAGCCTGG
CGATCGGGAAATA
CGATATCGCGCGCGGCCGCGGATCTCATTCCGGGCG
GGTGGTGCCCGGT
GTTGTAAAACGACGGCCAGTGCCAACGCTCACCCCT
TCGAGGCCGCCCA
ATTTCCCGATCGCCAGGCTTTAACCACCACTTGTCG
TACGACGTCCGCGCGGTGCGC
GCGCACCGCGCGGACGTCGTACGACAAGTGGTGGT
TAAAGCCTGGCGATCGGGAAAT
CGATATCGCGCGCGGCCGCGGATCGCCGGTGCTGCT
CGGGACTGGCCA
AAAATACCGCATCAGGCGCCATTC
CAACAGGTATGACCTGCGGT
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PCR us for pKN018

PCR ds for pKN018

PCR us for pKN017

PCR ds for pKN017

PCR us for pKN019

PCR ds for pKN019

PCR us for pKN028

PCR ds for pKN028

PCR us for pKN031

PCR ds for pKN031

Sequencing primers for
pKN028 and pKN038

-528_-31seqds-F
-528_-31seqds-R
-528_-31mutF
-528_-31mutR
-35JV254-usF
-35JV254-usR
-35JV254-dsF
-35JV254-dsR
-35JV255-usF
-35JV255-usR
-35JV255-dsF
-35JV255-dsR
-35JV256-usF
-35JV256-usR
-35JV256-dsF
-35JV256-dsR
-35JV257-usF
-35JV257-usR
-35JV257-dsF
-35JV257-dsR
Seq35box_JV183
6-F
Seq35box_JV183
6-F

ATCTCCTCCGCGTTGACCTC
AAAGCGGGCAGTGAGCGCAAC
TGCGCGAGAAGTCGAAGGTGAG

verify PftdA ∆(−528_−31) and
(−528_−38) mutants

ATCCCATCCCAGGCGTAATG
GTTGTAAAACGACGGCCAGTGCCAACGCGGACAGT
CCCACGCGCA
TATTTCCCGATCGCCAGGCTTTAATCACGCCTTGTC
GTACGACGTCCGCGCGGTG
CACCGCGCGGACGTCGTACGACAAGGCGTGATTAA
AGCCTGGCGATCGGGAAATA
CGATATCGCGCGCGGCCGCGGATCTCATTCCGGGCG
GGTGGTGCCCGGT
GTTGTAAAACGACGGCCAGTGCCAACGCGGACAGT
CCCACGCGCA
TATTTCCCGATCGCCAGGCTTTAACCACGCCTTGTC
GTACGACGTCCGCGCGGTG
CACCGCGCGGACGTCGTACGACAAGGCGTGGTTAA
AGCCTGGCGATCGGGAAATA
CGATATCGCGCGCGGCCGCGGATCTCATTCCGGGCG
GGTGGTGCCCGGT
GTTGTAAAACGACGGCCAGTGCCAACGCGGACAGT
CCCACGCGCA
TATTTCCCGATCGCCAGGCTTTAATCACGACTTGTC
GTACGACGTCCGCGCGGTG
CACCGCGCGGACGTCGTACGACAAGTCGTGATTAA
AGCCTGGCGATCGGGAAATA
CGATATCGCGCGCGGCCGCGGATCTCATTCCGGGCG
GGTGGTGCCCGGT
GTTGTAAAACGACGGCCAGTGCCAACGCGGACAGT
CCCACGCGCA
TATTTCCCGATCGCCAGGCTTTAATCACGGCTTGTC
GTACGACGTCCGCGCGGTG
CACCGCGCGGACGTCGTACGACAAGCCGTGATTAA
AGCCTGGCGATCGGGAAATA
CGATATCGCGCGCGGCCGCGGATCTCATTCCGGGCG
GGTGGTGCCCGGT
AGGACGATCTCCTCCGCG

GAGGAGGCGAACCGATTGT
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PCR us for pKN047

PCR ds for pKN047

PCR us for pKN048

PCR ds for pKN048

PCR us for pKN049

PCR ds for pKN049

PCR us for pKN050

PCR ds for pKN050

verify double crossover for −35
box mutants

G35T-us-F
G35T-us-R
G35T-ds-F
G35T-ds-R
C37A-us-F
C37A-us-R
C37A-ds-F
C37A-ds-R
G40T-us-F
G40T-us-R
G40T-ds-F
G40T-ds-R
C42A-us-F
C42A-us-R
C42A-ds-F
C42A-ds-F
Seq-AdpA-usF
Seq-AdpA-usR
Seq-AdpA-dsF
Seq-AdpA-dsR
AdpAMT-R

TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
TCATTCCGGCCGTGAAGTGAACCGATGCCCCCCTGA
CCC
GGGCATCGGTTCACTTCACGGCCGGAATGATCCGA
AG
ATATCGCGCGCGGCCGCGGATCGGAGGCCGACGGC
GGTGGGCT
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
GATCATTCCGGCCGTTACGTGAACCGATGCCCCCCT
GACC
GCATCGGTTCACGTAACGGCCGGAATGATCCGAAG
CCGG
ATATCGCGCGCGGCCGCGGATCGGAGGCCGACGGC
GGTGGGCT
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
TCGGATCATTCCGGCAGTGACGTGAACCGATGCCCC
CCT
TCGGTTCACGTCACTGCCGGAATGATCCGAAGCCGG
GCG
ATATCGCGCGCGGCCGCGGATCGGAGGCCGACGGC
GGTGGGCT
TAAAACGACGGCCAGTGCCATCACCGCGACCACCC
GGGTCCG
CTTCGGATCATTCCGTCCGTGACGTGAACCGATGCC
CCC
GGTTCACGTCACGGACGGAATGATCCGAAGCCGGG
CGTC
ATATCGCGCGCGGCCGCGGATCGGAGGCCGACGGC
GGTGGGCT
AAAATACCGCATCAGGCGCCATTC

PCR us for pKN001

PCR ds for pKN001

PCR us for pKN003

PCR ds for pKN003

PCR us for pKN002

PCR ds for pKN002

PCR us for pKN004

PCR ds for pKN004

Sequencing primers for
pKN001-004

ACTGACCCAGGCCGGATCCCAT
TAATCCTACTAAGGAATGTCC
AAAGCGGGCAGTGAGCGCAAC
ATGCTTCCGGCTCGTATGTTG

AdpAMT-R1

CAGGACAGGTCGGAGCCGTA

AdpAMT35-F

GTTCACTTCACGGCCGGAAT

AdpAMT37-F

GTTCACGTAACGGCCGGAAT

verify double cross-over for
AdpA binding site mutants
verify double cross-over for
G35T mutant
verify double cross-over for
C37A mutant
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AdpAMT40-F

GTTCACGTCACTGCCGGAAT

AdpAMT42-F

GTTCACGTCACGGACGGAAT

AdpAop-seqF1
AdpAop-seqR1
grhR1-grhEus-F
grhR1-grhEus-R
grhR1-grhEds-F
grhR1-grhEds-R
grhR1-grhEseq-us-F
grhR1-grhEseq-us-R
grhR1-grhEseq-ds-F
grhR1-grhEseq-ds-R
grhR1-E-mutF1
grhR1-E-mutR1
grhR1-E-mutF2
grhR1-E-mutR2
grhR1-E-mutF3
grhR1-E-mutR3
grhR1-E-mutF4
grhR1-E-mutR4
grhF-grhH-usF
grhF-grhH-usR
grhF-grhH-dsF

CTCGACGGGGAACCGCGGGGT

verify double cross-over for
G40T mutant
verify double cross-over for
C42A mutant
amplify AdpA binding site to
sequence binding site mutations

ACCCAGGCCGGATCCCATCCCAG
GTTGTAAAACGACGGCCAGTGCCAAAGGGGGTGCG
GCCCGTCGAGCGGGA
GAAGGGGCGCACGGGCGTCCGCCGTCTGCGCTCCA
CCCGCGGTCGATACGGGT
ACCCGTATCGACCGCGGGTGGAGCGCAGACGGCGG
ACGCCCGTGCGCCCCTTC
CGATATCGCGCGCGGCCGCGGATCAGCGCCCGGTG
GGCGCCGAAGGTCCA
AAAATACCGCATCAGGCGCCATTC

PCR us for pKN027

PCR ds for pKN027

Sequencing primers for
pKN027

TCGGAGGGTGCTGGGATGG
CCATCCCAGCACCCTCCGA
AAAGCGGGCAGTGAGCGCAAC
TGCACGGCCGCTTACCGGAAG

Primers PCR used to verify
∆grhR1-E

CTGCGTGTACGACCTCCAGCAT
TCGTCTACGGACTGGTCGCG
CTCCGTACGCGTTTCCGTGT
ACTCGGTGTTCCACCGGTG
CGGCGGTCTCAGGGATGT
TGCTGTGGGCGCTGACCG
TTCGGCGTCCACCCCGATC
GTTGTAAAACGACGGCCAGTGCCAACGGCCTTCCA
CCACACGTCCCACCGT
TGGCGCGGCGGCCCGGCCGGGCGGGGGCGTCCGCC
GTTCAGGGCTTCG
CGAAGCCCTGAACGGCGGACGCCCCCGCCCGGCCG
GGCCGCCGCGCCA
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PCR us for pKN029

PCR ds for pKN029

grhF-grhH-dsR
grhF-grhHseq-us-F
grhF-grhHseq-us-R
grhF-grhHseq-ds-F
grhF-grhHseq-ds-R
grhF-H-mutF1
grhF-H-mutR1
grhF-H-mutF2
grhF-H-mutR2
grhF-H-mutF3
grhF-H-mutR3
grhI-grhP-usF
grhI-grhP-usR
grhI-grhP-dsF
grhI-grhP-dsR
grhI-grhP-sequs-F
grhI-grhP-sequs-R
grhI-grhP-seqds-F
grhI-grhP-seqds-R
grhI-P-mut-F1

CGATATCGCGCGCGGCCGCGGATCTCCGGTCGCTCG
CCACCCCGAACT
AAAATACCGCATCAGGCGCCATTC

grhI-P-mut-R1

AGGGTCTCGAAGGCGGTCA

grhI-P-mut-F2

ACCTCTTCGCCTGGGTGACC

grhI-P-mut-R2

GCCGAAGACCACCATGTAGA

grhI-P-mut-F3

TCCGCGCCGAACGGGACG

grhI-P-mut-R3

GATCGGGACCAGCAGCGAGT

pET11aAdpA-F

TATCATATGAGCCAGGACTCCGCCACC

Sequencing primer for pKN029

ACGCGTACGGAGTCGGGCAC
GTGCCCGACTCCGTACGCGT
AAAGCGGGCAGTGAGCGCAAC
Primers used to verify ∆grhF-H

AGACCGACCCGGCGGAGC
TCGTGGCGGGCCACGCCG
GTCTCGCTGGCCTGGCCGA
TGCCAGCCGGTGCCGGTG
TACGCGCAGAGCGCCGTG
CGGTCGTCGGAGACGAACT
GTTGTAAAACGACGGCCAGTGCCATCGATCCCGCTG
GTGACCCTGGTCGA
ACCGGCCTGGACCGGTCTCCGGCGGCCGGTGGGTCT
CTCCTGACGTGGGTCCGAG
CTCGGACCCACGTCAGGAGAGACCCACCGGCCGCC
GGAGACCGGTCCAGGCCGGT
CGATATCGCGCGCGGCCGCGGATCGGCGACCTGCG
AGCGGAACGCCGACGCGT
AAAATACCGCATCAGGCGCCATTC

PCR us for pKN030

PCR ds for pKN030

Sequencing primers for
pKN030

AGATGACCGCCCGGCCGGGC
GCCCGGCCGGGCGGTCATCT
AAAGCGGGCAGTGAGCGCAAC
Primers used to verify ∆grhI-P

ACCGAGCTGGAGGACGAC
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clone adpA for pKN052

pET11aAdpA-R
JV180EMSA
DS_sense
JV180EMSA
DS_anti
IFO13350EM
SADS_sense
IFO13350EM
SADS_anti
JV180G35TE
MSADSsense
JV180G35TE
MSADSanti
JV180C37AE
MSADSsense
JV180C37AE
MSADSanti
JV180G40TE
MSADSsense
JV180G40TE
MSADSanti
JV180C42AE
MSADSsense
JV180C42AE
MSADSanti

AATGCTAGCTCAGTGGTGGTGGTGGTGGTGCTCGAG
CGGGGCGCTCCGCTGTCCCGG
TTCGGATCATTCCGGCCGTGACGTGAACCGATGCC

JV180 PftdA AdpA binding site
for EMSA

GGCATCGGTTCACGTCACGGCCGGAATGATCCGAA
TTCGGATCAATGCGGCCGTGGCGTGAACCGATGCC

IFO13350 PftdA AdpA binding
site for EMSA

GGCATCGGTTCACGCCACGGCCGCATTGATCCGAA
GGCATCGGTTCACTTCACGGCCGGAATGATCCGAA

JV180 PftdA AdpA binding site
G35T mutant for EMSA

TTCGGATCATTCCGGCCGTGAAGTGAACCGATGCC
GGCATCGGTTCACGTAACGGCCGGAATGATCCGAA

JV180 PftdA AdpA binding site
C37A mutant for EMSA

TTCGGATCATTCCGGCCGTTACGTGAACCGATGCC
GGCATCGGTTCACGTCACTGCCGGAATGATCCGAA

JV180 PftdA AdpA binding site
G40T mutant for EMSA

TTCGGATCATTCCGGCAGTGACGTGAACCGATGCC
GGCATCGGTTCACGTCACGGACGGAATGATCCGAA
TTCGGATCATTCCGTCCGTGACGTGAACCGATGCC
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JV180 PftdA AdpA binding site
C42A mutant for EMSA

Table S4. % identity of 16S, concatenated MLST genes, and PTM enzyme amino acid
sequences of the strains used in this study, relative to Streptomyces sp. strain JV180.
Strain
16S MLST# FtdA FtdB FtdC FtdD FtdE FtdF
Streptomyces sp. strain JV180

100

100

100

100

100

100

100

S. sp. strain SP18CM02

100

99.91

99.36 99.4 100

S. californicus strain NRRL B-3320 (JV251)

99.93 99.75

99.36 98.52 99.64 99.30 99.72 99.74

S. floridae strain NRRL 2423 (JV252)

99.79 99.72

99.68 98.74 99.82 99.65 99.15 99.48

S. puniceus strain NRRL B-2895 (JV253)

99.11 99.80

99.36 98.89 99.82 99.83 99.43 98.96

S. griseus subsp. griseus strain NRRL F-5144 (JV254)

99.79 97.37

83.44 87.74 91.34 91.30 91.17 87.21

S. globisporus subsp. globisporus strain NRRL B-2709
(JV255)

99.59 97.49

81.21 87.11 87.95 92.00 89.74 86.68

S. albus subsp. albus strain NRRL B-2445 (JV256)

99.59 97.19

81.37 88.64 93.04 92.32 91.74 87.21

S. griseus subsp. griseus strain NRRL WC-3480 (JV257)

99.73 97.74

82.48 88.01 91.96 92.86 91.45 87.99

S. baarnensis strain NRRL B-2842 (JV258)

99.59 97.14

81.37 88.55 93.04 92.32 91.74 87.21

S. griseus subsp. griseus strain IFO13350

99.73 97.70

83.44 88.11 92.14 93.03 91.17 87.99

99.83 100

100
98.96

# - MLST: concatenated partial sequences of atpD, gyrB, recA, rpoB, and trpB corresponding to
the sequences used in references (13, 14)
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Figure S1. Maximum likelihood phylogenetic tree of selected S. griseus clade strains. Strains
used in this study are highlighted in red, and the strain JV180-like group is highlighted in green.
atpD, gyrB, recA, rpoB, and trpB sequences of previously established S. griseus clade strains
were taken from previous published lists (see refs (13, 14)). S. griseus clusters I-IX, as defined
by Rong et al(13, 14) are represented in the tree. Sequences were aligned with MUSCLE and the
alignments were concatenated. The maximum likelihood tree was built using the GTR+I+G
model using CLC Main Workbench. Branches supported by less than 50% of 500 bootstrap
simulations were collapsed.

204

Figure S2. Genetic and metabolomic identification of PTMs produced by 13C5-ornithine
feeding. (A) LC-MS chromatograms of extracts from JV180 rpsL and ΔftdA-F mutants. The
retention times of major PTM peaks were marked in gray. (B) Mass spectra of clifednamide A
produced by the known clifednamide producer S. torulosus strain NRRL B-3889(11) on media
supplemented with 50 mg/L of L-ornithine or 13C5-labeled L-ornithine. Mass spectra of selected
PTM peaks produced by JV180 on media supplemented with 50 mg/L of L-ornithine or 13C5labeled L-ornithine, which eluted at (C) 8.4, (D) 11.2, and (E) 7.9 minutes.
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Figure S3. Tandem mass spectrometry-based identification and quantification of PTMs.
(A) The structures of known clifednamides A and B, which differ by an FtdA-installed
hydroxylation (shown in red). The product ion spectra of (B) clifednamide A and (C)
clifednamide B produced by collision-induced dissociation at 20 V. Mass spectra were converted
to centroids for visual clarity. S. torulosus strain NRRL B-3889 was grown on media
supplemented with (top) L-ornithine or (bottom) 13C5-labeled L-ornithine. Inset: proposed
structures of ornithine-derived fragments, with 13C5 atoms indicated by heavy dots, which would
result in the heavier daughter ions observed (red).
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Figure S4. PTM production by S. griseus clade strains on various media: (A) ISP2 (Difco),
(B) ISP4 (Difco), (C) ISP-S (see methods), and (D) YMS8 (0.4% yeast extract; 1% malt extract;
1.2% soluble starch; 2% agar; pH 7.4). Retention times for PTM peaks are highlighted in gray.
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Figure S5. PTM production by S. griseus clade strains on various media: (A) supplemented
minimal medium (15), (B) minimal medium (15), (C) low tryptone-yeast extract (15), and (D)
medium 2 (16). Retention times for PTM peaks are highlighted in gray.
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Figure S6. PTM production by S. griseus clade strains on various media: (A) YMS (15), (B)
ATCC172, (C) Hickey-Tresner (17), and (D) SFM (15). Retention times for PTM peaks are
highlighted in gray. A peak marked with an asterisk in the extract of JV255 from SFM had a
similar retention time as PTMs but did not have the correct absorbance spectrum.
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Figure S7. Improved detection for PTMs via LC-MS/MS. Chromatograms of extracts of
(Red) Streptomyces sp. strain JV180 and (blue) Streptomyces griseus subsp. griseus strain
IFO13350 monitored using (A) UV absorbance at 280 nm, (B) MS scan mode in positive mode
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for m/z from 100-1000, and (C) precursor ion scan mode for ions fragmenting into m/z 139 or
154 daughter ions. Retention times for prominent PTM peaks are marked with dotted grey lines.

Figure S8. ftdA-F are transcribed on one mRNA molecule. (A) Diagram of the PTM
biosynthetic gene cluster, and PCR probes for intergenic regions. (B) PCR amplification of PTM
intergenic regions using genomic DNA (positive control), RNA (negative control), and cDNA
templates. Ladder: GeneRuler 1kb Plus DNA marker (Thermo Fisher)
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Figure S9. Nucleotide alignment of PTM promoters and 5’ UTRs belonging to S. griseus
clade strains used in this study. Nucleotides in blue have >70% conservation, while nucleotides
in red have <30% conservation. Many nucleotides in black (between 30-70% conservation) are
still conserved within the JV180-like strain (green) and IFO13350-like strain groups (red).
Nucleotides were aligned using MUSCLE with 500 bootstrap simulations.
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Figure S10. PftdA_JV180 drives stronger xylE transcription than PftdA_IFO13350. RT-qPCR was
used to compare xylE transcript abundance from different PftdA-ftdA-xylE constructs in both
JV180 and IFO13350 hosts. We used the PftdA-ftdA-xylE constructs in case proper expression
required mRNA secondary structures forming from the 5’ UTR and the ftdA coding sequences.
Relative transcription and statistical significance were calculated by Student’s T-test relative to
the JV180 PftdA in each respective host strain (n = 6; *p < 0.05, **p < 0.01, ***p < 0.001).

213

Figure S11. Transcript start site mapping of the JV180 PftdA by cRACE. The sequencing
read was aligned with the JV180 genome sequence.
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Figure S12. Mutations in the −35 box cause slight decreases in PTM BGC expression. (A) A
diagram of the PftdA region in −35 box mutants. Due to difficulties in cloning, IFO13350-type
−35 boxes were introduced into the Δ−528_−31 mutant background. (B) Relative PTM
production from −35 box mutants (n = 3). (C) Relative ftdB transcript abundance from −35 box
mutants (n = 6). Statistical significance was calculated by Student’s T-test relative to the
Δ−528_−38 strain (*p < 0.05, **p < 0.01, ***p < 0.001). Bars represent standard deviation.
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Figure S13. Predicted secondary structure of the JV180 PftdA UTR. The structure was
predicted with mFold using the RNA folding form for the UTR sequence and the first 30
nucleotides of ftdA. The 5’ end, 3’ end, Shine-Dalgarno sequence, and the start codon are
labeled.
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Figure S14. Predicted secondary structure of the PftdA UTR from JV180-like PftdA’s. The
structures were predicted with mFold using the RNA folding form for the UTR sequence and the
first 30 nucleotides of ftdA for (A) SP18CM02, (B) JV251, (C) JV252, and (D) JV253. The
SP18CM02 has an additional nucleotide (indicated with a red circle) that greatly alters its
structure.
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Figure S15. Predicted secondary structure of the PftdA UTR from strains (A) IFO13350 and
(B) JV257. The structures were predicted with mFold using the RNA folding form for the UTR
sequence and the first 30 nucleotides of ftdA.
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Figure S16. Predicted secondary structure of the PftdA UTR from strains (A) JV254 and (B)
JV255. The structures were predicted with mFold using the RNA folding form for the UTR
sequence and the first 30 nucleotides of ftdA.
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Figure S17. Predicted secondary structure of the PftdA UTR from strains (A) JV256 and (B)
JV258. The structures were predicted with mFold using the RNA folding form for the UTR
sequence and the first 30 nucleotides of ftdA.
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Figure S18. adpA is required for morphological development and secondary metabolite
expression. (top) Wild-type JV180 and (bottom) its ΔadpA mutant (JV556) were streaked on
ISP2 agar and incubated for 2 days at 28 °C. The ΔadpA mutant is deficient in secondary
metabolite production (red pigment) and morphological differentiation (white aerial mycelia),
which are exhibited by the parent strain.
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Figure S19. Additional complementation data for ΔadpA. Relative PTM production (A) on
solid agar media (n = 3) and (B) in shake flasks (n = 4, except for JV180 rpsL where n = 3). The
pSET152-adpA constructs were designed to express adpA under its native promoter and failed to
express properly in flask cultures, whereas the pJMD3 vector uses the constitutive PermE*. We
speculate the pSET152-adpA construct failed to express properly in flask cultures due to
differences in culture conditions, which is in line with the previous report that AdpA only
appeared to be a transcriptional activator for the PTM BGC in strain IFO13350 when grown on
solid media(18). Additionally, the actual adpA promoter could contain more regulatory binding
regions upstream which were not included in the construct. Statistical significance was
calculated by Student’s T-test relative to the JV180 rpsL parent strain (*p < 0.05, **p < 0.01,
***p < 0.001). Bars represent standard deviation.
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Figure S20. Additional electrophoretic mobility shift assays with AdpA-PftdA. (A)
Competition assay with unlabeled DNA probe. (B-D) assays with JV180 probes containing
transversion mutations in nucleotides reported to directly interact with AdpA. The lane marked
by the (+) sign is a positive control, using wild-type probe sequence.
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Figure S21. S. griseus clade strains contain different secondary metabolite BGCs. BGCs
were identified using AntiSMASH (19). Each row represents a unique BGC. Green boxes
indicate BGCs shared by all 11 strains. Yellow boxes indicate BGCs shared by two or more
strains. Gray boxes indicate BGCs that are unique to strains.
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Figure S22. JV180-subclade strains produce a red pigment absent in other S. griseus clade
strains. Strains JV180, IFO13350, SP18CM02, and JV251-JV258 were streaked on ISP2 and
incubated for 2 days at 28°C.
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Figure S23. Identification of griseorhodin in JV180 culture extracts. (A) UV chromatogram
of JV180 rpsL and ΔgrhR2-V mutant mutants. (Inset) absorbance spectrum of the putative
griseorhodin A peak, which closely matches the absorbance characteristics reported
previously(20). PTM peaks (marked with p) were also missing in the ΔgrhR2-V mutant. (B) The
structure of griseorhodin A and the expected and observed m/z. (C) Image of JV180 rpsL (top)
and the ΔgrhR2-V mutant (bottom) streaked on ISP2 agar and incubated for 2 days at 28°C. The
ΔgrhR2-V mutant lacks griseorhodin pigmentation. (D) griseorhodin production observed from
various grh cluster mutants.
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Figure S24. Sporulation is reduced in the ΔgrhR2-V mutant and partially complemented by
ectopically expressing grhGH. Statistical significance was calculated by Student’s T-test
relative to the JV180 rpsL parent strain or otherwise indicated (n = 3; *p < 0.05, **p < 0.01,
***p < 0.001). Bars represent standard deviation.
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Figure S25. Griseorhodin does not act as a signaling compound in Streptomyces sp. strain
JV180. (A) UV chromatogram of the griseorhodin-enriched fraction. The m/z 509, 511, and 527
peaks have the same masses as griseorhodin A (21), griseorhodin G (20), and griseorhodin C
(22). (B) PTM production by JV180 and its ΔgrhR2-V mutant in flasks with added DMSO
(negative control), the griseorhodin- enriched fraction, or γ-rubromycin (n = 3). (C) Disc
diffusion assay of ΔgrhR2-V mutant with DMSO (negative control), the griseorhodin- enriched
fraction, and γ-rubromycin. PTM production and sporulation were not restored by a chemical
signaling mechanism. Instead, production and growth inhibition were observed. Statistical
significance was calculated by Student’s T-test relative to the DMSO control (*p < 0.05, **p <
0.01, ***p < 0.001).
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Figure S26. Two acetyl-CoA carboxylase genes play a key role in the grh-PTM BGC
interaction. (A) PTM production by the ΔgrhR2-V mutant (JV564) on solid media and
complementation by various constructs. grhR2, grhR3, and grhF were not able to restore PTM
production, while grhG and/or grhH were able to restore some PTM production. Additionally,
accBE and their homologs from strain IFO13350 were also able to restore some PTM production
(n = 3 for JV180 rpsL and JV564, n = 2 for complementation strains). (B) PTM production by
the ΔgrhFGH and ΔgrhGH mutants on solid media barely differs (n = 3). Statistical significance
was calculated by Student’s T-test relative to the JV180 rpsL parent strain (*p < 0.05, **p <
0.01, ***p < 0.001). Bars represent standard deviation.
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Figure S27. Heterologous expression of grhG in IFO13350-like strains increases PTM
production and transcription. (A) Relative PTM production by strains JV180, IFO13350,
JV254, and JV258 heterologously expressing grhG on solid agar (for IFO13350, JV254, and
JV258, n = 3; otherwise, n = 2). (B) Relative ftdB transcript abundance in strain IFO13350
heterologously expressing grhG. Methods for culturing and extracting RNA were largely the
same as for JV180-derived strains, except the samples were harvested after 2 days of culturing
for RT-qPCR (n = 3). Statistical significance was calculated by Student’s T-test relative to the
wild-type strains (*p < 0.05, **p < 0.01, ***p < 0.001). Bars represent standard deviation.
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Appendix II: Supplementary Information for
Chapter 5: Native and Engineered
Clifednamide Biosynthesis in Multiple
Streptomyces spp.
Supplementary methods
XylE reporter comparison of PermE* promoters
The two PermE* promoter variants used in this study were characterized using the xylE reporter
gene1. The promoters were constructed by PCR amplifying PermE* from pIJ102572,
concomitantly adding 5’-UTR sequences adapted from pHM11a or pDA1652. To construct the
pHM11a promoter variant, primers YQ102 and YQ103 were used, with YQ103 encoding the 5’
UTR of PermE*pHM11a. Similarly, primers YQ106 and YQ107 were used to recreate
PermE*pDA1652 (pDA1652 PermE* gratefully provided by Dylan Alexander, personal
communication) in two successive PCR reactions. The resulting 5’UTR sequences of the two
promoters were: PermE*pHM11a:
5’-TAGGATCAGCTTACAGAACCACTCCACAGGAGGACCCATATG-3’
and PermE*pDA1652:
5’TAGGATCCGGTTAATTAAGCAGTACCAGATCTGACTGAGTGACCAAAGGAGGCGGA
CATATG-3’
(bold: promoter -10 region, underlined: Shine-Dalgarno sequence, italicized: NdeI restriction site
containing the start codon).
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Reporter cassettes to measure xylE expression from the variant PermE* promoters were created
by overlap extension PCR. The 5’ end of xylE was amplified from pJMD1, a pSET152-derived
integrating vector, using primers YQ67 and xylE-REV. After fusing the xylE fragment with the
PermE* promoters by PCR, the amplicons and pJMD1 were digested with AscI and HpaI and
ligated. The resulting plasmids were introduced into Streptomyces albus strain J1074 by
intrageneric conjugation.
XylE reporter activity was measured based on the method described by Luo et al3. Briefly, 5 mL
of cell culture at different time points were collected and centrifuged at 3,214 × g for 10 min to
remove the supernatant. The pellets were washed with 20 mM phosphate buffer, pH 7.5 and repelleted. Two milliliters of sample buffer (100 mM phosphate buffer, pH 7.5; 20 mM Na-EDTA,
pH 8.0; 10% v/v acetone) were added to resuspend the cell pellets followed by sonication on ice.
0.1% Triton X-100 solution was added into the samples, which were then incubated on ice for 15
min. Then, the samples were centrifuged for 5 min (15,000 × g, 4°C), and the supernatants were
transferred to fresh tubes. In a 96-well plate, 180 μL assay buffer (10 mM phosphate buffer, pH
7.5; 0.2 mM catechol) was added to 20 μL of clarified lysate, and accumulation of 2hydroxymuconic semialdehyde was monitored by absorbance at 375 nm over 10 minutes. Total
protein concentration was determined by the Bradford method. The slope of the linear portion of
the absorbance curve was used to compare xylE expression between samples.

Isolation and characterization of Streptomyces sp. strain KL33
Streptomyces sp. strain KL33 was isolated as part of an actinomycete enrichment culture from
soil samples collected at Tyson Valley Research Center in Eureka, Missouri using methods
previously described4. During WUSTL undergraduate laboratory classwork, strain KL33 was
identified as a potential PTM producing Streptomycete during PCR-based characterization of
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environmental isolates. Specifically, strain KL33 was confirmed as a member of the
Streptomyces genus after cloning and sequencing a fragment of the 16S ribosomal RNA gene
using oligos S-C-Act-235-a-S-20 and S-C-Act-878-a-A-195. The resulting amplicon sequence
was deposited to GenBank with accession number MG575211. The strain was assessed for
potential PTM production after amplifying a conserved ikaA/ftdB gene fragment from its genome
using degenerate primers YQ158 and YQ159 (designed using CODEHOP6). Being PTM-locus
positive, strain KL33 was found to produce substantial clifednamide A by LC/MS (see main
text). The DNA sequence of its ikaA amplicon was most similar to that of Streptomyces sp. strain
FxanaA7 (Figure S4). Notably, the clifednamide cluster of strain FxanaA7 lacks a ftdA homolog,
likely making the strain incapable of clifednamide B production. We only observed clifednamide
A production in strain KL33, consistent with it also harboring a ftdA-less clifednamide locus.
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Supplementary Tables and Figures
Table S1 Strains used in this study
Strain
Escherichia coli
NEB10
JV36

Streptomycetes
Streptomyces sp. strain
JV178
Streptomyces
purpeofuscus NRRL B1817
Streptomyces sp. strain
NRRL F-6131
JV739
JV837
Streptomyces torulosus
(NRRL B-3889)
Streptomyces sp. strain
NRRL F-2890
JV770
JV772
JV774
JV776
JV778
JV780
JV782
JV784
Streptomyces
neyagawaensis strain
NRRL B-3092
Streptomyces sp. strain
KL33
Streptomyces albus
JV944
JV947
a

Relevant characteristics

Reference or
source

DH10B derivative, cloning host
dam-3 dcm-6 metB1 galK2 galT27 lacY1 tsx-78 supE44
thi-1 mel-1 tonA31 ΔhsdRMS-mrr::Frt(rK- mK-)
attHK::pJK202 (ΔoriR6K-aadA::Frt bla::pir) (Tra+, AmpS)

NEB
Blodgett et
al4

Environmental isolate, original clifednamide producer
Wild-type clifednamide producer

Blodgett et
al4
NRRL

Wild-type , clifednamide producer

NRRL

rpsL (K43N)
rpsL (K43N) ΔcftA
Wild-type, clifednamide producer

This study
This study
NRRL

Wild-type, ikarugamycin producer

NRRL

attBΦC31::pED1
attBΦC31::pED2
attBΦC31::pED3
attBΦC31::pED4
attBΦC31::pED5
attBΦC31::pED6
attBΦC31::pED7
attBΦC31::pED8
Wild-type, clifednamide producer

This study
This study
This study
This study
This study
This study
This study
This study
This study

Environmental isolate (Streptomyces ossamyceticus)a,
clifednamide producer
Strain J1074
attBΦC31::pJMD1-PermE*pHM11a
attBΦC31:: pJMD1-PermE*pDA1652

This study

Identity of closest 16S rDNA BLAST hit in GenBank
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Jon Clardy
This study
This study

Table S2 Plasmids used in this study
Plasmid

Description

Reference or
Source

pUC19
pJVD52.1
pSET152

bla reppUC cloning vector
aac(3)IV oriT reppSG5(ts) reppUC rpsL+ shuttle vector
aac(3)IV oriT attP-intΦC31 reppUC self-integrating
vector
hyg oriT attP-intΦBT1 vector containing PermE*
pSET152 derivative containing promoter-less xylE
pSET152 derivative containing PermE*pDA1652
promoter
pSET152 derivative containing PermE*pHM11a
promoter
pUC19 derivative with insertion of 2 kb fragment for
deletion of cftA gene, constructed by Gibson
Assembly
pJVD52.1 derivative with insertion of 2 kb XbaIHindIII fragment for deletion of cftA gene
pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from JV178
pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from JV178
pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. purpeofuscus
pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. purpeofuscus
pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. sp. F-6131
pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. sp. F-6131
pJMD2 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. torulosus
pJMD3 derivative with insertion of 1.2 kb NdeI-XbaI
PCR fragment containing cftA from S. torulosus
pJMD1 derivative with insertion of PermE*pHM11a
pJMD1 derivative with insertion of PermE*pDA1652

NEB
Blodgett et al7
Bierman et al8

pIJ10257
pJMD1
pJMD2
pJMD3
pUC19-ΔcftA

pJVD52.1-ΔcftA
pED1
pED2
pED3
pED4
pED5
pED6
pED7
pED8
pJMD1-PermE*pHM11a
pJMD1-PermE* pDA1652
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Hong et al2
Unpublished
Unpublished
Unpublished
This study

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Table S3. PCR primers used in this study. Restriction enzyme sites are underlined.
Primers
YQ268
YQ269
YQ273
YQ274
YQ275
YQ276
YQ277
YQ278
YQ279
YQ280
ED9

ED10

ED11

ED12

ED13
ED14
ED15

Description

Sequence (5’ - 3’)

Construction of cftA deletion
cassette
Construction of cftA deletion
cassette
Construction of cftA deletion
cassette
Construction of cftA deletion
cassette
Construction of cftA deletion
cassette
Construction of cftA deletion
cassette
Confirmation of cftA deletion
Confirmation of cftA deletion
Confirmation of cftA deletion
Confirmation of cftA deletion
Amplification of
Streptomyces purpeofuscus
cftA
Amplification of
Streptomyces purpeofuscus
cftA
Amplification of
Streptomyces sp. strain F6131 cftA
Amplification of
Streptomyces sp. strain F6131 cftA
Amplification of
Streptomyces torulosus cftA
Amplification of
Streptomyces torulosus cftA
Amplification of
Streptomyces sp. strain
JV178 cftA

TCTAGAGGATCCCCGGGTAC
AAGCTTGGCGTAATCATGGTC
GGCCAGTGAATTCGAGCTCGGTACCCGGGGATCCT
CTAGACCTCCAGCACGACTTCTTC
GGTCAGCGGCGGGTGCTGCC
ACGGACCCGACCATGCTCCGGCAGCACCCGCCGCT
GACCGGTCTGCAGGCGCTCCCGATC
TCACACAGGAAACAGCTATGACCATGATTACGCCA
AGCTTCCCTTGAGCAGCTTCATCAC
ACCTGCCGACCTTCATGATC
GAGTTCATCGCCCACAACG
CGGAGAAGTACGTGGCGAAC
CGAAGATCCTGGTGCGGTAC
ACTAGTGACATATGCTCCGGCAGCACCCGCC

ACTAGTGATCTAGATCACCAGGCGATCGGGAGCG

ACTAGTGACATATGCTCCGGCAGCACCCGCC

ACTAGTGATCTAGATCACCAGACGATCGGGAGCG

ACTAGTGACATATGCCGGATCAACACCCCCC
ACTAGTGATCTAGATCACCAGGCGACCGGGAGTG
ACTAGTGACATATGTCGGATCAACACCCC
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ED16

PermE*-fw
PXS6
R2NJ
F3NJ
Int 7NJ
Int 8NJ
YQ67
xylE-REV
YQ102
YQ103

YQ106

Amplification of
Streptomyces sp. strain
JV178 cftA
Confirmation of cloning
Confirmation of cloning
Confirmation of conjugation
Confirmation of conjugation
Confirmation of conjugation
Confirmation of conjugation
Amplification of xylE
Amplification of xylE
Amplification of PermE*
Amplification of
PermE*pHM11a

Amplification of
PermE*pDA1652
YQ107
Amplification of
PermE*pDA1652
S-C-ActAmplification of 16S
235-a-S-20 ribosomal RNA gene
fragment
S-C-ActAmplification of 16S
878-a-A-19 ribosomal RNA gene
fragment
YQ158
Degenerate PCR screen for
ikaA
YQ159
Degenerate PCR screen for
ikaA

ACTAGTGATCTAGATCACCAGGCGACCGGGAGTG

TTGACGGCTGGCGAGAGG
GGCCGATTCATTAATGCAGC
TCGTGGCCGTCCAGCYCNCCNGCDAT
GACCCGTTCATCATGATGGAYCARATGGG
CTCTTCGTTCGTCTGGAAGG
CTTGTCTTCGTTGGCGCTAC
ATGAACAAAGGTGTAATGCG
CAGTGAGCTGTTAACCAGGTGAGCACGGTCATGAA
TCG
GGCGCGCCAGCCCGACCCGAGCACGC
ATGGCCCGGTCGCATTACACCTTTGTTCATATGGG
TCCTCCTGTGGAGTGGTTCTGTAAGCTGAATCCTA
CCAACCGGCACG
CTTTGGTCACTCAGTCAGATCTGGTACTGCTTAATT
AACCGGATCCTACCAACCGGCACG
ATGGCCCGGTCGCATTACACCTTTGTTCATCATATG
TCCGCCTCCTTTGGTCACTCAGTCAGATC
CGCGGCCTATCAGCTTGTTG

CCGTACTCCCCAGGCGGGG

CCTGTCCATCGACTGGGGNCCNTGGGC
TCAGCTGCTTGAGGAACCANADNGC
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Figure S1. Biosynthesis and subsequent tailoring of ikarugamycin by enzymes discussed in this
study. Modifications installed by each tailoring step are highlighted in red.
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Figure S2. Clifednamide biosynthetic clusters identified in this study. Streptomyces sp. strain
FxanaA7 represents the closest match to the partially sequenced clifednamide biosynthetic
cluster found in strain KL33.
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Figure S3. PermE*-driven xylE reporter expression in Streptomyces albus strain J1074. Assays
were performed in triplicate on 1-, 2-, and 3-day old cultures.
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Figure S4. Production of PTMs in Streptomyces sp. strain NRRL F-2890 expressing CftA
isozymes. (A) strain F-2890 attBΦC31::PermE*pDA1652-cftApurpeofuscus, (B) strain F-2890
attBΦC31::PermE*pHM11a-cftApurpeofuscus, (C) strain F-2890 attBΦC31::PermE*pDA1652-cftAF-6131,
(D) strain F-2890 attBΦC31::PermE*pHM11a-cftAF-6131, (E) strain F-2890
attBΦC31::PermE*pDA1652-cftAtorulosus, and (F) strain F-2890 attBΦC31::PermE*pHM11a-cftAtorulosus.
Strains were grown in triplicate and extracted at days 2, 4, and 6.
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Figure S5. Overlaid UV spectra of PTM compounds produced by Streptomyces sp. NRRL F2890 or Streptomyces sp. NRRL F-2890 attBΦC31::PermE*pHM11a-cftAJV178 after two days of
growth. Spectra corresponding to ikarugamycin (green, elution time 15.863 min), clifednamide
A (red, elution time 7.349 min), and clifednamide C (blue, elution time 5.154 min) are shown.
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Figure S6. High-resolution mass spectroscopy analysis of clifednamides. An extract from
Streptomyces sp. strain NRRL F-2890 attBΦC31::PermE*pHM11a-cftAJV178 was analyzed via
HRMS (Q-Exactive, Thermo-Fisher Scientific). The 493.2696 ion corresponds to clifednamide
A [C29H36N2O5, calculated (M + H)+ 493.2696]. The 509.2645 ion corresponds to clifednamide
C [C29H36N2O6, calculated (M + H)+ 509.2646].
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Figure S7. 2H7 L-ornithine labeling of clifednamide base mass and daughter ions. Streptomyces
sp. strain F-2890 attBΦC31::PermE*pHM11a-cftAJV178 was grown on solid ATCC172 medium
supplemented with 50 mg/L 2H7-L-ornithine. PTMs lacking C25 hydroxylation will fragment
(CID = 30V) with a diagnostic daughter ion of m/z 139.2 (or +7 = 146.2) containing the
ornithine-tetramate region of the molecules9. Analyses of labeled clifednamide A spectra (RT =
7.20 min) show clear labeling of the base mass (Panel A, m/z 493.2 base, 500.2 labeled) and the
diagnostic daughter ions (Panel C, m/z 139.2 base and 146.2 labeled). Similar labeling and
fragmentation patterns were seen for clifednamide C (RT = 4.98 min, Panel B, m/z 509.2 base,
516.2 labeled, Panel D, diagnostic m/z 139.2 & 146.2 daughter ions, respectively).
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Figure S8. Fragmentation analysis of PTMs. (A) Ikarugamycin, (B) clifednamide A, (C) and
clifednamide C were fragmented by collision-induced dissociation (20 V) with an Agilent 6420
Triple Quadrupole Mass Spectrometer. (D) Fragmentation of capsimycin as proposed by Yu et al
(2017)9. Diagnostic 139.09 and 181.10 daughter ions (highlighted) mapping to the ornithinecontaining substructure of capsimycin were found in the ikarugamycin, clifednamide A and
clifednamide C spectra. Because all four PTMs are likely identical in the ornithine-tetramate
chromophore region (see Fig. S5), this was expected. However, the remaining fragments in each
spectra, presumably incorporating the differentially oxidized 5,6,5 carbocyclic structures unique
to each compound, have different mass profiles. These data support the identification of
clifednamide C as a chemically distinct PTM. Due to the complex dehydration patterns seen
during fragmentation, precisely mapping the oxidation event that differentiates clifednamide C
from clifednamide A was not possible; further structural studies are required.
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Figure S9. Phylogenetic analysis of PTM cluster associated P450s. The maximum likelihood tree
was built using the JTT substitution model. The Bacillus megaterium BM3 enzyme was used to
root the tree. Protein sequences were aligned using ClustalOmega and manually degapped.
Bootstrap values are expressed as percentages of 500 replicates at branch points. Scale bar shows
substitutions per nucleotide position. The blue box highlights CftA orthologs identified in this
study.
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Figure S10. Representative PTM clusters with associated with cytochrome P450 genes in yellow.
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Appendix III: Miscellaneous projects
Engineering of IFO13350-type PftdA’s
Background
Through earlier experiments, I found conserved differences between the PTM BGC promoters of
JV180-like robust PTM-producing strains and the other S. griseus clade poor PTM-producing
strains. Replacement of the PftdA in JV180 with PftdA’s from JV180-like strains largely maintained
similar levels of PTM production and BGC transcription, while replacement with PftdA’s from
IFO13350 and the other S. griseus clade poor-PTM producing strains caused strong reductions in
PTM production and BGC transcription in JV180. Part of this appeared to stem from a conserved
two-nucleotide indel located slightly downstream of the transcript start site of PftdA, which is
present in JV180-like PftdA’s but absent in IFO13350-like PftdA’s.

Engineering of the JV258 PftdA
I aimed to replace the PftdA of IFO13350 or other S. griseus clade poor-PTM producing strains
with the PftdA of JV180, or to insert the missing AG dinucleotide into their native PftdA’s. I
hypothesized that this would result in increased PTM production and BGC transcription. To test
if these strains were genetically tractable, I plated strains IFO13350, JV254-258 on ISP-S media
for sporulation. Dense spores were collected from the plates for IFO13350, JV254, and JV258. I
attempted to conjugate these strains with an E. coli conjugal donor strain harboring pJVD52.1.
Apramycin-resistant colonies were obtained from conjugation plates of JV254 and JV258.
Therefore, I designed promoter-replacement/editing constructs to replace the PftdA’s of JV254 and
JV258 with PftdA_JV180 or PermE* (Table 1). I also designed additional constructs to insert the AG
dinucleotide into PftdA_JV254 and PftdA_JV258.
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Table 1. List of plasmids and JV254 and JV258 mutants
Plasmid
Strain
Genotype
pUC19-254PftdA+AG
JV254
S. griseus NRRL F-5144 wild-type
pUC19-254ΔPftdA::P180
JV1001 JV254 rpsL(K88R)
pJVD52.1-254PftdA+AG
JV1002 JV254 rpsL(K88E)
pJVD52.1-254ΔPftdA::P180
JV1003 JV254 rpsL(K88E)
pUC19-258PftdA+AG
JV258
S. baarnensis NRRL B-2842 wild-type
pUC19-258ΔPftdA::P180
JV1106 JV258 rpsL(K43M)
pUC19-258ΔPftdA::PermE*_pHM11a
JV1107 JV258 rpsL(K88E)
pJVD52.1-258PftdA+AG
JV1194 JV1106 PftdA+AG colony a
pJVD52.1-258ΔPftdA::P180
JV1195 JV1106 PftdA+AG colony b
pJVD52.1-258ΔPftdA::PermE*_pHM11a JV1196 JV1107 PftdA+AG colony a
JV1197 JV1107 PftdA+AG colony b
JV1198 JV1106 ΔPftdA::P180 colony a
JV1199 JV1106 ΔPftdA::P180 colony b
JV1551 JV1106 ΔPftdA::PermE*_pHM11a colony a
JV1552 JV1106 ΔPftdA::PermE*_pHM11a colony b

I plated spores of JV254 and JV258 on ISP2 with 100 mg/L streptomycin to select for
spontaneous rpsL mutations to use as a counterselection marker. I obtained three rpsL mutants
for JV254, and two rpsL mutants for JV258. These mutants were assessed for growth and PTM
production phenotype changes. Of the JV254 rpsL mutants, JV1001 (K88R), showed reduced
sporulation and loss of PTM production; JV1002 (K88E) had similar growth phenotypes as wildtype JV254 and slightly lower PTM production; and JV1003 (K88N) had similar growth
phenotypes as wild-type JV254 and slightly higher PTM production (Figure 1). Due to reduced
sensitivity of the LC-MS/MS instrument (possibly due to the long timespan since the last system
maintenance and tuning), no PTMs could be detected from JV258 or its rpsL mutants JV1106
(K43M) and JV1107 (K88E). Even in previous experiments where PTMs were detected, JV258
typically produced the least amount of PTMs from the S. griseus clade strains in our lab (JV180,
IFO13350, JV251-258).
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Figure 1. PTM production by JV254 and JV258 rpsL mutants.

The promoter editing/replacement constructs were conjugated into JV1002, JV1106, and
JV1107. After going through the recombination process, no successful promoter mutants were
obtained for JV1002, as all colonies had wild-type promoters. I was able to recover
PftdA_JV258+AG mutants for both JV1106 and JV1107. Additionally, I recovered a
ΔPftdA::PftdA_JV180 mutant in the JV1107 background. However, when these strains were grown on
8340 agar and analyzed for PTM production, no increase in PTM production was observed
(Figure 2). As JV258 belongs to a different phylogenetic subclade from JV180 and IFO13350, I
could not be certain if there were other deficiencies causing the lack of PTM production. One
possible source of concern is that the rpsL mutations in JV1106 and JV1107 may have been
detrimental to PTM production.
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Figure 2. PftdA replacement and insertion of AG did not increase PTM production in JV258.

In further attempts to elicit increased PTM production from JV258, I conjugated the
PftdA_JV258+AG and ΔPftdA::PftdA_JV180 mutants with integrative plasmids expressing grhG in hopes
of eliciting increased PTM expression. I also attempted to increase the ornithine precursor supply
by adding exogenous ornithine to the growth media. However, no increase in PTM production
was achieved.

Table 2. List of JV258 strains expressing grhG, accB, or adpA
Strain
Genotype
Strain
Genotype
JV874

NEB10 + pJMD2-grhG

JV891

JV156 + pJMD2-grhG

JV1023

NEB10 + pJMD2-accBJV180

JV1034

JV36 + pJMD2-accBJV180

JV1026

NEB10 + pJMD2-SGR1944 (accBIFO13350)

JV1037

JV36 + pJMD2-SGR1944

254

JV1029

NEB10 + pJMD2-SGR3281 (grhGIFO13350)

JV1040

JV36 + pJMD2-SGR3281

JV436

DH5a + pJMD3-adpAJV180

JV439

JV156 + pJMD3-adpAJV180

JV437

DH5a + pJMD3-adpAIFO13350

JV440

JV156 + pJMD3-adpAIFO13350

JV605

NEB10 + pSET152-adpAJV180

JV606

JV156 + pSET152-adpAJV180

JV639

NEB10 + pSET152-adpAIFO13350

JV640

JV156 + pSET152-adpAIFO13350

JV1245

JV1106 + pJMD2-grhG colony a

JV1280

JV1198 + pJMD2-accBJV180 colony b

JV1246

JV1106 + pJMD2-grhG colony b

JV1281

JV1198 + pJMD2-SGR1944 colony a

JV1247

JV1106 + pJMD2-accBJV180 colony a

JV1282

JV1198 + pJMD2-SGR1944 colony b

JV1248

JV1106 + pJMD2-accBJV180 colony b

JV1283

JV1198 + pJMD2-SGR3281 colony a

JV1249

JV1106 + pJMD2-SGR1944 colony a

JV1284

JV1198 + pJMD2-SGR3281 colony b

JV1250

JV1106 + pJMD2-SGR1944 colony b

JV1350

JV1106 + pJMD3-adpAJV180 colony a

JV1251

JV1106 + pJMD2-SGR3281 colony a

JV1351

JV1106 + pJMD3-adpAJV180 colony b

JV1252

JV1106 + pJMD2-SGR3281 colony b

JV1352

JV1106 + pJMD3-adpAIFO13350 colony a

JV1253

JV1107 + pJMD2-grhG colony a

JV1353

JV1106 + pJMD3-adpAIFO13350 colony b

JV1254

JV1107 + pJMD2-grhG colony b

JV1354

JV1106 + pSET152-adpAJV180 colony a

JV1255

JV1107 + pJMD2-accBJV180 colony a

JV1355

JV1106 + pSET152-adpAJV180 colony b

JV1256

JV1107 + pJMD2-accBJV180 colony b

JV1356

JV1107 + pJMD3-adpAJV180 colony a

JV1257

JV1107 + pJMD2-SGR1944 colony a

JV1357

JV1107 + pJMD3-adpAJV180 colony b

JV1258

JV1107 + pJMD2-SGR1944 colony b

JV1358

JV1107 + pJMD3-adpAIFO13350 colony a

JV1259

JV1107 + pJMD2-SGR3281 colony a

JV1359

JV1107 + pJMD3-adpAIFO13350 colony b

JV1260

JV1107 + pJMD2-SGR3281 colony b

JV1360

JV1107 + pSET152-adpAJV180 colony a

JV1261

JV1194 + pJMD2-grhG colony a

JV1361

JV1107 + pSET152-adpAJV180 colony b

JV1262

JV1194 + pJMD2-grhG colony b

JV1362

JV1194 + pJMD3-adpAJV180 colony a

JV1263

JV1194 + pJMD2-accBJV180 colony a

JV1363

JV1194 + pJMD3-adpAJV180 colony b

JV1264

JV1194 + pJMD2-accBJV180 colony b

JV1364

JV1194 + pJMD3-adpA_158 colony a

JV1265

JV1194 + pJMD2-SGR1944 colony a

JV1365

JV1194 + pJMD3-adpA_158 colony b

JV1266

JV1194 + pJMD2-SGR1944 colony b

JV1366

JV1194 + pSET152-adpAJV180 colony a

JV1267

JV1194 + pJMD2-SGR3281 colony a

JV1367

JV1194 + pSET152-adpAJV180 colony b

JV1268

JV1194 + pJMD2-SGR3281 colony b

JV1368

JV1196 + pJMD3-adpAJV180 colony a

JV1269

JV1196 + pJMD2-grhG colony a

JV1369

JV1196 + pJMD3-adpAJV180 colony b

JV1270

JV1196 + pJMD2-grhG colony b

JV1370

JV1196 + pJMD3-adpAIFO13350 colony a

JV1271

JV1196 + pJMD2-accBJV180 colony a

JV1371

JV1196 + pJMD3-adpAIFO13350 colony b

JV1272

JV1196 + pJMD2-accBJV180 colony b

JV1372

JV1196 + pSET152-adpAJV180 colony a

JV1273

JV1196 + pJMD2-SGR1944 colony a

JV1373

JV1196 + pSET152-adpAJV180 colony b

JV1274

JV1196 + pJMD2-SGR1944 colony b

JV1374

JV1198 + pJMD3-adpAJV180 colony a

JV1275

JV1196 + pJMD2-SGR3281 colony a

JV1375

JV1198 + pJMD3-adpAJV180 colony b

JV1276

JV1196 + pJMD2-SGR3281 colony b

JV1376

JV1198 + pJMD3-adpAIFO13350 colony a

JV1277

JV1198 + pJMD2-grhG colony a

JV1377

JV1198 + pJMD3-adpAIFO13350 colony b

JV1278

JV1198 + pJMD2-grhG colony b

JV1378

JV1198 + pSET152-adpAJV180 colony a

JV1279

JV1198 + pJMD2-accBJV180 colony a

JV1379

JV1198 + pSET152-adpAJV180 colony b
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Figure 3. Overexpression of grhG/accB did not increase PTM production in JV258 PftdA mutants.
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Figure 4. Exogenous ornithine does not increase PTM production by JV258.
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Similarly, I attempted to elicit increased PTM production by overexpressing adpA in JV258 and
its mutants. In some cases, increased sporulation was observed, but no increase in PTM
production was observed (data not shown). I also attempted to construct ΔPftdA::PermE* mutants in
JV1106 and JV1107, as this strategy has been successfully used to activate numerous BGCs. I
successfully constructed ΔPftdA::PermE* mutants in the JV1106 background strain, but the mutants
do not appear to have been characterized. To further characterize the mutants, the JV1106 rpsL
mutant and its derivatives were cultured in liquid ATCC-MOPS media and relative ftdB
transcript abundance was analyzed by qRT-PCR. Likely due to the culturing conditions, no PTM
production was detected. qRT-PCR analysis revealed no increase in transcript abundance from
the PftdA_JV258+AG and ΔPftdA::PftdA_JV180 mutants over the parent strains. However, increased ftdB
transcript abundance was observed when adpA was ectopically overexpressed in both JV1106
and its ΔPftdA::PftdA_JV180 derivative. It is unclear why this was not reflected in increased PTM
production.

257

Relative ftdB transcripts

4
3.5
3
2.5
2
1.5
1
0.5
0

Figure 5. Ectopic expression of adpA is sufficient to increase ftdB transcript abundance in JV258

Attempts to engineer the IFO13350 PftdA
Further experiments were conducted to attempt to engineer the PftdA of strain IFO13350. The
Ohnishi group, which characterized the AdpA regulon, had demonstrated their ability to edit the
genome of this strain. According to the methods published in these studies, a suicide vector was
often used to facilitate the recombination between the genome and the desired editing template
(1, 2). In the Blodgett lab, we typically use pJVD52.1, a self-replicating plasmid with a
temperature sensitive oripSG5, to edit genomic sequences by homologous recombination.
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Therefore, I cloned the promoter editing construct into a suicide pOJ260 vector. However, no
apramycin resistant colonies were obtained after conjugation.
A few studies had demonstrated a way to bypass the highly active DNA restriction system in
strain IFO13350 by in vitro methylation of the plasmids before protoplast transformation (3). A
protoplast transformation protocol was adapted from several sources (3–6). Although I was
eventually unsuccessful in obtaining transformants, the protocol I used is detailed here for future
reference.

Protoplast preparation
In a 125 mL flask with 6 mm beads, 25 mL of trypticase soy broth (TSB) supplemented with 5
mM MgCl2 and 1% glycine was inoculated with 100 μL of S. griseus IFO13350 spore
suspension. The flask was shaken at 250 rpm in a 28°C incubator for approximately 6 hours.
After the spores were confirmed to have begun germinating by phase-contrast microscopy,
autoclaved 50% PEG8000 solution was added to a final concentration of 5%. After
approximately 24 hours, the culture was pelleted by centrifugation at 1,000 x g for 10 minutes.
The pellet was washed twice gently with 15 mL of 10.3% sucrose (if needed, the sucrose-washed
pellet was saved in the −20°C freezer). The pellet was resuspended in 4 mL of 1 mg/mL
lysozyme solution in P-buffer [mix 103 g sucrose, 0.25 g K2SO4, 2.02 g MgCl2-6H2O, 2 mL R2
trace elements, and water to 800 mL and autoclave as 80 mL aliquots; add 1 mL KH2PO4 (0.5%),
10 mL CaCl2-2H2O (3.68%), and TES buffer (5.73%, pH 7.2) before use]. The suspension was
incubated at 30°C for approximately 30 minutes and monitored by microscopy for protoplast
formation. The solution was then mixed by pipetting up and down with a 5 mL serological pipet
for three times and incubated at 30°C. After 15 minutes, 5 mL of P-buffer was added and mixed
as before. The protoplasts were filtered through a plug of sterilized glass wool in a syringe. The
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protoplasts were gently sedimented by centrifugation at 1,000 x g for 7 minutes. The supernatant
was poured out and the protoplasts were gently resuspended 1 mL of additional P-buffer and
saved as 200 μL aliquots in the −20°C freezer.
As the hemocytometer was damaged, serial dilutions of the protoplast stock was plated on S.
griseus protoplast regeneration medium [SpMR; 10.3% sucrose; 1% MgCl2-6H2O; 0.5%
glucose; 0.5% Difco yeast extract; 2% TES-NaOH (1 M, pH 7.6); 0.2% R2 trace element
solution; 2.2% Bacto agar; and 0.2% CaCl2 (5 M, autoclaved separately)]. A lawn formed on all
plates, and as the highest dilution factor used was 105, I determined that the protoplast stock
contained at least 1 x 109 cfu/mL.

Protoplast transformation
Plasmids were transformed into JV36, a methylation-deficient E. coli donor strain. Overnight
cultures of JV36 transformants were used for plasmid purification with a Qiagen miniprep kit.
The purified plasmid was treated with HpaII methyltransferase (NEB) in the following reaction
mixture: 10 μL CutSmart buffer, 2.5 μL S-adenosylmethionine (SAM, 1.6 mM), 1 μL HpaII MT,
up to 500 ng of plasmid DNA, and water up to 50 μL. The reaction was incubated at 37°C for 1
hour.
After thawing, the protoplasts were sedimented by centrifuging at 700 x g for 7 minutes at room
temperature. The supernatant was poured off and the remaining protoplasts were resuspended in
the remaining (approx. 50 μL) P-buffer by tapping the tube. The protoplasts were heat shocked at
42°C for 10 minutes. For each transformation, 5 μL of the methylated plasmid (10 – 60 ng DNA)
was added, followed immediately by 200 μL of T-buffer [mix sterile 25 mL sucrose (10.3%), 75
mL water, 0.2 mL R2 trace element solution, and 1 mL K2SO4 (2.5%); aliquot 7 mL and add 150
μL CaCl2 (5 M), 375 μL Tris-maleic acid buffer (1 M Tris base, adjusted to pH 8 with maleic
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acid), and 5 mL PEG1000 (50% w/v)] and mixed by pipetting four times. Next, 1.3 mL of Pbuffer was added and 150-200 μL aliquots of the transformation mixture were spread on SpMR
plates. After overnight incubation, the transformation plates were overlaid with soft SpMR (30%
agar content) containing 30 mg/L apramycin. No apramycin resistant colonies were recovered
from any of the attempted transformation experiments.

Heterologous expression of the JV180 polycyclic tetramate
macrolactam biosynthetic gene cluster
Background
We explored our lab’s ability to clone the biosynthetic gene cluster (BGC) for polycyclic
tetramate macrolactams (PTMs) into a large, single-copy shuttle vector. This was motivated by
the fact that genetic manipulation of the BGC and its promoter by homologous recombination
could be carried out more rapidly in an E. coli cloning host. Due to the number of times that cells
need to be restreaked to select for recombinants and the difference in growth rate between E. coli
and Streptomyces, this could potentially save a large amount of time. The resulting plasmid could
then be reintroduced into Streptomyces and integrated into the chromosome using the highly
efficient and site-specific ΦC31 integrase. Another motivation for cloning the PTM BGC into a
shuttle vector was to explore the use of other Streptomyces strains as potential heterologous hosts
for increased PTM production. Increased PTM production and the absence of other secondary
metabolites in engineered host strains could streamline purification of sufficient quantity of
PTMs produced by our strains of interest for structural elucidation.

Results and discussion
The pJK050 fosmid vector was provided by the Metcalf lab at University of Illinois – Urbana
Champaign (7). A fosmid library was prepared from a sample of Streptomyces sp. strain JV180
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genomic DNA, which I had purified for genome-sequencing. Briefly, the genomic DNA sample
was partially digested with Sau3AI and ligated with BamHI-digested pJK050. A fosmid
containing the entire JV180 PTM BGC, fosmid 17A10, was obtained by PCR screening. This
fosmid was also saved under the name pJMD10. Subsequently, features required to turn the
fosmid into an E. coli – Streptomyces shuttle vector by λ recombination between the λ attB site
derived from pJK050 and the λ attP site of pAE4, which contains a conditionally high-copy
origin of replication (oriR6K), Apramycin resistance marker (aprR), ΦC31 integrase (int) and
attP sequence, and origin of conjugal transfer (oriT). The resulting plasmid, pJMD11, was
conjugated into a panel of strains (Table 3). Aside from purification of the JV180 genomic DNA,
the steps described above were performed by John D’Alessandro, a former technician in the
Blodgett lab.

Table 3. pJMD11 host strains and exconjugants
Host strain
Description
JV352
JV180 ΔftdA-F
JV2
S. avermitilis ATCC31267
JV51
S. lividans 66
JV16
S. coelicolor M145
JV28
S. viridochromogenes DSM 40736

Strain # for exconjugants
JV877-878
JV879-880
JV881-882
JV883-884
JV885-886

None of the host strains contained PTM BGCs on their chromosomes. I grew each exconjugant,
parent strain, and wild-type JV180 in 3 mL TSB in a 24-well deep well plate with one 4 mm
glass bead added to disrupt mycelial clumping. The deep-well plate was shaken at 300 rpm for 2
days at 28°C. 200 μL were then plated on agar plates of three different media formulations: ISP2,
ATCC172, and 8340. The plates were incubated for 6 days at 28°C and extracted with ethyl
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acetate overnight. The ethyl acetate was then removed under by vacuum in a speedvac and the
dried extracts were resuspended in 500 μL of methanol for LC-MS/MS analysis using the
standard precursor ion scan method. However, no PTM production was observed outside of
JV180, the positive control (Figure 6).
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Figure 6. No PTM production was observed from pJMD11 exconjugants. LC-MS/MS
chromatograms of extracts from strains grown on ATCC172.

To verify that the entire PTM BGC was integrated at the ΦC31 attB site, primers were designed
to PCR overlapping 1~2 kilobase fragments of the PTM BGC (Table 4). When this was done, no
bands were obtained from JV877-878 (Figure 7). Additionally, the conjugal donor strain was
tested by colony PCR and no bands were observed, suggesting that either the plasmid was
unstable or the PTM BGC insert was lost through recombination.
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Table 4. Primer pairs to verify PTM BGC integration and expected product sizes
Primer
Fw primer sequence
pair

Rv primer sequence

Product
size (bp)

1

TGCGTGCGCCTCCGCGCTC

GAAGCCGTCGATGTATCCGC

1619

2

ACGGAACAAGGTGGCGATC

CTTGACCGAGCCGACGTAG

1036

3

CGGCGACCTCCAGTACATG

ATGGCGACGCTGTGGTAAG

1317

4

AGTTCGCCAAGTTCCTCACC

TGAGGAGGGTCTGGAAGCAG

1140

5

TTCCAGACCCTCCTCACCC

GTCCTCGTCGGTGATGTCG

1362

6

GGCCACGTTCGACATCACC

TCAGCTGCTTGAGGAACCANADNGC

996

7

CGAACTCCACACCGACGAG

AGGGTTATGTCGAACTGCCC

1158

8

TCCAGGCGATGTTCATCCTC

CCGTTCGCAGTGGTCCATC

1148

9

GACCTCCTCTTCGACACCAC

CGTTGAAGGTGAGGCTGGG

1168

10

CATCGAACTCCTCCACCACC

AAGTACCTCTTCCCGTTGCG

1675

11

TGCTCCCGTACCTCTTCAAC

CAGATCTGGTGCATCTCGTTG

1272

12

AGTACCTCTGCCGTGAACTC

GATGAGGTGGGTCGTGCAG

1192

13

ACTACCGCAAGCTCTACACC

ACCACCTCCATGATCGAGTC

999

14

GGAACTGATCAAGAAGCACGG

CTGGTTGAACATGAGGTCGG

1593

15

AGATCACCTTCGACCACACC

GTGGGCGAGGTGTTCAACAC

1833

Figure 7. PCR verification of PTM genes in pJMD11 and pJMD11 exconjugants
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To increase the stability of the plasmid in E. coli and reduce the likelihood of unwanted
recombination, I used λ RED recombination (8) to delete an approximately 12.5 kilobase
sequence from pJMD11. This region contained additional JV180 chromosomal DNA sequence
downstream of the PTM BGC and was unneeded for PTM production. This would reduce the
size of the plasmid from 45,907 base pairs for pJMD11 to 34,111 base pairs, a decrease of over
25%. The resulting plasmid was named pJMD12 (Figure 8).

Figure 8. Plasmid map of pJMD12
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Table 5. pJMD12 host strains and exconjugants
Host strain
Description
JV352
JV180 ΔftdA-F
JV51
S. lividans 66
JV16
S. coelicolor M145
JV975
S. coelicolor M1152
JV28
S. viridochromogenes DSM 40736
JV110
S. roseosporus NRRL 15998
JV158
S. griseus IFO13350

Strain # for exconjugants

JV939-940
JV992-993

pJMD12 was conjugated into a panel of host strains to test for heterologous PTM production
(Table 5). Successful integration at the ΦC31 attB site was confirmed for all strains except for
JV158 (S. griseus IFO13350). Additional PCR verification for the introduction of PTM BGC
genes revealed that while the pJMD12 vector was successfully inserted into the attB sites, the
PTM BGC was only stably integrated in JV16 (S. coelicolor M145) exconjugants, JV939 &
JV940 (Figure 9). Some false positive bands appeared in the PCR screen for JV110 (S.
roseosporus NRRL 15998) exconjugants as this strain has a silent PTM BGC. However, most
specific primers did not produce PCR bands, suggesting that the PTM BGC was also lost from
these exconjugants. At this point, I also discovered that John D’Alessandro had not verified
integration at the ΦC31 attB site for the earlier pJMD11 conjugations, so it could not be
determined if the strains failed to produce PTMs due to loss of PTM BGC genes from
recombination or failure for pJMD11 to integrate at the ΦC31 attB site.
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Figure 9. PCR verification of PTM genes in pJMD12 exconjugants. Primer pairs are the same as
those listed in Table 4. Two colonies were tested for JV352 (negative control) and exconjugants
of S. viridochromogenes (S.v.), S. coelicolor (S.c.), S. lividans (S.l.), and S. roseosporus (S.r.).

The S. coelicolor strains containing the full pJMD12 were grown on various agar plates and
extracted with ethyl acetate for PTM analysis by LC-MS/MS. I observed several peaks which
matched the retention times and mass transitions of PTMs produced by JV180 (Figure 10). We
also obtained S. coelicolor strain M1152 from the Bibb laboratory at the John Innes Centre (UK)
to test as a host for PTM production. S. coelicolor strain M1152 was engineered to be a host for
heterologous BGC expression through the deletion of the act, red, cpk, and cda BGCs and
introduction of the rpoB[C1298T] mutation (9). pJDM12 was also successfully integrated into
this strain. PTM production was observed from both S. coelicolor strains containing pJMD12
when grown on ISP2 agar, but interestingly, lower PTM production was observed from the
M1152 host strain compared to the original M145 parent strain.
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Figure 10. Heterologous PTM production in S. coelicolor. LC-MS/MS chromatograms of
extracts of JV180 grown on ATCC172, and S. coelicolor derivatives grown on ISP2.

Two hypotheses for this discrepancy are the loss of the cpk BGC in M1152 and the presence of
the rpoB[C1298T] mutation. The cpk BGC encodes cpkKL, which are homologs of the acetylCoA carboxylase genes from the grh BGC, grhGH. As we have reported, the deletion of grhGH
in Streptomyces sp. strain JV180 reduces PTM transcription and production, and this may be due
to reduced malonyl-CoA availability. It has also been reported that introduction of the
rpoB[C1298T] mutation impaired growth and differentiation. This may have also affected the
strain’s ability to produce PTMs and optimization of culture conditions could have alleviated this
issue. Unfortunately, we were unable to obtain additional strains such as M1146 (no rpoB
mutation) or M1142 (no cpk BGC deletion). I attempted to reintroduce cpkKL by integration at
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the ΦBT1 attB site. However, the exconjugants had poor growth and this line of inquiry was
discontinued.

The influence of the PTM BGC on griseorhodin biosynthesis
Background
As described in chapter 2, polycyclic tetramate macrolactam (PTM) biosynthesis in Streptomyces
sp. strain JV180 was found to be dependent on the griseorhodin biosynthetic gene cluster (BGC).
PTM production and BGC transcription were severely reduced when the grh BGC was deleted
(ΔgrhR2-V). Further genetic analyses showed that grhGH, encoding for malonyl-CoA
production, may play a key role in this interaction.

Results and discussion
In a converse experiment, I noticed that the extracts of some JV180 mutants with reduced PTM
production due to manipulation of the PTM BGC and its promoter appeared to contain less red
pigment (griseorhodins). To test if this was a real trend or an experimental artifact, I attempted to
quantify relative griseorhodin production from some JV180 mutants (Table 6).

Table 6. Strains used to compare griseorhodin production
Strain
Genotype
Notes
JV307
JV180 rpsL (K43R) Parent strain
JV352
JV307 ΔftdA-F
PTM BGC KO
JV564
JV307 ΔgrhR2-V
Control, no griseorhodin production
JV1698 JV307 ΔgrhGH
Control, reduced griseorhodin production

The strains were streaked from −80°C glycerol stocks onto ISP2 agar. After incubating for 2
days at 28°C, an agar plug from each plate was used to inoculate 3 mL of TSB in a 24-deep well
plate with one 4 mm bead added to disrupt clumping. The seed cultures were shaken at 300 rpm
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in a 28°C shaker. After 2 days, 200 μL of the seed cultures were spread on 8340 agar plates in
triplicate. After 6 days, griseorhodins were extracted using a protocol adapted from those
described by (10, 11). The top layer of agar with the adherent cells were scraped off with a
spatula and collected in 50 mL centrifuge tubes. Approximately 10 mL acidified MilliQ water
(pH adjusted to approximately 3.5 with HCl) and sonicated for approximately 20 minutes. The
tubes were centrifuged at 3,214 x g for 5 minutes and the water, which remained colorless, was
decanted and neutralized. Approximately 20 mL of ethyl acetate was added, and the tubes were
vortexed vigorously. The tubes were centrifuged at 3,214 x g for 5 minutes and the ethyl acetate
was decanted into glass scintillation vials to be dried under low pressure. The agar/cell pellet was
extracted again with approximately 20 mL of acetonitrile + 0.1% formic acid. The tubes were
vortexed vigorously and centrifuged at 3,214 x g for 5 minutes, and the acetonitrile was decanted
into glass scintillation vials to be dried under low pressure. Compared to ethyl acetate,
acetonitrile appeared to extract griseorhodins more efficiently, and the red pigmentation
appeared to be absent in the agar/cell pellet afterward. The residual water/acetonitrile were
extracted with ethyl acetate and the ethyl acetate fractions were collected and dried under low
pressure. The dried extracts were resuspended in 1 mL of acetonitrile and filtered before LC-MS
analysis.
Griseorhodin production was analyzed using a Phenomenex Luna C18 column (75 x 3 mm, 3 µm
pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad
mass spectrometer. For each run, 10 µL sample was injected and the chromatography conditions
were as follows: T = 0, 5% B; T = 2, 5% B; T = 16, 100% B, T = 20, 100% B; where solvent A
was water + 0.1% formic acid and solvent B was acetonitrile + 0.1% formic acid. The flow rate
was 0.7 mL/min. The diode array detector was set to measure absorbance at 488 nm. The mass
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spectrometer was set to mass scan mode with m/z ranges 100 – 1000 for positive and negative
ions and the fragmentor voltage was set to = 70 V. The main griseorhodin peak, which had a
positive m/z of 509 corresponding to griseorhodin A, eluted at approximately 10 minutes. The
absorbance chromatogram at 488 nm was integrated and the area of the griseorhodin peak was
used to compare relative griseorhodin production (Figure 11). As expected, griseorhodins were
absent in the ΔgrhR2-V mutant and reduced in the ΔgrhGH mutant. Interestingly, griseorhodin
production was also reduced in the ΔftdA-F mutant. This result runs counter to the popular
strategy of deleting competing BGCs can be used to increase antibiotic production. In the future,
this connection could be further explored by qPCR analysis of grh BGC genes in the ΔftdA-F
mutant. Similarly, PftdA mutants exhibiting reduced PTM transcription could also be tested for
griseorhodin production.
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Figure 11. Deletion of the PTM BGC negatively impacts griseorhodin production.
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The malonyl-CoA metabolism of Streptomyces sp. strain
JV180
Background
Through genetic studies of the griseorhodin biosynthetic gene cluster’s effects on polycyclic
tetramate macrolactam (PTM) production, I found that the genes grhGH played an important role
in this interaction. These genes encode the β and ε subunits of acetyl-CoA carboxylase (ACC),
which converts acetyl-CoA to malonyl-CoA. Malonyl-CoA is a common precursor for PTM,
griseorhodin, and fatty acid biosynthesis. Plants and bacteria encode multi-subunit ACC
enzymes. The α subunit contains the biotin carboxylase domain and the biotin carboxyl carrier
protein domain, responsible for carboxylating an attached biotin molecule. The β subunit
contains the carboxyltransferase domain, which transfers the carboxyl group to acetyl-CoA to
form malonyl-CoA. Finally, the ε subunit appears to be a unique subunit found in actinomycetes,
and increases the turnover rate of the ACC complex despite not having any catalytic function of
its own (12). Actinomycetes encode multiple copies of ACC genes with distinct roles. Some
ACC genes are essential housekeeping genes which drive fatty acid biosynthesis, while other
non-essential copies are found in BGCs for secondary metabolites (13, 14).
Based on our data, we hypothesized that the PTM biosynthetic gene cluster (BGC) responded
transcriptionally to malonyl-CoA availability in the cell. This may involve direct malonyl-CoA
sensing, which occurs in B. subtilis (15), or indirect sensing via free fatty acids, which occurs in
E. coli (16). In actinomycetes, regulation of fatty acid metabolism is less well-understood due to
the number of biosynthetic genes (17), but seems to be partially controlled by FasR, a TetR-type
transcriptional regulator (18, 19). In vitro experiments with the FasR of Mycobacterium
tuberculosis indicates that this protein’s ability to bind its target promoters is controlled by long272

chain acyl-CoA’s (20). To better understand how the PTM BGC of Streptomyces sp. JV180
might respond to malonyl-CoA metabolism, I set out to develop a LC-MS/MS protocol to
quantify intracellular malonyl-CoA concentrations. Additionally, due to the number of ACC
genes and the possibility of genetic redundancy, I also attempted to characterize the transcription
of ACC genes in JV180.

Malonyl-CoA extraction and quantification
After comparing the protocols described by several papers, I developed a protocol for MalonylCoA extraction and quantification for Streptomyces sp. strain JV180. The extraction protocol
was largely adapted from that described by (21), while the LC-MS/MS protocol was adapted
from that described by (22).
For malonyl-CoA quantification, strains were cultured in flask cultures. Strains were streaked
from −80°C glycerol stocks onto ISP2 agar plates and incubated at 28°C for 2 days. An agar plug
was used to inoculate 3 mL of TSB in a 24-well deep well plate with one 4 mm glass bead added
to disrupt mycelial clumps. The seed cultures were shaken at 300 rpm in a 28°C incubator for 2
days. In a 125 mL flask with 6 mm glass beads, 20 mL of ATCC-MOPS was inoculated with 200
μL of the seed culture. The flasks were shaken at 250 rpm in a 28°C incubator.
Before harvesting the cultures, 2 mL of 15% trichloroacetic acid (TCA w/v) was aliquoted into a
15 mL tube and chilled on ice. A 2:1 mixture of AR200:DC200 silicone oils was added as a layer
over the TCA. From each flask, 3 mL of the Streptomyces culture was sampled and added slowly
to the silicone oil layer as to not disturb the oil layer. The samples were centrifuged at 3,214 x g
for 10 minutes at 4°C. Immediately afterwards, approximately 2 mL of the TCA layer was
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withdrawn with a Pasteur pipet into microcentrifuge tubes. The samples were centrifuged at
10,000 x g for 5 minutes to separate residual silicone oil.
A 3 mL OASIS HLB reverse-phase Solid Phase Extraction (SPE) column (Waters catalog #
WAT094226) was loaded on a vacuum manifold and conditioned with 3 mL of methanol
followed by 3 mL of 0.15% TCA. The cell extract was loaded onto the column and washed with
2 mL of 0.15% TCA followed by 2 mL n-heptane. The malonyl-CoA enriched fraction was
eluted twice with 0.5 mL of a methanol-ammonium hydroxide (99:1 v/v) solution into a glass
test tube. The solvent was evaporated by vacuum in a speedvac and the dried material was
resuspended in 100 μL of LC-MS grade water and syringe filtered before analysis.
Malonyl-CoA was analyzed using a Waters Atlantis T3 column (100 x 2.1 mm, 3 μm pore size)
installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass
spectrometer. For each run, 10 μL of the sample was injected and the chromatography conditions
were as follows: T = 0 min, 0% B; T = 3 min, 0% B; T = 7 min, 100% B; T = 9 min, 100% B; T
= 11 min, 0% B; T = 13 min, 0% B; where solvent A was water + 50 mM ammonium acetate
(pH 6.9) and solvent B was acetonitrile. The flow rate was 0.25 ml/min. The mass spectrometer
was set to single reaction monitoring mode for the malonyl-CoA mass transition: precursor ion
m/z = 854.1, product ion m/z = 347, fragmentor = 10 V, collision energy = 35 V, and polarity =
positive. The resulting data was analyzed offline with Agilent MassHunter Quantitative Analysis
software. Malonyl-CoA was quantified using a standard curve of 50 ng/mL – 50 μg/mL.
I attempted to use this protocol to quantify intracellular malonyl-CoA concentrations in JV180and IFO13350 strains bearing deletions in the grh cluster or overexpressing grhG. Strains were
grown in triplicate sampled for malonyl-CoA quantification after 2 and 4 days of growth (Figure
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12). The malonyl-CoA measurements showed large variance, especially for samples collected
after 2 days of growth. The variance was much smaller for samples collected after 4 days of
growth. This may reflect the fact that the metabolisms of the replicates were better synchronized
after 4 days of growth, when all of the cultures should have entered stationary phase. Even so,
the only sample which showed statistically significant difference at 4 days was the ΔgrhR2-V
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mutant compared to the JV180 rpsL parent strain.
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Figure 12. First attempt to quantify malonyl-CoA.

I repeated the experiment with a different set of strains overexpressing grhG (Figure 13).
However, I continued to see large variance. Additionally, the data for the JV180-derived strains
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were not consistent with the previous data set. While there did seem to be some differences
between the wild-type strains, the overexpression of grhG oddly did not seem to increase
malonyl-CoA significantly. This could be due to biological mechanisms working to maintain
fatty acid homeostasis or flaws in the protocol. In the future, reproducibility and variance could
be further improved by extracting a larger sample volume. Additionally, I observed issues with

[MaCoA] (ng/mL)

the chromatography conditions, which created split peaks in LC-MS analysis.
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Figure 13. Second attempt to quantify malonyl-CoA.
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Transcriptomic analysis of ACC genes in Streptomyces sp. strain JV180
In a related experiment, I worked with Kevin Blake, a rotating graduate student, to characterize
the transcription of ACC genes in Streptomyces sp. strain JV180. This strain possesses four
genes encoding for the β subunit of ACC, including grhG. Wild-type JV180 was inoculated into
16 flasks of ATCC-MOPS and harvested every 2 days for PTM, RNA, and protein extraction
(Figures 14 and 15). PTM and protein extraction and quantification were performed by Kevin,
and RNA extraction, quantification, and RT-qPCR was done by myself.
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Figure 14. JV180 biomass reaches a maximum by 2 days of growth in flasks.
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Figure 15. JV180 PTM production is completed by 4 days of growth in flasks.

The PTM and protein over time graphs show that while maximum biomass is reached within 2
days of growth, PTM production continues to take place for another 2 days. This suggests that
the flask cultures finish exponential growth and transition into stationary phase around 36 hours
under the conditions tested. Homologs of SCO5535 (accB) and SCO2776 (accD1) were
identified in the JV180 draft genome using BLASTn and aligned with their homologs in S.
griseus IFO13350 and S. coelicolor A(3) to assign predicted functions (Figure 16). Primers for
RT-qPCR were designed using the IDT PrimerQuest tool. Additionally, primers were designed
for the most likely homolog of the housekeeping accA gene, encoding for the ACC α subunit,
which was similarly identified by sequence homology and gene neighborhood synteny.
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Figure 16. Identification of ACC β-subunits in Streptomyces sp. strain JV180. Amino acid
sequences were aligned with ClustalOmega, degapped, and used to construct a neighbor-joining
tree using the Jukes-Cantor substitution model. The B. subtilis YqjD (AccB) protein sequence
was used as an outgroup and 500 bootstrap simulations were performed.

RT-qPCR analysis of the expression patterns of these genes over time revealed several
interesting trends (Figure 17). First, the transcription of the PTM BGC decreased from day 2 to
day 8. However, PTM quantification clearly showed that most PTMs were produced between
day 2 and day 4. This lag between transcription, translation (not measured here), and metabolite
production has been previously observed (23, 24). Interestingly, accB transcript abundance
increased over time, while grhG transcript abundance stayed at similar levels. This appears to be
the opposite of what might be expected, as accB should encode the essential, housekeeping ACC
β-subunit, while the expression of the grh BGC should show a peak like ftdA. Indeed, the
transcript abundance of accA stayed similar over time, as one would expect from a housekeeping
gene. Transcript abundance of accD1 and accD2 increased dramatically over time, but the
functions of these enzymes are unclear so far (17). Further RT-qPCR experiments in JV180
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mutants could explore for potential redundancy and the regulation of ACC genes by global
regulators like adpA. Additionally, absolute quantification of transcripts by RT-qPCR or
RNAseq could determine the relative transcript abundance of different ACC genes, which would
lead to a better understanding of their roles.

Relative transcript abundance
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Figure 17. Transcription patterns for ACC genes in Streptomyces sp. strain JV180. The accD2
sample collected at day 8 was omitted due to contaminated cDNA.
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Abstract
Piperazate (Piz) is a nonproteinogenic amino acid noted for its unusual N−N bond motif. Piz is a
proline mimic that imparts conformational rigidity to peptides. Consequently, piperazyl
molecules are often bioactive and desirable for therapeutic exploration. The in vitro
characterization of Kutzneria enzymes KtzI and KtzT recently led to a biosynthetic pathway for
Piz. However, Piz anabolism in vivo has remained completely uncharacterized. Herein, we
describe the systematic interrogation of actinobacterial Piz metabolism using a combination of
bioinformatics, genetics, and select biochemistry. Following studies in Streptomyces flaveolus,
Streptomyces lividans, and several environmental Streptomyces isolates, our data suggest that
KtzI-type enzymes are conditionally dispensable for Piz production. We also demonstrate the
feasibility of Piz monomer production using engineered actinobacteria for the first time. Finally,
we show that some actinobacteria employ fused KtzI−KtzT chimeric enzymes to produce Piz.
Our findings have implications for future piperazyl drug discovery, pathway engineering, and
fine chemical bioproduction.

Graphical abstract
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Introduction
New drugs for treating antibiotic-resistant infections are urgently needed.1 Piperazate (Piz) is a
nonproteinogenic amino acid and a largely overlooked pharmacophore. Since Piz was originally
discovered as a building block of the antibacterial monamycins in 1971,2 several piperazyl
antibiotics from filamentous actinomycete bacteria have been discovered. These include the
matlystatins (peptide deformylase inhibitors),3,4 the luzopeptins (antitumor agents),5 the
kutznerides (antifungals),6 and the sanglifehrins (antivirals and immunosuppressants)7,8 (Figure
1A). Piz imparts intramolecular rigidity and prolyl mimicry9 to parent molecules, making it
particularly desirable in the context of peptidyl turn analogues and other peptidomimetics.10,11

Figure 1. Piz natural products and biosynthesis. (A) Piperazic acid (Piz, red) is incorporated into
structurally diverse peptidyl natural products. (B) Current biosynthetic pathway for Piz
production based on the characterization of Kutzneria sp. strain 744 KtzI and KtzT.

Until recently, the biosynthesis of Piz and its N−N bond remained enigmatic. Following the
biochemical characterization of two Kutzneria sp. strain 744 enzymes, KtzI12 and KtzT,13 a
two-step pathway converting L-ornithine (L-Orn) to L-Piz (Figure 1B) was revealed.
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Specifically, KtzI first converts L-Orn to its N-hydroxyl derivative N5 -OH-L-Orn, which is then
cyclized to L-Piz by the hemoenzyme KtzT. An important advance in N−N bond biocatalysis,
this model also suggested a new path for genomics-guided piperazyl molecule discovery.
However, much remains unknown about Piz biosynthesis. Importantly, its production has never
been investigated in vivo. This limits the bioengineering potential of this important drug building
block. In addition, a family of proteins annotated as PaiB-type regulators13 share significant
homology with KtzT, but the functional relationship of PaiB proteins and KtzT-type enzymes,
and how this impacts Piz production, remained unclear. Understanding these relationships is the
key to revealing the extent of Piz metabolism in nature and creating refined genome-mining
methods to discover new piperazyl molecules. To further understand Piz biosynthesis, we
utilized a combination of bioinformatics, genetics, and biochemistry to investigate production in
several Streptomyces species.
Several lines of evidence suggest in vivo Piz production is more nuanced than initially expected.
Contrary to the KtzI− KtzT model, we found that the KtzI ortholog SfaB is dispensable during
sanglifehrin production in Streptomyces flaveolus and that expressing the strain’s KtzT ortholog,
SfaC, is sufficient for Piz monomer production in Streptomyces lividans. These observations
strongly suggest piperazyl molecule biosyntheses likely benefit from N5 -OH-L-Orn production
encoded outside of their cognate genomic loci, a trend supported by heterologous Piz production
tests in several environmental Streptomyces stains. Following extensive phylogenetic analysis of
KtzT/SfaC enzymes, we also discovered certain actinomycetes carry out Piz biosynthesis by
chimeric enzymes featuring fused KtzI- and KtzT-type domains. Two chimeras were tested,
revealing one from Micromonospora tulbaghiae with significant activity. Finally, our
bioinformatic efforts also revealed specific residue patterns that differentiate PaiB- and KtzT286

family proteins, and these patterns were experimentally validated using SfaC point mutants.
Together, our data expand upon the current biosynthetic model and reveal new opportunities for
piperazate pathway recognition and bioengineering.

RESULTS AND DISCUSSION
Analysis of Piz Metabolism during Sanglifehrin Production.
The current Piz biosynthetic model is based on enzymes sourced from the kuzneride biosynthetic
locus of Kutzneria sp. strain 744. However, this strain is challenging to transform, leading us to
initiate our Piz metabolic studies in S. flaveolus DSM 9954. The characterized producer of the
sanglifehrins, a family of therapeutically interesting piperazyl antivirals, S. flaveolus is readily
transformed via intergeneric conjugation.14
The sanglifehrin biosynthetic locus was sequenced previously,14 and the cluster encodes
homologues of ktzI and ktzT (sfaB and sfaC, respectively). On the basis of the KtzI/KtzTbased
Piz pathway, we predicted deleting either gene should abrogate sanglifehrin production via Piz
precursor loss. S. flaveolus is known to produce >20 sanglifehrin congeners,14 with
therapeutically relevant sanglifehrin A (m/z 1090.7) being among the most highly produced.15
Liquid chromatography and tandem mass spectrometry (LC−MS/MS) detected sanglifehrin A
production in both wild-type (JV270) and rpsL (JV571) strain extracts (Figure 2A and Figure
S1). In contrast, our unmarked ΔsfaC (JV575) deletion mutant was deficient for sanglifehrin A
production in addition to several other peaks that likely correspond to other sangifehrin-family
compounds. Suggesting sfaC is indeed involved in Piz production, we found that either feeding
exogenous L-Piz (0.25 mM) or ectopic sfaC expression (JV577) restored sanglifehrin production
in the mutant background. Together, these findings are consistent with the current Piz
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biosynthetic model and confirm the ktzT homologue sfaC is essential for S. flaveolus Piz
production.

Figure 2. Genetic analysis of pzbB in Piz production in vivo. (A) LC− MS/MS detection of
sanglifehrins (SRM, m/z 1090.7 → 294.1) produced by S. flaveolus rpsLK43R (JV571), S.
flaveolus rpsLK43R ΔsfaC (JV575), S. flaveolus rpsLK43R ΔsfaC + sfaC (JV577), and S.
flaveolus rpsLK43R ΔsfaB (JV574). The gray bar highlights the retention time for an authentic
standard of sanglifehrin A. (B) Piz detection in transgenic S. lividans by LC−MS (m/z 131.1): (I)
wild type (WT), (II) WT with sfaB (JV593), (III) WT with sfaC (JV594), (IV) WT with sfaB and
sfaC (JV596), and (V) 50 μM L-Piz standard. The gray bar indicates the position of authentic
Piz. (C) LC−MS/MS quantification of L-Piz production in sfaC-transformed Streptomyces
species. Strains JV1403−JV1413 are environmental isolates; JV1405 (starred) produces similar
quantities of Piz in the absence of sfaC (see the text). Error bars indicate standard deviations
between biological triplicates. JV594 and JV596 are S. lividans transformants in panel B.
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In contrast with sfaC, our sfaB (JV574) deletion mutant retains sanglifehrin production (Figure
2A). This was unexpected because sfaB is a ktzI homologue and thus should be required for the
Piz intermediate N5 -OH-L-Orn. On the basis of this observation, we surmised the S. flaveolus
genome must encode additional functionally redundant N-hydroxylases. Lacking a sequenced
genome to verify this, we designed degenerate polymerase chain reaction (PCR) primers to
detect such genes using several published Orn N-OHase sequences (see the Supporting
Information). This revealed the presence of at least one additional flavin-dependent N-OHase
encoded within the genome of the S. flaveolus ΔsfaB strain.

Heterologous L-Piz Production in Multiple Streptomyces Species.
To further investigate Piz anabolism via SfaB/ SfaC, we carried out heterologous expression
experiments in S. lividans strain 66. This commonly used heterologous host lacks apparent
ktzT/sfaC homologues in its genome and is not known to produce piperazyl compounds. S.
lividans was transformed with integrative plasmids expressing either sfaB (pYH014), sfaC
(pYH015), or a combination of both plasmids. The resulting Piz production was monitored by
LC−MS. As expected, wild-type S. lividans and the sfaB transgenic strain (JV593) lacked
detectable Piz. In contrast, S. lividans expressing both sfaB and sfaC (JV596) or sfaC alone
(JV594) produced Piz (Figure 2B). The finding that S. lividans can produce Piz via sfaC in the
absence of sfaB echoed our S. flaveolus observations. While N5 -OH-L-Orn metabolism in S.
lividans is poorly documented, the strain’s genome16 harbors multiple ktzI/sfaB homologues
that may support its production (e.g., EFD65609.1 and EFD71462.1, the latter encoded within a
predicted hydroxamate-type siderophore biosynthetic locus).
The experiments described above revealed for the first time that Piz, a desirable drug building
block, can be produced by engineered actinobacteria. They further suggested that N5 -OHL-Orn
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metabolism, which remains poorly explored in the literature, may be fairly active within most
Streptomycetes. To further understand this, we assayed several environmental Streptomyces
isolates for the ability to produce Piz following transformation with pYH015, a sfaC expression
plasmid (Table S1). Of 22 obtained transformants, 12 produced plasmiddependent Piz (Figure
2C). A single strain, SP18CS05, also produced Piz in the absence of the plasmid. Further
investigation by degenerate PCR with primers designed to amplify sfaC/ktzT homologues
confirmed that this organism harbors a native copy. Thus, our summed observations reveal N5 OH-L-Orn metabolism is indeed a fairly common and potentially exploitable feature of many
Streptomyces.

Bioinformatic Analysis of KtzT/SfaC-Type Enzymes and PaiB Homologues.
Prior to the biochemical characterization of KtzT, KtzT/SfaC homologues encoded within
sequenced piperazyl molecule biosynthetic loci were often misannotated as PaiB-family
transcriptional regulators.13 PaiB- and KtzT/SfaC-type proteins show significant amino acid
similarity and likely share similar protein structures13 (Figure S8). Following KtzT’s recent
functional assignment as a hemoenzyme, whether these protein families have identical or distinct
catalytic functions remained unclear. Indeed, the recent revelation that Geobacillus
stearothermophilus PaiB also binds heme indicates PaiB-family proteins could also function
outside of transcriptional control.13
To begin addressing if PaiB and KtzT/SfaC proteins are functionally distinct or are in fact
identical, we first assembled a collection of high-confidence SfaC/KtzT ortholog sequences. This
was done by screening genomes for co-localized ktzI/sfaB and ktzT/sfaC homologues and then
scanning nearby gene neighborhoods for nonribosomal peptide synthase (NRPS) genes having
Piz adenylation domains (see Methods; for an NRPS review, see ref 17). Because most resulting
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hits lacked functional locus names, we annotated putative KtzI/SfaB and KtzT/SfaC orthologs as
PzbA’s and PzbB’s (for piperazate biosynthesis A and B), respectively. This effort revealed >80
predicted Piz biosynthetic loci (Table S4). To date, all known natural piperazyl molecules are
produced by filamentous actinomycetes. Perhaps unsurprisingly, the vast majority of the
identified putative piperazyl loci were discovered within actinobacterial genomes. However, our
PzbA/B co-localization and PzbB sequence analyses suggest Piz metabolism likely extends to
the proteobacteria, as well, identifying certain Collimonas fungivorans and Photorhabdus
luminescens isolates as candidate piperazyl molecule producers (Table S4 and Figure 3).

Figure 3. Maximum-likelihood phylogeny of PzbB homologues. PzbB enzymes (blue) are
closely related to PaiB proteins (green) that are found in multiple bacterial phyla and some fungi.
This analysis reveals a clade of PzbAB fusion enzymes (orange) whose PzbB domains are
sequence-distinct from stand-alone PzbB’s. Nodes a−e correspond to PzbB’s tested in vivo in
Figures 2 and 4 (from S. flaveolus, Actinoalloteichus cyanogriseus, Lentzea flaviverrucosa, and
Kutzneria sp. 744 and Streptomyces himastatinicus, respectively). Nodes f and g correspond to
PzbAB fusion proteins investigated herein from M. tulbaghiae and Amycolatopsis alba,
respectively. All PzbAB’s and all except for two PzbB’s are sourced from actinobacteria. Node h
corresponds to a putative stand-alone PzbB protein from the proteobacterium Photorhabdus;
another proteobacterial PzbB from C. fungivorans is part of the actinobacterial PzbB tree
(unmarked). A single stand-alone PzbB from actinobacterium Mycobacterium xenopi
RIVM700367 clades within the PzbAB group (unmarked).
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To identify and analyze PaiB-type proteins, we assembled a representative set of homologues
mined from public databases (see methods) that were not associated with pzbA and/or NRPS
genes. Whereas the vast majority of candidate pzbB genes were found in actinobacteria (all
except 2; Figure 3), we found putative paiB genes to be more broadly distributed among a
diversity of microorganisms, including firmicutes, proteobacteria, and some fungi. Notably, a
maximum-likelihood phylogeny clearly separates the manually curated PzbB sequences from the
other PaiB-type homologues, indicating PzbB’s are distinct and suggest the potential for
different biological roles between the two protein clades (Figure 3).

Sequence Diversity among PzbB Proteins.
After determining that PaiB and PzbB proteins are clearly sequence-distinct, we further noted
significant sequence variation within the PzbB group itself. For example, SfaC is 89.6% identical
to PzbB from Streptomyces sp. strain PBH53 but only 33.6% identical to PzbB from
Actinoalloteichus cyanogriseus. With PzbB’s ranging in length from only 200 to 252 amino
acids, this raised the question of whether all members of the PzbB clade are indeed capable of
Piz catalysis.
To test if sequence diversity within the PzbB group affects Piz catalysis, we expressed a panel of
diverse PzbB homologues (Figure 3) cloned from several actinomycetes (Lentzea flaviverrucosa,
Streptomyces himastatinicus, Kutzneria sp. strain 744, and A. cyanogriseus) in S. flaveolus and
S. lividans. Although all are weakly conserved with SfaC (33.6−40.8% amino acid identity), we
found each tested PzbB is functional in Piz biogenesis in both heterologous hosts (Figure 4A,B).
In contrast, PaiB cloned from Bacillus subtilis strain 168 (24.5% amino acid identity with SfaC)
failed to rescue the ΔsfaC mutation (not shown). Along with the phylogenetic analysis presented
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above, these data further support the PzbB group as a functionally conservative clade and further
suggest PaiB proteins are functionally distinct (analyzed further below).

Figure 4. Piz production by PzbB orthologs. (A) LC−MS/MS quantification of sanglifehrin A
production in S. flaveolus rpsLK43R (JV571), rpsLK43R ΔsfaC (JV575), and ΔsfaC
complemented with sequence-diverse pzbB’s: sfaC (JV577), ktzT (JV578), hmtC (JV579),
pzbBA. cyanogriseus (JV585), and pzbBL. flaviverrucosa (JV586). JV575 was also
complemented with PzbAB chimeras of Am. alba and M. tulbaghiae (JV580 and JV582,
respectively) as well as the pzbB domains cloned from the same genes (JV581 and JV583,
respectively). Error bars indicate standard deviations among biological triplicates. (B) LC−MS
chromatograms for Piz production in (I) S. lividans with sfaB (JV593) expressing (II) hmtCS.
himistatinicus (JV598), (III) pzbBA. cyanogriseus (JV599), (IV) pzbBL. flaviverrucosa (JV600),
and (V) ktzT (JV597). (C) PzbAB fusion proteins have an N-terminal PzbA (ornithine
hydroxylase) domain and a C-terminal PzbB domain. Conserved residues are indicated by black
bars. Residues conserved in only PzbAB sequences are indicated by red bars.
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Discovery and Characterization of Chimeric pzbAB Genes and Enzymes.
Our data-mining efforts also led to the discovery of a subgroup of piperazyl molecule
biosynthetic loci that harbor apparent PzbAB chimeric proteins. These enzymes are characterized
by a linkerless amino-terminal PzbA domain fused to a carboxyl PzbB terminus (Figure 4C and
Figure S8). PzbB domains extracted from these chimeras form a distinct clade within the PzbB
tree and have greater sequence similarity with PaiB’s than their stand-alone counterparts (Figure
3). By comparing the sequences of 83 stand-alone PzbA and PzbB pairs against 11 available
chimeric PzbAB’s, we found that the fusion proteins are distinguished by unique positionspecific amino acid utilization patterns compared to stand-alone homologues (Figure 4C).
To test if these chimeras catalyze Piz production, we expressed pzbAB genes cloned from Am.
alba and M. tulbaghiae in S. flaveolus ΔsfaC. Both chimeras restored sanglifehrin, but to a lesser
extent than stand-alone PzbB’s tested in Figure 4A. The Am. alba chimera barely complemented
the mutant, while the M. tulbaghiae gene restored ∼75% of wild-type (WT) activity (Figure 4A).
To test if both PzbA and PzbB of the fused proteins domains are functional (as the chimeric
PzbB domains might have sourced N5 -OH-L-Orn from background S. flaveolus metabolism),
we expressed truncations of both pzbAB chimeras in S. flaveolus ΔsfaC. The truncated gene
encompassing the M. tulbaghiae PzbB domain (amino acids 453−672) also rescued sanglifehrin
production, retaining ∼40% of the activity of the full-length pzbAB gene. Similar to the fulllength pzbAB from Am. alba, the cloned pzbB (amino acids 456−661) domain showed little
activity. Why the chimeras of Am. alba and M. tulbaghiae show such distinct activity differences
in our heterologous assay remains unclear. Despite this, our data importantly demonstrate that
PzbAB from M. tulbaghiae is catalytically competent and its PzbB domain supports Piz
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catalysis. Other newly identified PzbAB proteins documented in this work (Figure 3 and Table
S8) may be similarly active.

Figure 5. In vitro PzbB and coupled PzbA/B assays. (A) LC−MS chromatograms for (I) the 50
μM L-Piz standard and in vitro end point products of (II) SfaC and (III) PzbABM. tulbaghiae
using L-N5 - hydroxyornithine as the substrate. (B) LC−MS chromatograms of in vitro reaction
end points of (I) coupled SfaB/SfaC and (II) PzbABM. tulbaghiae using L-ornithine as the
substrate. (C and D) Logo plots of residues surrounding the conserved KLSQ motifs of PzbB and
PaiB proteins, respectively. The numbers below the first and last amino acids correspond to their
respective positions in S. flaveolus SfaC and B. subtilis 168 PaiB, respectively.

Following the in vivo assays described above, we employed in vitro assays to confirm that
purified PzbAB from M. tulbaghiae catalyzes Piz catalysis from both N5 -OH-L-Orn and L-Orn
(Figure 5A,B). For these experiments, we employed SfaC or SfaB/SfaC coupled reactions as
controls. SfaB, SfaC, and PzbAB were purified by Ni2+-affinity chromatography after
expression in Escherichia coli (Supporting Methods and Figures S2, S6, and S7). From prior
KtzT observations, we expected both SfaC and PzbAB should be hemoproteins. We confirmed
this by direct prosthetic group analysis (Figures S2 and S7) and catalytic rate calculations
(below). Once heme B binding was established for both proteins, the transformation of synthetic
N5 -OH-L-Orn to L-Piz from heme B-replete SfaC and M. tulbaghiae PzbAB was monitored by
LC−MS/MS, HRMS, and 1 H NMR (Figure 5a and Figures S3−S5). We confirmed both proteins
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produced L-Piz under these conditions. While this activity was expected from SfaC (a KtzT
ortholog), these assays conclusively demonstrate exogenous N5 -OH-L-Orn can enter the PzbB
active site of the intact M. tulbaghiae PzbAB chimera.
Building on these results and prior coupled KtzI−KtzT studies,13 we predicted a single-pot
reaction containing either SfaB and SfaC or PzbAB should generate L-Piz from L-Orn in the
presence of O2, NADPH, FAD, and b-heme. For the SfaB− SfaC coupled assay, purified SfaB
was first tested for activity as described for KtzI. NADPH consumption in the presence of LOrn,
FAD, and O2 indicated a kcat of ∼7.7 min−1 (Figure S6), comparable to that of KtzI (kcat = 7.0
min−1 ). Subsequent assays testing SfaB and SfaC or M. tulbaghaiae PzbAB revealed production
of Piz from L-Orn (Figure 5B), confirming the activity of both M. tulbaghiae enzyme domains.
Taken together, our in vivo and in vitro experiments reveal M. tulbaghiae PzbAB as a versatile
catalyst capable of transforming both L-Orn and N5 -OH-L-Orn to L-Piz. This work also
highlights PzbAB proteins for future substrate channeling, domain−domain interaction, and
evolutionary covariation investigations.

Identifying Hallmark PzbB Sequence Signatures.
Finally, following our in vivo and in vitro explorations of several pzbB and pzbAB genes, we
initiated combined bioinformatic and mutational studies to differentiate piperazate-linked pzbB
genes from apparent paiB’s. To do this, 85 PzbB and 51 PaiB protein sequences were aligned,
revealing a highly conserved sequence motif shared in both protein groups [KLSQ,
corresponding to SfaC residues 183−186 (Figure S8 and Figure 5C,D)]. Scrutinizing the amino
acid differences surrounding this common motif revealed two residue position identity
differences between PzbB’s and PaiB’s. At position 181, PzbB’s typically have methionine while
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PaiB’s have lysine. At position 187, PzbB homologues have aspartate or glutamate while PaiB
homologues typically have asparagine.
We then tested the effects of substituting PaiB-type residues at these positions into SfaC. Thus,
SfaC M181K and E187N mutant proteins were purified and assayed for Piz production.
Assuming Michaelis−Menten kinetics, WT heme-replete SfaC progress curves indicate an
apparent Km of 360 μM (Figure S9). In assays supplemented with the N5 -OH-L-Orn substrate
at ∼10Km, the WT SfaC (+hemin) kcat was found to be 8000 ± 500 min−1 (without hemin, 88 ±
2 min−1 ). In contrast, the SfaC M181K (with hemin, 99 ± 8 min−1 ; without hemin, 0.41 ± 0.01
min−1 ) and E187N (with hemin, 110 ± 10 min−1 ; without hemin, 0.89 ± 0.02 min−1 ) mutants
had turnover numbers multiple orders of magnitude lower than that of the WT.
Both mutant proteins were purified with absorbance maxima at 411 nm, suggesting decreased
activity is independent of heme loss. Attempts to directly measure mutant Km values were
hindered by visible precipitation caused by elevated N5 - OH-L-Orn levels. Despite this, the
observed reduction in the level of L-Piz catalysis by the mutant enzymes clearly demonstrates a
negative correlation with PaiB position-specific residues. On the basis of these observations and
our phylogenetic analyses presented above, our work contributes further evidence that PaiB
proteins likely function outside of piperazate metabolism. These findings are potentially
important for accurate recognition of piperazyl molecule biosynthetic loci during genome mining
efforts and future mechanistic inquiries.

METHODS
Reagents, Media, and Enzymes.
All chemicals and medium components were purchased from Sigma-Aldrich, Fisher Scientific,
or Santa Cruz Biotechnology unless otherwise noted. N5 -OH-LOrnithine hydrochloride (>90%)
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was synthesized by and purchased from AKos Consulting & Solutions GmbH. L-Piperazic acid
dihydrochloride (>95%) was synthesized by and purchased from WuXi AppTec. DL-Piz
racemate was purchased from BOC Sciences. Restriction endonucleases, T4 DNA ligase, and
Taq polymerase were purchased from New England BioLabs. DNA purification kits were
purchased from Qiagen. KOD Hot Start DNA Polymerase (EMD Millipore) and FailSafe PCR
2X PreMixes (Epicenter) were used for PCR from Streptomyces genomic DNA.
Oligonucleotides (Table S2) were purchased from Integrated DNA Technologies (IDT).

Instrumentation.
Unless otherwise specified, LC−MS/MS analysis was performed on an Agilent 1260 Infinity
HPLC instrument connected to an Agilent 6420 triple-quadrupole mass spectrometer with an
electrospray ionization (ESI) source. The resulting data were analyzed offline with Agilent
MassHunter software. Ultraviolet spectroscopy was performed using a Shimadzu UV-1800
spectrophotometer.

Bacterial Growth and Actinomycete Isolations.
All strains used in this work are listed in Table S1, and plasmids are listed in Table S3.
Actinomycetes were routinely propagated on ISP2 (Difco) agar plates or in Trypticase Soy Broth
(TSB, Difco) at 28 °C. E. coli strains were grown on standard Luria-Bertani (LB) plates or in
equivalent liquid media. Sterile glass beads (6 mm) were added to actinomycete liquid cultures
to disrupt mycelial clumps. PCR templates for verifying transgenic or mutant actinomycetes
were prepared by grinding cells in 100 μL of dimethyl sulfoxide, similar to the method of Van
Dessel et al.18 Several Streptomyces strains were isolated using standard enrichment methods19
from soils collected at the Tyson Valley Research Center in Eureka, MO. Isolates were
confirmed as Streptomyces by 16S rDNA amplicon sequencing as described elsewhere20
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(Tables S1 and S6). Prior to conjugation with pYH015, each isolate was screened for native
pzbB’s. This was done using degenerate primers designed using BLOCKMAKER21 and
CODEHOP22 software (Table S2).

Actinomycete Conjugations.
Streptomyces conjugations were performed essentially as described previously.23 S. flaveolus
and S. lividans were grown on ISP2 agar (Difco) and ISP-S agar (Difco malt extract, 1.5%;
Difco soluble starch, 0.5%; Difco yeast extract, 0.5%; CaCO3, 0.3%; Bacto agar, 2%; pH
7.2−7.5), respectively, for sporulation. Spores were harvested using TX Buffer.24 E. coli strain
JV36 was used as the conjugal donor. Exconjugants were selected with 50 μg/mL apramycin.
After conjugation, JV36 was selected against with either 15 μg/mL polymyxin B or 30 μg/mL
colistin. For plasmids using ΦC31 integration, multiplex PCR was used to verify correct attB
insertion as previously described.23

S. flaveolus Gene Deletions.
Genes of interest were removed by double homologous recombination essentially as previously
described using pJVD52.1.25 Streptomycin-resistant (StrR) mutants necessary for
counterselection26 were isolated on ISP2 agar with 100 μg/mL streptomycin. S. flaveolus
rpsL(K43R) was chosen for further sanglifehrin analysis because its production parallels that of
the wild type. Deletion constructs were transformed into S. flaveolus rpsL(K43R), and
exconjugants were selected via apramycin resistance. Double recombinants were identified via
counterselection after growth for 3 days at 37 °C in TSB. Gene deletions were confirmed by
PCR.

S. flaveolus Sanglifehrin Detection.
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S. flaveolus spores were used to inoculate 15 mL of TSB in a 125 mL Erlenmeyer flask at 28 °C
with vigorous shaking. Glass beads were added to disrupt mycelial clumps. After overnight
growth, the culture was spread for confluence to sanglifehrin production medium14 with 2%
agar and incubated at 28 °C for 3 days. The agar with adherent cells was subsequently diced and
immersed in ethyl acetate overnight. The resulting extract was evaporated at low pressure and
resuspended in 500 μL of HPLCgrade methanol. Analysis was performed using a Phenomenex
Luna C18 column (75 mm × 3 mm, 3 μm) using the following method: T = 0, 10% B; T = 5,
10% B; T = 25, 100% B; T = 27, 100% B; T = 29, 10% B; T = 30, 10% B; A, water and 0.1%
formic acid; B, acetonitrile and 0.1% formic acid; rate, 0.6 mL/min. Authentic sanglifehrin A
was used to develop the m/z 1090.7 → 294.2 mass transition (fragmentor energy of 135 V and
collision energy of 40 V) for single-reaction monitoring using MassHunter Optimizer (Agilent).
For quantification, a standard curve was created using concentrations ranging from 100 ng/mL to
1 mg/mL.

Heterologous Piz Production.
Streptomyces strains expressing SfaC were plated on YEME27-NSG [yeast extract-malt extractno sucrose or glycine; Difco yeast extract, 0.3%; Difco Bacto-peptone, 0.5%; Difco malt extract,
0.3%; dextrose, 1.0%; Bacto agar, 2%; after autoclaving, MgCl2 (2.5 M), 0.2%] supplemented
with 50 mg/L LOrn and incubated at 28 °C for 3 days. The agar was subsequently diced and
immersed in methanol overnight. The methanol fraction was evaporated to dryness and
resuspended in 500 μL of LC−MSgrade water and 500 μL of 6% sulfosalicylic acid. Samples
were clarified by centrifugation (21000g for 5 min) and 0.2 μm filtration prior to LC−MS/MS.

Detection of Piz via LC−MS and Quantification via LC−MS/ MS.
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Analysis was performed using an Imtakt Intrada Amino Acid column (50 mm × 3 mm, 3 μm)
using the following method: T = 0, 86% B; T = 3, 86% B; T = 10, 0% B; T = 11, 0% B; T = 12,
86% B; T = 14, 86% B; A, water and 100 mM ammonium formate; B, MeCN and 0.1% formic
acid; rate, 0.6 mL/min; 35 °C column. The flow was routed to waste between T = 7.6 and T = 7.9
to avoid buffer salts. LPiz was detected at T = 5.8 (m/z 131.1 [M + H]+ ). For Piz quantification,
an SRM transition (m/z 131.1 → 56.3; source voltage, 86 V; collision energy, 37 V) was
monitored, and a standard curve (second-order polynomial; R2 = 0.9996) was generated between
0.1 and 100 μM L-Piz-2HCl standard.

PzbB/PaiB Sequence Mining and Phylogeny.
Potential PzbB orthologs were identified in the JGI database using BLASTp with SfaC as the
query. The following criteria were used to identify potential PzbB orthologs: the presence of a
PzbA homologue and/or an NRPS having predicted Piz adenylation domain signatures within
∼15 kb. Hits having low identity scores (0.01) were excluded, and likely Piz loading modules
were identified by PRISM28 or AntiSmash.29 Identities of PzbB’s used to create the PzbB
phylogeny in Figure 3 are listed in Table S4. BLASTp 2.6.0+ was used to calculate e values,
coverages, and protein identities. PaiB homologues were found via InterPro, using the term
“Transcriptional regulator PAI 2-type”. PaiB from Geobacillus stearothermophilus30 (Protein
Data Bank entry 2OL5, chain A) was selected as a structural archetype for PaiB/PzbB
ESPRIPT31 alignment. Efforts were taken to sample PaiB sequences from diverse
microorganisms. To create a phylogeny of PzbB and PaiB proteins, the amino acid sequences of
85 putative PzbB’s, 51 PaiB’s, and the C-terminal domains of 10 putative PzbAB chimeras were
aligned with ClustalOmega. Highly similar PzbB sequences from overrepresented species were
omitted, and the alignment was manually degapped. A maximum-likelihood phylogeny was
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estimated using the WAG substitution model with 500 bootstrap simulations. Low-confidence
branches (<50% of bootstrap replicates) were collapsed in CLC Main Workbench version 8.1.
Sequence logos were generated from alignments at https://weblogo.berkeley.edu.

Purification of SfaB, SfaC, and PzbAB.
First, 5 mL cultures of E. coli Rosetta 2(DE3) carrying expression plasmid pYH004, pYH048, or
pYH089 were grown overnight and used to inoculate 1 L of LB containing ampicillin (100
μg/mL) and chloramphenicol (12 μg/ mL), in 2.8 L baffled flasks. After being shaken at 30 °C to
mid log phase, cultures were cold shocked in an ice−water bath and induced with isopropyl β-D1-thiogalactopyranoside (final concentration of 100 μM). After being returned to an 18 °C shaker
overnight, induced cells were pelleted, decanted, and suspended in 50 mL of lysis buffer [50 mM
Tris-HCl, 500 mM NaCl, and 25 mM imidazole (pH 8.0)]. The resulting suspension was passed
through an Avestin high-pressure homogenizer (16000 psi), and the lysate was cleared via
centrifugation at 13000g for 30 min. For SfaC-His, ammonium sulfate (final concentration of
40%) precipitation was additionally required to enrich the soluble fraction prior to affinity
purification. Cleared lysates were incubated with lysis buffer-equilibrated Ni-NTA resin for 30
min at 4 °C. After being loaded onto a gravity column, the resin was washed three times with
five column volumes of wash buffer [50 mM HEPES, 500 mM NaCl, and 50 mM imidazole (pH
8.0)]. For His6-SfaB, the column turned noticeably yellow. For SfaC-His6, the column turned
noticeably brownish-red. Bound proteins were eluted with 5 mL of elution buffer [50 mM
HEPES, 500 mM NaCl, and 500 mM imidazole (pH 8.0)]. After sodium dodecyl sulfate−
polyacrylamide gel electrophoresis (SDS−PAGE) analysis, the elution fraction was concentrated
[Pierce Concentrators, 9K molecular weight cutoff (MWCO), 7 mL] to ∼0.5 mL and
subsequently desalted into 50 mM HEPES (pH 8.0) using Zeba Spin Desalting Columns (7K
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MWCO, 2 mL). Protein concentrations were measured via the Bradford assay with a bovine
serum albumin standard curve. Enzyme fractions estimated to be >90% pure following
SDS−PAGE were immediately assayed or were frozen on dry ice and stored at −80 °C. See the
Supporting Information for enzyme cofactor characterization and SfaB assay details.

SfaC Kinetic Assay.
A 1 mM hemin stock solution was prepared in 20 mM NaOH. Kinetic assays were set up with
the following conditions: SfaC-His6 (0.05−10 μM), N5 -OH-L-ornithine-HCl (5 mM,
saturating), hemin (0.5−100 μM), and Tris-HCl (50 mM, pH 8.0). The hemin:enzyme ratio was
maintained in each assay at 10:1. The reaction mixture was incubated at 22 °C for 10 min before
the substrate was added. At 30, 60, and 90 s, an aliquot was removed from the mixture and
quenched with an equal volume of 6% sulfosalicylic acid for protein precipitation and sample
acidification. The cloudy mixture was centrifuged at 21000g for 5 min, and the supernatant was
analyzed by LC−MS/MS for Piz as described above. The rate of Piz formation was divided by
the enzyme concentration to obtain kcat. The apparent Km was calculated from reaction progress
curves using DynaFit32 (Figure S9A).

Coupled PzbA/B End Point Assays.
SfaB/C enzyme assays were set up with the following components: His6-SfaB (10 μM), SfaCHis6 (50 nM), L-ornithine-HCl (1 mM), hemin (0.5 μM), FAD (50 μM), NADPH (2 mM), and
Tris-HCl (50 mM, pH 8.0). PzbAB (M. tulbaghiae) enzyme assays were set up with the
following components: PzbAB-His6 (5 μM), L-ornithine-HCl (1 mM), hemin (50 μM), FAD (50
μM), NADPH (2 mM), and Tris-HCl (50 mM, pH 8.0). Prior to these assays being set up, the
reaction buffer was vigorously shaken just prior to use to increase the level of dissolved oxygen.
Reaction mixtures were incubated at 22 °C for 10 min before the substrate was added to allow
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cofactor incorporation. Fifteen minutes after catalysis had been initiated with L-Orn, reactions
were stopped with an equal volume of 6% sulfosalicylic acid. Mixtures were cleared via
centrifugation at 21000g for 5 min, and supernatants were analyzed by LC−MS as described
above.

Characterization of Enzymatically Produced L-Piz.
First, 200 μL SfaC reaction mixtures were set up as follows: 50 mM phosphate buffer (pH 8.0),
SfaC-His6 (50 nM), hemin (500 nM), and N5 -OH-Lornithine-HCl (5 mM). After the solution
had been mixed and the reaction allowed to proceed for ∼15 min, an equal volume of 6%
sulfosalicylic acid was added to precipitate the protein and quench the reaction. The solution was
centrifuged at 21000g for 5 min. The supernatant was diluted 1:10 with 20 mM acetic acid. For
cation exchange purification, a Discovery DSC-SCX SPE column (500 mg, Sigma) was
conditioned with 2 mL of methanol followed by 2 mL of 20 mM acetic acid. The sample was
applied to the column and washed with 2 mL of methanol. L-Piz was eluted with 2 mL of 5%
ammonium hydroxide in 80% methanol. The elution fraction was evaporated under vacuum and
resuspended in 100 μL of LC−MS grade water for HRMS analysis (Figure S3).

Marfey’s Analysis.
Enzymatic Piz was derivatized with 1-fluoro2,4-dinitrophenyl-5-L-alanine amide (FDAA,
Marfey’s reagent) to determine stereochemistry; 50 μL of 1% FDAA in acetone was added to a
100 μL aqueous sample. The resulting yellow solution slowly became cloudy, and following
incubation at 50 °C for 1 h, the solution turned orange. Then 100 μL of 1 M HCl was added to
quench the reaction. Finally, 100 μL of MeCN was added to dissolve the precipitate. The
supernatant was filtered (Agilent Captiva Econo Filter, 0.2 μm) before LC−MS/MS. Analysis
was performed using a Phenomenex Luna C18 column (75 mm × 3 mm, 3 μm) using the
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following method: T = 0, 10% B; T = 5, 10% B; T = 25, 100% B; T = 27, 100% B; T = 29, 10%
B; T = 30, 10% B; A, water and 0.1% formic acid; B, MeCN and 0.1% formic acid; rate, 0.6
mL/min. The stereochemistry was determined against FDAA-derivatized authentic ACS
Chemical Biology Articles DOI: 10.1021/acschembio.8b01086 ACS Chem. Biol. 2019, 14,
696−703 701 L-Piz and DL-Piz racemate controls via LC−MS at [M + H]+ m/z 383.1 and 340
nm (Figure S5).

L-Piz NMR.
1 H NMR spectroscopy was carried out at the Washington University in St. Louis Chemistry
NMR Facility. Spectra were recorded using an Agilent 600 MHz instrument with a DD2 console
and an Agilent 600 HCN cold probe. L-Piz was purified from in vitro reactions via SAX
chromatography prior to NMR and dissolved in D2O (Figure S4).
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Hreggvidsson, G. Ó., Lambert, C., Badcock, D., Bernaerts, K., Anne, J., Economou, A., and
Kalinowski, J. (2015) Complete genome sequence of Streptomyces lividans TK24. J. Biotechnol.
199, 21−22.
(17) Fischbach, M. A., and Walsh, C. T. (2006) Assembly-line enzymology for polyketide and
nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev. 106,
3468−3496.
(18) Van Dessel, W., Van Mellaert, L., Geukens, N., and Anne, J. ́ (2003) Improved PCR-based
method for the direct screening of Streptomyces transformants. J. Microbiol. Methods 53,
401−403.
(19) Blodgett, J. A. V., Oh, D.-C., Cao, S., Currie, C. R., Kolter, R., and Clardy, J. (2010)
Common biosynthetic origins for polycyclic tetramate macrolactams from phylogenetically
diverse bacteria. Proc. Natl. Acad. Sci. U. S. A. 107, 11692−11697.
(20) Stach, J. E. M., Maldonado, L. A., Ward, A. C., Goodfellow, M., and Bull, A. T. (2003)
New primers for the class Actinobacteria: application to marine and terrestrial environments.
Environ. Microbiol. 5, 828−841.
307

(21) Henikoff, S., Henikoff, J., Alford, W., and Pietrokovski, S. (1995) Automated construction
and graphical presentation of protein blocks from unaligned sequences. Gene 163, GC17−26.
(22) Rose, T., Schultz, E., Henikoff, J., Pietrokovski, S., McCallum, C., and Henikoff, S. (1998)
Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related
sequences. Nucleic Acids Res. 26, 1628−1635.
(23) Qi, Y., Ding, E., and Blodgett, J. A. (2018) Native and engineered clifednamide
biosynthesis in multiple Streptomyces spp. ACS Synth. Biol. 7, 357−362.
(24) Hirsch, C., and Ensign, J. (1976) Heat activation of Streptomyces viridochromogenes
spores. J. Bacteriol. 126, 24−30.
(25) Blodgett, J. A. V., Thomas, P. M., Li, G., Velasquez, J. E., van der Donk, W. A., Kelleher,
N. L., and Metcalf, W. W. (2007) Unusual transformations in the biosynthesis of the antibiotic
phosphinothricin tripeptide. Nat. Chem. Biol. 3, 480−485.
(26) Hosted, T., and Baltz, R. (1997) Use of rpsL for dominance selection and gene replacement
in Streptomyces roseosporus. J. Bacteriol. 179, 180−186.
(27) Keiser, T., Bibb, M., Buttner, M., Chater, K., and Hopwood, D. (2000) in Practical
Streptomyces Genetics, The John Innes Foundation, Norwich, U.K.
(28) Skinnider, M. A., Dejong, C. A., Rees, P. N., Johnston, C. W., Li, H., Webster, A. L.,
Wyatt, M. A., and Magarvey, N. A. (2015) Genomes to natural products prediction informatics
for secondary metabolomes (PRISM). Nucleic Acids Res. 43, 9645−9662.
(29) Blin, K., Medema, M. H., Kazempour, D., Fischbach, M. A., Breitling, R., Takano, E., and
Weber, T. (2013) antiSMASH 2.0–a versatile platform for genome mining of secondary
metabolite producers. Nucleic Acids Res. 41, W204−212.
(30) Filippova, E. V., Brunzelle, J. S., Cuff, M. E., Li, H., Joachimiak, A., and Anderson, W. F.
(2011) Crystal structure of the novel PaiB transcriptional regulator from Geobacillus
stearothermophilus. Proteins: Struct., Funct., Genet. 79, 2578−2582.
(31) Gouet, P., Robert, X., and Courcelle, E. (2003) ESPript/ ENDscript: Extracting and
rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res.
31, 3320−3323.
(32) Kuzmic, P. (1996) Program DYNAFIT for the analysis of ̌ enzyme kinetic data: application
to HIV proteinase. Anal. Biochem. 237, 260−273.

308

